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PREFACE 
This thesis deals with a fundamental study on the mechanisms and 
interactions of organic anion transport in the dog kidney. The clinical 
importance of the renal organic anion transport system has been recog-
nized for many years . A large number of drugs , many of which are used 
frequently in daily practice, are actively removed from the body by this 
secretory system. Accordingly, knowledge of the fundamental processes 
underlying renal anionic drug secretion is of value in drug development 
and essential for a rational pharmacotherapy. 
The thesis is divided into four par ts . Part I contains a general intro-
duction into the state of the ar t , and a description of the clearance tech-
nique which was used throughout the in vivo investigations. Part II 
presents a physiologically based modeling approach to the renal clearance 
of anionic drugs . Special attention is paid to drug interactions at the 
level of tubular secretion. Part III deals with the specificity of organic 
anion secretion in vivo. The renal clearance of a series of mono-
substituted hippurates was studied, and analyzed with the physiologically 
based kidney model described in Part II. Part IV examines the molecular 
mechanisms and specificity of p-aminohippurate transport in renal plasma 
membrane vesicles isolated from dog kidney cortex. 
This study has a fundamental character, but I hope it will contribute to 
a better insight into the mechanisms by which anionic drugs are cleared 
by the kidney, especially in those situations were two or more drugs are 
administered concurrently, and that this may eventually lead to a more 
rational management of pharmacotherapy. 
Accomplishing this study would not have been possible without the ded-
icated support of my family, friends and colleagues, whom I all gratefully 
acknowledge at the end of the thesis. In writing this thesis, I have ben-
efitted greatly from one of the old and profound 'Principles of Chinese 
Writing': 
"Were I to await perfection, my book 
would never be finished" 
Tai T'ung (13th century) 
Frans Rüssel 
Э 
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PART I 
INTRODUCTION 
Facilius natura intellegltur quam 
enarratur 
(Nature is easier understood than 
explained) 
Lucius Annaeus Seneca 

CHAPTER 1 
RENAL HANDLING OF ORGANIC ANIONS 
Frans G.M. Rüssel and Cees A.M. van Ginneken 
Abstract - The kidney is the principal route for the elimination of drugs 
and their metabolites from the body. The processes that determine net 
drug excretion are closely related to the physiological events occurring in 
the functional units of the kidney, i . e . , the nephrons. The proximal 
tubular cells are an important site for the carrier-mediated secretion of 
anionic drugs . Organic anions are actively transported at the basolateral 
membrane, concentrated intracellularly, and subsequently transported 
from the cell into the tubular lumen by mediated (facilitated) diffusion. 
The organic anion secretory system accepts a wide variety of compounds 
which may compete with each other for t ransport . This may have impor-
tant clinical implications. 
1.1 INTRODUCTION 
The study of the mechanisms by which the kidney excretes foreign 
anions has traditionally belonged to the field of renal physiology. It was 
only many years after Marshall and coworkers in 1923 obtained the first 
conclusive proof of active secretion with phenolsulfonphthalein [82], that 
pharmacologists recognized the clinical importance of the renal organic 
anion transport system. The primary function of the organic anion system 
appears to be the facilitated elimination of endogenous metabolites and 
exogenous compounds, which are not easily degraded by the body, and 
which might be toxic if allowed to accumulate. In accordance with this 
vast task, the transport system accepts a wide variety of organic anions, 
having in common only a negative charge and a hydrophobic backbone. 
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Many organic cations are also actively secreted by the kidney 
[39,108,110,155], but the transport system for these compounds is clearly 
distinct from the organic anion system and it operates at a different cel-
lular site [52,69,86,132]. 
In the past decade considerable progress has been made in the elucida-
tion of the mechanisms involved in the tubular secretion of organic ions. 
These advances are inextricably linked to the advances in techniques for 
studying kidney function, e . g . , isolated perfused kidney, isolated per-
fused tubules, microperfusion methods, cultured renal cells, isolated mem-
brane vesicles [139]. 
The renal organic anion transport system has been the subject of a 
number of excellent reviews [39,41,46,90,106,110,131,144,154,155]. The 
purpose of the present paper is to summarize shortly the current knowl-
edge on the renal handling of organic anions as an introduction to the 
investigations described in this thesis. 
1.2 RENAL EXCRETION OF DRUGS 
Physiology 
Apart from its excretory function, the kidney plays a dominant role in 
the regulation of the constancy of the volume and composition of the 
internal environment. To perform this task, it is an organ of a high 
functional selectivity, capable of reabsorbing the necessary valuable sub-
stances and excreting waste products and undesirable excess of exoge-
nous compounds taken into the body. 
The action of the kidney is intimately related to its anatomical s t ruc-
tu re . The functional units of the kidney are the nephrons, of which there 
are about 1.5 million per kidney in the human. A schematic drawing of a 
nephron with the associated vascular supply in the cortex is given in 
Fig. 1.1. The basic components of the nephron are the glomerulus, sur-
rounded by a Bowman's capsule, the proximal tubule, the loop of Henle, 
the distal tubule and the collecting tubule. A single layer of epithelial 
cells lines the lumen of the nephron throughout its entire length, and a 
close network of arterial and venous capillaries provide a tight contact 
between the blood circulation and these cells. The glomeruli receive the 
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Fig. 1.1 The functional nephron with representative blood supply in the 
cor t ica l region [From reference 63 with permission]. 
arterial blood first, and the glomerular filtrate passes down the tubule 
where electrolyte transport takes place and where most of the water is 
reabsorbed. Less than only 1% of the water in the initial ultrafiltrate 
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leaves the kidney as urine. The blood that has passed the glomerular 
capillary bed is transported via an efferent arteriole to a second network 
of capillaries that perfuses the proximal and distal portions of the 
tubules. More than 80% of the arterial blood flows to the cortex, while a 
fraction of the total blood supply reaches the medullary parts of the 
nephron. 
The renal mechanisms which account for the formation and final compo-
sition of urine also determine the rate and extent by which drugs appear 
in the urine. Four different processes are the main determinants of drug 
excretion, viz . , glomerular filtration, passive reabsorption, active tubular 
secretion, and active tubular reabsorption. 
Glomerular Filtration and Passive Reabsorption 
In man, about 25% of the cardiac output (1200 - 1500 ml/min) reaches 
the kidney, and of this volume about 109Ó is filtered at the glomeruli. The 
energy required for filtration is supplied by the hydrostatic pressure of 
the blood, which must overcome both the intracapsular pressure and the 
osmotic pressure of the plasma proteins. Compounds with a molecular 
weight of approximately 40,000 or less and a diameter up to 20Â are fil-
tered by the glomerulus. Larger molecules are restricted from the filtrate, 
particularly those molecules which are negatively charged like, for exam-
ple, albumin. Since most drugs are small enough to be filtered, only drug 
molecules bound to plasma proteins are excluded from the glomerular fil-
t rate . From a kinetic point of view this implies that the effective clear-
ance of a drug by glomerular filtration is equal to the glomerular filtra-
tion rate of an unbound substance ( e . g . , inulin, mannitol) times the 
fraction of drug not bound to plasma proteins. 
The effective renal clearance may be further decreased by passive dif-
fusion of the drug from the tubular fluid back into the blood stream. As 
nearly all the water of the filtrate is reabsorbed, steep concentration gra-
dients of drug between the tubular fluid and the blood may exist all over 
the nephron. This situation strongly favors the movement of drug out of 
the tubular lumen, and in accordance with their physicochemical proper-
ties, drug molecules will passively diffuse back into the renal blood circu-
lation. As usual when permeation of biological membranes by non-active 
mechanisms is concerned, back-diffusion is only possible for drug 
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molecules which are sufficiently lipophilic in nature. This practically 
always means that the drug should be unionized in urine. Therefore, the 
pK of. the drug and the pH of the tubular urine determine the extent 
and rate of passive drug reabsorption. 
The urinary pH can vary between 4.0 and 8.0 during its formation, 
depending on several metabolic factors. Normally, the urine is somewhat 
acidic as a result of the secretion of protons along the tubule. The acidi-
fication of urine facilitates the nonionic back-diffusion of weak acids, 
such as salicylic acid. Conversely, alkalinization of the urine promotes the 
renal excretion of salicylic acid. For weak basic drugs obviously the 
opposite holds t rue . This principle is, for instance, used clinically in the 
treatment of salicylate poisoning by administration of sodium bicarbonate 
to produce an alkaline urine, which accelerates the elimination of drug . 
Another important factor in the process of back-diffusion is the urine 
flow. When less water is reabsorbed more urine will be produced and less 
concentration of drug in the tubular fluid will occur. Clearly, this means 
a smaller concentration gradient and consequently, less back-diffusion. 
Tubular Secretion 
A number of substances are excreted from the capillaries surrounding 
the renal tubules into the luminal fluid by a carrier-mediated process 
(tubular secretion). With several experimental techniques it has been 
shown independently that many organic compounds are actively secreted 
by the proximal tubular cells of the nephron [90] . The pathways for 
organic anions and cations appear to be separate, but both transport sys-
tems are characterized by a broad specificity. Tubular secretion is an 
active carrier-mediated process in that it is concentration-, temperature-, 
and energy-dependent and susceptible to competition by similar sub-
strates. 
The characteristics of the renal organic anion transport system have 
been extensively studied with p-aminohippurate (PAH). Most of our 
knowledge about the exact anatomical location of PAH secretion derives 
from studies with isolated perfused rabbit tubules. The proximal tubule 
can be divided functionally into three segments, viz . , S.., S„, and S„ 
(Fig. 1.2). The highest rate of PAH secretion is seen in the S„ segment 
of both the superficial and juxtamedullary nephrons of the rabbit kidney 
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Fig. 1.2 Heterogeneity of PAH transport in rabbit proximal tubules. PAH 
is secreted in a l l parts of the tubule but most avidly in the S„ segment 
[From reference 39 with permission]. 
[83,136,160]. Shimomura et al. [121] showed that the К values of the 
three segments were the same, while the maximal transport rate (V ) in 0
 ' ι- ν max' 
the S„ segment was 5 to 6 times greater than in the other segments. 
They suggested that heterogeneity of PAH secretion along the proximal 
tubule is a result of an unequal distribution of transporters with common 
affinity. However, this pattern of heterogeneity is probably not represen­
tative for all mammalian species. For example in the pig, the S1 segment 
is the predominant site of PAH secretion [117] . 
Whereas protein binding always decreases the extent of glomerular fil­
tration, the tubular secretion of most organic anions seems to be unaf­
fected, presumably due to the high dissociation rate of the drug-protein 
complex relative to its exposure time to the secretory system. Of course, 
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also the affinity of the carrier system has to be high enough to compete 
effectively with the plasma-protein molecules. However, these conditions 
are not universal as there are examples of drugs for which protein bind-
ing impedes tubular secretion [17,48, G5, 9G] . 
Active Reabsorption 
Carrier-mediated reabsorption from the tubular fluid occurs for many 
endogenous compounds which are indispensable to the body, e . g . , glu-
cose, amino acids, and some vitamins. The physicochemical properties of 
these nutrients preclude their effective return to the circulation by pas-
sive oack-diffusion. Glucose, for example, is under physiological condi-
tions not present in the voided urine because it is completely reabsorbed 
from the glomerular filtrate in the proximal tubules. Only when the 
amounts delivered to the kidney exceed the transport capacity of the car-
rier system, glucose appears in the urine. 
Renal excretion of most organic anions is dominated by tubular secre-
tion. Reabsorption, if any, takes usually place by simple diffusion. How-
ever, some compounds are known to be transported by tubular secretion 
as well as active reabsorption. Urate is an interesting example of an 
endogenous anion that undergoes bidirectional active transport [75,109]. 
The combined action of oppositely operating transport mechanisms explains 
the paradoxical effects of drugs like salicylate, probenecid, and 
phenylbutazone on urate excretion. In low doses they act as hyper-
uricemic drugs by inhibiting tubular urate secretion, whereas with high 
doses they exert a hypouricemic effect by inhibiting tubular urate reab-
sorption [44,124,162,163]. 
Exogenous organic anions for which active bidirectional transport has 
been reported are m-hydroxybenzoate [84,85], nicotinate [24], and 
pyrazinoate [153] . The transport systems which are involved in the spe-
cific secretion and reabsorption of these compounds are still not complete-
ly characterized, but there is evidence that they are , at least in part , 
different from the urate system [155] . 
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1.3 RENAL CLEARANCE 
Clearance 
The concept of clearance was originally developed by renal physiologists 
as a means to measure kidney function in health and disease [131]. In 
pharmacokinetics, clearance is now generally considered as the most use-
ful parameter for the evaluation of an elimination mechanism 
[111,135,158]. 
The renal clearance (CLp) of a drug may be viewed as the volume of 
plasma from which drug is completely removed per unit time by the kid-
ney. It is often defined as the rate of renal drug excretion at time t 
(RTj= dAe/dt) divided by its plasma concentration at time t (C): 
CLR = R R /C 
In practice it is of course impossible to determine the momentaneous renal 
excretion rate of a drug. Therefore, urine is collected over a finite peri-
od and the mean excretion rate is divided by the plasma concentration 
measured at the midpoint of the collection interval [112] . 
Inulin 
The rate at which a drug will be excreted in the urine is the net result 
of the four renal processes: glomerular filtration, passive back-diffusion, 
and active tubular reabsorption and secretion. If a drug does not under-
go active reabsorption and secretion, its renal excretion rate will be lin-
early related to its plasma concentration and the renal clearance will be 
constant over a wide plasma concentration range. When the drug is fur-
thermore not protein bound and not subject to passive reabsorption (for 
example inulin) its clearance will be equivalent to the glomerular filtration 
rate (Fig. 1.3). 
Glucose and PAH 
The processes of tubular secretion and active reabsorption are princi-
pally nonlinear in nature . Only at relatively low drug concentrations these 
mechanisms can be represented by a constant concentration-independent 
clearance. The classical examples of active tubular reabsorption and 
22 
200
 Γ α ) 
χ 
á 
»Γ 
ΙΛ 
ο 
150 
100 
с 
Ε 
σ> 
Ε 
> 
3 
ÖUU 
_ 600 
с 
E 
I 
I 400 
υ 
с 
s 
s 
о 200 
η 
"b) 
^ 
- \ 
\ 
- \ 
. \ 
~ 
1 ^ 
> — Р А Н 
Inulin 
ι ι I 
ι ι 
100 200 300 400 
pglucose o r Pinulin i™) %) 
Fp A H (mg%) 
3 0 6 0 9 0 120 150 180 
pglucose ^ Pinuiin (mg%) 
FpAH (mg%) 
Fig. 1.3 Renal excretion rates (a) and corresponding clearances (b) of 
РАН, inulin, and glucose as a function of plasma concentrations in humans 
[From reference 119 with permission]. 
secretion are the clearance patterns of glucose and PAH, respectively 
(Fig. 1.3). 
Usually no glucose is present in the urine, but when the plasma glucose 
concentration (P . ) is elevated above about 2 me/ml, the so-called 
glucose a 
treshold value, glucose appears in the urine. As Ρ , is further 
glucose 
raised, tubular reabsorption becomes increasingly saturated until the max­
imum rate of reabsorptive transport is reached. From this point the clear­
ance is constant and equal to the glomerular filtration rate, since glucose 
is practically not bound to plasma proteins. 
It is apparent from Fig. 1.3 that the renal excretion rate and clearance 
of PAH at low plasma concentrations are much greater than those of 
inulin, i . e . , PAH undergoes net secretion. In fact, tubular secretion is 
so efficient under these conditions that nearly all PAH is removed from 
the blood as it passes through the kidney. In man, the clearance is 600 -
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700 ml/min and approximately 909o of the total renal plasma flow. Correc-
tion of this value for hematocrit gives the effective renal blood flow. 
Although PAH is hardly bound to plasma proteins, extraction is never 
complete since always some blood passes directly from the glomerular cap-
illaries into the medulla, thus escaping from clearance in the proximal 
tubules [95] . As the plasma concentration of PAH in plasma is increased 
the secretory system becomes saturated and renal clearance falls toward 
the level of the glomerular filtration rate. Ideally, the renal clearance of 
PAH can be described in terms of concomitant glomerular filtration and 
tubular secretion. However, there is evidence that PAH may undergo 
some tubular reabsorption [4,23], and in several species, including man, 
PAH is metabolized during transit through the kidney [35,45,80]. 
Intrarenal metabolism should always be taken into consideration, because 
it can have far-reaching consequences for the excretory pattern of the 
parent compound. 
1.4 MECHANISMS OF ANION SECRETION 
Experimental Techniques 
From renal clearance studies an overall impression of the occurrence 
and kinetics of carrier transport can be obtained. Interaction studies 
may also provide evidence for the existence of carrier transport. In this 
respect special reference should be made to probenecid, a drug developed 
almost fourty years ago to inhibit penicillin secretion, because of the 
scarce availability of the antibiotic in those days [13] . Ever since, 
probenecid has been the standard inhibitor in studies directed at the 
tubular secretion of anionic drugs . 
For more detailed studies on the selectivity, localization, and energetics 
of the carrier systems obviously more sophisticated experimental methods 
are required. A number of in vivo and in vitro techniques [139] has been 
employed to study the sequence of movement of organic anions through 
the proximal tubular cells. Especially the relatively new technique of iso-
lated renal plasma membrane vesicles has proven to be of great value for 
the study of transport mechanisms at specific membrane sites. Most stud-
ies have been carried out with a prototype of secreted anions, i . e . , PAH 
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[106] . The picture of transtubular organic anion transport that emerged 
from these investigations is summarized in Fig. 1.4. 
lumen I peritubular 
probenecid 
-5mV • 70mV OmV 
Fig. 1.4 Schematic model for proximal tubular transport of 
p-aminohippurate (PAH). PAH is actively transported at the basolateral 
membrane by a sodium gradient-dependent anion exchange mechanism. The high 
in t race l lu lar PAH concentration provides a driving force for the f ac i l i -
tated diffusion across the brush border membrane. This step occurs ei ther 
via an anion exchange mechanism or a (gated) channel. PAH transport across 
both membranes is probenecid-sensitive. 
Membrane Transport 
The initial step in tubular secretion involves the carrier-mediated 
uptake of PAH from the interstitial fluid across the peritubular (basolat-
eral) membrane into the proximal tubular cell. This transport step is 
active since PAH is taken up against an electrochemical gradient to 
achieve intracellular concentrations up to 30 times higher than those in 
the extracellular fluid. There is abundant evidence to indicate that PAH 
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transport is coupled to the transmembrane sodium gradient. However, 
recent studies with basolateral membrane vesicles have shown that this 
sodium-coupled mechanism can be stimulated additionally by an opposing 
anion gradient, suggesting a sodium gradient-stimulated anion exchange 
mechanism [33,67,115]. 
The movement of PAH out of the coll across the brush border membrane 
into the tubular lumen occurs by carrier-mediated (facilitated) diffusion, 
a process which can be considered as passive in the sense that the sub-
stance is transported down its electrochemical gradient. Recent studies 
strongly support the involvement of an anion exchange mechanism in the 
brush border membrane, but there are also indications for a (gated) 
channel that mediates the movement of PAH out the cell [55,64,106,110]. 
At present it is not clear whether both types of transport proceed via a 
single carrier or whether distinct carriers are involved. 
The PAH transport system in the brush border membrane has a lower 
affinity but higher capacity than the transport system in the basolateral 
membrane. Both transport systems are competitively inhibited by 
probenecid, but the basolateral membrane system is more susceptible to 
inhibition [69,115]. 
1.5 KINETIC MODELING OF TUBULAR SECRETION 
Classical Pharmacokinetics 
In classical pharmacokinetics renal clearance is considered as a process 
operating directly from the central compartment. It is assumed implicitly 
that an equilibrium exists between the concentrations of drug in plasma 
and urine. However, this assumption is only valid in some special cases. 
Especially when carrier-mediated transcellular transport is involved, a 
simple equilibrium between plasma and urine is unlikely on theoretical 
grounds. For example, experiments on plasma kinetics and renal excretion 
of iodopyracet in the dog revealed that the classical Michaelis-Menten 
approach is unable to cover the pharmacokinetic profile of this compound. 
The main reason is that the equilibrium assumption is not valid for 
iodopyracet and other drugs that are eliminated by tubular secretion so 
rapidly that at low plasma concentrations the rate of excretion becomes 
limited by the renal plasma flow. 
26 
Physiologically Based Modeling 
The limitations of classical pharmacokinetics have led to the need for a 
more physiological approach. Recently, a prototype of a new generation of 
physiologically based pharmacokinetic models was proposed, in which the 
kidney is set apart as a subsystem containing several compartments, 
e . g . , plasma, glomerular, tubular as well as luminal compartments 
[49,50]. With such a model the transport systems can be accomodated at 
the exact site where they are operating. By using this type of kinetic 
modeling it appeared possible to describe the excretion kinetics of iodopy-
racet in a consistent way. It has been shown that the flow-dependent 
profile is just a limiting case of this general approach, whereas also the 
Michaelis-Menten equilibrium state follows directly from the model [49]. 
Furthermore, the models appeared to be useful in the characterization of 
drug interactions at the level of tubular secretion [50,113,114]. 
1.6 SPECIFICITY OF ORGANIC ANION SECRETION 
One of the remarkable characteristics of the renal organic anion system 
is that it accepts compounds with a tremendous diversity in chemical 
s tructure. A wide variety of drugs and their metabolites as well as 
numerous endogenous substrates are excreted by the kidney by tubular 
secretion. A list with a number of representative compounds is given in 
Table 1.1. 
A considerable effort has been made, particularly by Despopoulos [27] 
and M0Uer and Sheikh [90], to elucidate the structural features necessary 
for t ransport . However, none of these attempts have led to a comprehen-
sive model accounting for all the s t ructures that are accepted by the 
anion system. Recently, Ullrich and coworkers [141,142] showed that an 
organic backbone and a negative charge are in fact sufficient for affinity 
to the PAH transport system in the basolateral membrane. It has been 
suggested that this apparent lack of substrate specificity, which is 
unusual for carrier-mediated processes, stems from multiple transport 
systems with overlapping structural specificities [8,51,140]. However, at 
the present time evidence for this hypothesis is not conclusive. 
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Table 1.1 Examples of compounds which are excreted by the renal organic 
anion transport system. 
Endogenous Compounds 
Aromatic amino acids [159] 
Bile salts [9,165] 
Bilirubin [A] 
Cyclic AMP [15,25] 
Cyclic GMP [15,25] 
Fatty acids [6,7] 
Hydroxyindoleacetate [47] 
Oxalate [40,156] 
Prostaglandins [14,60,107] 
Urate [75,104,105] 
Drug Metabolites 
Acetylated sulfonamides [1,120, 
145,146] 
N-Acetylcysteine conjugates [59,91, 
94,118,127] 
Gentisate [152] 
Glucuronide conjugates [78,87, 
116,133] 
Glutathione conjugates [74,76, 
91,94] 
Glycine conjugates [72,73,92, 
130,161] 
Pyrazinoate [34,153] 
Sulfate conjugates [30,149] 
Drugs 
Acyclovir [89] 
Acetazolamide [150] 
Azidothymidine [71] 
p-Aminohippurate [46,106] 
p-Aminosalicylate [56] 
Benzoates [152] 
Bumethanide [107,128] 
Cephalosporins [58,65,70,138] 
Captopril [28,29,123] 
Cisplatin [22,61] 
Diatrizoate [93] 
Diflunisal [3] 
Diodrast [93] 
Ethacrynic acid [98] 
Furosemide [17,97,98] 
Gossypol [36] 
Hippuran [88,129] 
Ibuprofen [143] 
Indomethacin [2,126] 
lodipamide [12,88] 
lothalamate [100] 
Methotrexate [16,79] 
Nitrofurantoin [102,148] 
Penicillins [10,11,31,65,125] 
Phenolsulfonphthalein [37,96] 
Phenylbutazone [43,152] 
Piretanide [99] 
Probenecid [26,151] 
Quinolones [147] 
Salicylate [15,42,116] 
Saccharin [38] 
Sulfinpyrazone [77,103] 
Sulfonamides [53,65,101] 
Thiazides [157] 
Thymidine [164] 
Trimethoprim [20,21] 
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1.7 CLINICAL IMPLICATIONS OF ANION SECRETION 
Tubular secretion is an important process in the renal handling of many 
drugs, and may therefore be the basis of a variety of clinical implica-
tions. The presence of tubular secretion is often a vital link in the dispo-
sition and response of drugs with an intratubular site of action ( e . g . , 
diuretics, uricosurics, some antibiotics), especially when these drugs are 
highly bound to plasma proteins [19,39]. 
The organic anion transport system may also play a role in the develop-
ment of nephrotoxicity with compounds that are highly accumulated in the 
proximal tubular cells, thereby exerting a direct toxic effect. A clinically 
important example is cephaloridine [137], and it has been suggested that 
the acute renal failure that is sometimes seen with renal contrast agents, 
is also a consequence of very high intracellular drug concentrations [57] . 
Since carrier-mediated processes are involved in organic anion secre-
tion, there will be the potential problems of saturation and competition. 
Saturation of tubular secretion invariably leads to a decrease of the total 
body drug clearance and consequently, to a risk of unwanted drug accu-
mulation in the body [18] . Drug interactions at the level of tubular 
secretion have been described many times. In principle, all compounds 
listed in Table 1.1 have the potential to compete with each others tubular 
secretion. For instance, it has been reported that several drugs are able 
to increase the half-life of penicillin in man [66] . An interaction with life-
threatening consequences has been described recently between methotrex-
ate and non-steroidal anti-inflammatory drugs [68,81,122,134]. Also 
interactions between drugs and endogenous substances may have clinical 
consequences, e . g . , the interaction with urate t ransport . 
Evidently, a proper understanding of the processes of tubular secretion 
and the renal handling of drugs in general, is a prerequisite for well-
considered drug prescribing. 
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CHAPTER 2 
QUANTITATIVE URINE COLLECTION IN RENAL CLEARANCE 
STUDIES IN THE DOG1 
Frans G.M. Rüssel, Alfons С. Wouterse, Peter Hekman, Gerry J . 
Grutters , and Cees A.M. van Ginneken 
Abstract - A double-walled urinary catheter is described which allows 
rapid and quantitative urine collection at short time intervals. The 
r 
catheter consists of a polyurethane outer cannula in which a small Teflon 
cannula is inserted. The essential of the catheter is that at the end of a 
collection period residual urine in the bladder can be collected completely 
via the outer cannula by flushing the bladder with physiological salt 
through the inner cannula. In this manner urine can be collected in a 
very reproducible way at intervals down to 5 min. The use of the 
catheter was illustrated in a study on the renal clearance of hippuric acid 
in the dog. Plasma concentration and renal excretion rate were followed 
after i.v. injection of 0.9 g sodium hippurate. In accordance with previ­
ous studies, it was found that the renal excretion of hippuric acid con­
sisted of glomerular filtration and active tubular secretion. A large vari­
ability was observed in the tubular transport maximum (3800 - 11600 
Vg/min) and the Michaelis-Menten constant (22 - 190 ug/ml), which were 
used to characterize the secretory system. The interpretation and value 
of these transport parameters is discussed briefly. 
Published in: J . Pharmacol. Methods 17, 125-136 (1987). 
Central Animal Laboratory, University of Nijmegen 
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2.1 INTRODUCTION 
Renal clearance is one of the major routes of elimination of drugs and 
their metabolites in the living organism. Especially when renal clearance 
contributes significantly to the total elimination of a drug, knowledge of 
the basic processes that determine transport is of great importance with 
relation to the duration and extent of effects and side-effects of the 
drug. The mechanisms that contribute to the renal excretion of a drug 
are directly related to the physiology of the kidney, but win also depend 
upon the plasma protein binding and upon the physicochemical properties 
of the substance. From a kinetic point of view four different transport 
processes can be distinguished, viz., glomerular filtration, passive back 
diffusion, active tubular secretion, and active tubular reabsorption [1]. 
Glomerular filtration and back diffusion can be considered as passive pro-
cesses in which the transport rates are linearly related to the plasma 
drug concentration. Active secretion and active reabsorption are carrier-
mediated processes; they are characterized by saturability and suscepti-
bility to competition by structurally related compounds. 
In pharmacokinetics the parameter clearance is used to describe the loss 
of drug across an eliminating organ. The kidney takes a privileged role 
in organ clearance studies in that it is the only organ that allows rela-
tively easy and direct sampling at the site of excretion without invasive 
methods. The renal clearance of a drug is defined as the ratio of renal 
excretion rate over the plasma concentration at the same time. In practice 
urine is collected over a finite period and the mean excretion rate is esti-
mated by dividing the amount excreted in the sample by the time interval. 
The appropriate plasma concentration is determined at the midpoint of the 
urine collection interval, assuming that the plasma concentration changes 
linearly with time. It is obvious that this will practically never be the 
case and that the assumption of linear change is only valid for small col-
lection intervals. This implies that an accurate determination of the course 
of renal drug clearance, especially when carrier-mediated processes are 
involved, requires quantitative collection of the urine produced during 
short time intervals. 
Several techniques were described for the collection of urine from mam-
mals, including surgical procedures in which one or both ureters are can-
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nulated [2-5] In the noninvasive methods urine is usually collected 
through a single-walled cannula that is brought into the bladder via the 
urethra A major disadvantage of such a catheter is that it can give rise 
to incomplete emptying of the bladder, especially when the sampling inter­
vals need to be small This causes contamination of the urine sample with 
residual urine from the foregoing collection interval, and incorrect estima­
tions of urine flow and renal excretion rate will be the result In this 
paper a double-walled urinary catheter is described which allows quantita­
tive urine sampling at intervals down to 5 mm During a collection period 
it is used as a conventional catheter through which the produced urine 
flows constantly via the outer cannula The essential point is that at the 
end of a collection period, the residual urine in the bladder now can be 
collected completely by rinsing the bladder with a measured amount of 
physiological salt through the inner cannula The usefulness of the 
catheter is demonstrated on the basis of a study on the renal clearance of 
hippunc acid in the dog 
2.2 MATERIALS AND METHODS 
Materials 
The Braunule Τ cannulas were obtained from Braun (Melsungen, FRG), 
the double-walled urinary catheter (URO 90 009) from Talas (Ommen, The 
Netherlands) The infusion sets used were from Medica (Den Bosch, The 
Netherlands) and were equiped with a disposable Dial-a-flow from Abbott 
(Amstelveen, The Netherlands) to adjust the flow Urinary pH was mea­
sured with a Sensorex pH electrode, Sensorex (Westminster, USA) Blood 
was withdrawn into heparmized 10 ml Monovettes from Sarstedt (Eind­
hoven, The Netherlands) Sodium hippurate was purchased from British 
Drug Houses Ltd (Poole, England), LiChrosorb RP18 and salicyluric acid 
from Merck (Darmstadt, FRG), sodium pentobarbital from Apharma (Arn­
hem, The Netherlands), heparin from Organon (Oss, The Netherlands), 
atropine sulphate, mannitol and inulin from Ο Ρ G (Utrecht, The Nether-
® lands). Hibitane from ICI HoUand (Rotterdam, The Netherlands), 
Albipen from Gist Brocades (Delft, The Netherlands), Aqualuma plus 
from Lumac (Schaesberg, The Netherlands), [3H]inulin (1 59 Ci/mmol) 
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from The Radiochemical Centre, Amersham (Buckinghamshire, England), 
and Visking 8 dialysis tubing from Instrumentenhandel Z.H. (Den Haag, 
The Netherlands). All other chemicals were of analytical grade and were 
purchased from Merck (Darmstadt, FRG). 
Analytical Methods 
Hippuric acid (HA) was determined in plasma and urine by high perfor­
mance liquid chromatography. A Hewlett Packard 1084B was used equipped 
with a variable wavelength detector, autosampler and terminal (HP 7850 
LC). The stainless-steel column (150 χ 4.6 mm I D . ) was packed with 
LiChrosorb RP-18, particle size 5 vm. The mobile phase consisted of a 
mixture of methanol and twice-distilled water (30:70) containing 0.01 M 
citrate (pH 2.6) and was delivered at a rate of 1.0 ml/min. The column 
temperature was 400C and the detector wavelength was set at 245 nm. 
Under these conditions the retention times of HA and the internal stan­
dard salicyluric acid were 3.3 and 5.5 min respectively. 
Into a screw-capped extraction tube 1.0 ml plasma, 100 yl internal stan­
dard solution (500 vg/ml in methanol) and 5.0 ml methanol were pipetted. 
After shaking for 1 min, the tube was centrifuged for 15 min at 2000g. 
The supernatant was transferred into another test tube and evaporated to 
dryness at 30°С with dry filtered air. The residue was redissolved in 1.0 
ml of the mobile phase and 10 yl was injected into the column. To 100 μΐ 
of the urine samples 100 μΐ internal standard and 800 yl mobile phase were 
added, after which 10 yl was injected into the HPLC system. The HA 
concentration in plasma and urine was determined by comparing the peak 
area ratio of HA and internal standard with a standard curve of peak 
area ratio versus HA concentrations spiked to blank plasma and urine. 
Linear calibration curves were obtained in all cases. 
Concentrations of [3H]inulin in plasma and urine were estimated in a 
Packard 3370 liquid scintillation counter. Samples of 0.5 ml plasma or 
urine were placed in a 20 ml counting vial and 10 ml scintillation fluid 
(Aqualuma plus) was added. Quench correction of samples was carried out 
using the channels-ratio method. 
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Fig. 2.1 Experimental setup for the quant i tat ive col lect ion of urine. The 
double-walled catheter (C) is provided at the t i p with four perforations 
(a) to prevent obstruction by the bladder wall. When the catheter is 
brought into the bladder the inner cannula (B) is pushed forward, so that 
the t i p st icks out of the outer cannula (b). Urine flows through the outer 
cannula via a perspex v ia l with a pH electrode (D) into a measuring glass. 
The bladder is flushed through the inner cannula with a p las t ic syringe 
placed in a hand-operated gun (A). 
Urinary Catheter 
For the quantitative collection of urine samples, a double-walled 
catheter was developed in our laboratory. The catheter consists of 
Polyurethane outer tubing having a length of 45 cm (2 mm I.D. χ 3 mm 
O.D.) and a 70 cm long inner cannula of Teflon (0.5 mm I.D. χ 1.0 mm 
O.D.) (Fig. 2.1С). The outer cannula is provided at the tip, over a 
distance of 5 cm, with four perforations having a diameter of approxi­
mately 3 mm (Fig. 2.1a,b). In this manner variations in urine flow caused 
by obstruction of the catheter by the bladder wall is prevented. The 
inner cannula is attached to a 60 ml plastic syringe and is inserted in the 
outer cannula through an Y-shaped connection sealed with silicone rubber 
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(Fig. 2.1B). Through this cannula the bladder can be rinsed at the end 
of a urine collection period. To ease this flushing procedure the syringe 
is placed in a hand-operated gun, obtained from a local tool shop, which 
is usually used for the application of plastic sealant (Fig. 2.1A). The 
voided urine flows through the outer cannula in a perspex vial in which a 
pH electrode fits (Fig. 2. ID). Finally, the urine is collected and the 
volume is measured. 
Clearance Experiments 
Male Beagle dogs, weighing 12 to 16 kg, were fasted overnight and 
anesthetized by intravenous administration of 30 mg/kg of pentobarbital 
sodium. As premedication, atropine sulfate (0.5%, 1 ml i .v .) was given 
to prevent vagal inhibition of the heart and to reduce salivary and 
bronchial secretions. After induction of anesthesia, the dogs received 
endotracheal intubation and were ventilated with room air using a Harvard 
(model G07) ventilator. The cephalic veins of both forelegs were cannulat-
ed (Braunule T, length 50 mm, Φ 1.0 χ 1.5 mm) for blood sampling and 
drug administration purposes. A constant infusion of 5% mannitol and 
0.5% inulin (2 ml/min) was administered throughout the experiment in 
order to obtain a sufficiently high and constant urine flow. The pH of the 
voided urine was controlled by an infusion of 8.4% sodium bicarbonate at 
a rate (3-8 ml/min) such that the urinary pH remained at a level of 7.0 ± 
0.5. 
Each dog received as an i.v. bolus a solution of 0.9 g sodium hippurate 
in 10 ml water, sterilized by filtration. At regular times throughout the 
experiment blood samples were taken into heparinized tubes. The first 
0.5 ml of a blood sample were discarded in order to fill and rinse the 
dead volume of the cannula (approximately 0.2 ml). Plasma was separated 
by centrifugation for 20 min at 2000g and stored at -20°С until analysis. 
After a blood sample was taken, the collecting cannula was flushed with 
0.5 ml heparin (50 U/ml) in physiological salt to prevent coagulation. 
Urine was collected during the first 50 min of the experiment at 5 min 
intervals, and afterwards at 10 min intervals. The double-walled urinary 
catheter was introduced through the urethra into the bladder using a 1% 
Chlorhexidine gluconate antiseptic cream (Hibitane ) as lubricant. While 
the catheter was inserted, care was taken that the tip of the inner can-
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nula was just inside the outer cannula (Fig. 2.1a). Once inside the blad­
der, the inner cannula was pushed further into the outer cannula so that 
the tip stuck out for about 0.5 cm (Fig. 2.1b). Up to 90 sec before the 
end of a collection period, the produced urine flowed through the outer 
cannula and the urinary pH was constantly measured. At that time the 
bladder was rinsed in about 30 sec with exactly 15 ml of physiological salt 
via the inner cannula. In the remaining 60 sec, the diluted bladder con­
tent was allowed to flow from the bladder through the outer cannula. The 
volume of voided urine and physiological salt was registered, and a sam­
ple was stored at -20°С until analysis. 
After the last blood and urine samples for the determination of HA were 
taken, the glomerular filtration rate was estimated by steady state inulin 
clearance during infusion of [ 3H]inulin. The [3H]inulin was added to the 
5% mannitol and 0.5% inulin infusion resulting in an activity of 0.04 
uCi/ml. At the same time 1 ml of this solution, but with an activity of 3.3 
цСі ['Hlinulin/ml, was rapidly injected. In this manner a constant plasma 
concentration of inulin (approximately 100 yg/ml) was obtained after about 
15 min. During the following 40 min six blood samples were taken and 
urine was collected quantitatively every 5 min. 
At the end of the experiment, the cannulas and the urinary catheter 
® 
were removed, and the dog was allowed to recover. Ampicillin (Albipen 
15%, 0.1 ml/kg) was given subcutaneously to protect against infections. 
The dog was kept in quarantaine until radioactivity of the voided urine 
was less then 1 pCi/ml. Before the dog was used for another experiment, 
at least 3 weeks of recovery were observed. In this way dogs could be 
used many times for an experiment. 
Protein Binding 
Plasma protein binding of HA was determined by ultrafiltration using 
Visking dialysis tubing (flat width, 10 mm; average pore, size 2.4 nm). 
The tubing was cut into pieces of 10 cm and soaked in distilled water for 
1 hour. Excess of water was removed by gentle wiping. One end of the 
tube was knotted, and 2 ml of plasma were carefully pipetted into the 
open end. Then the open end was knotted and the tubes were folded in a 
U-shape into a centrifuge tube. First the water bound to the membrane 
was removed by precentrifugation for 10 min at 1000g. After that the 
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bags were transferred to another tube and centrifuged at 1000g for the 
time required to obtain 150-200 ul ultrafiltrate (approximately 60 mm) 
With this procedure, volume reduction of the plasma sample was less then 
10ο, leaving the protein binding equilibrium almost unaffected No signifi­
cant binding of HA was found to the dialysis membrane. Ultrafiltrates 
wore treated and analyzed in the same way as urine samples were 
Pharmacokinetic Analysis 
Plasma concentration and renal excretion rate curves were fitted sepa­
rately to a linear open two compartment model. Applying statistical 
moments theory, basic pharmacokinetic parameters were estimated [6,7]. 
First the area under the plasma curve (AUG), the area under the first 
moment of the plasma curve (AUMC), and the area under the renal excre­
tion rate curve (AURD) were calculated Total plasma clearance (CL) was 
ft. 
defined as the reciprocal of the AUG normalized for the dose (D): 
CL = D/AUC (2.1) 
The mean residence time was determined as. 
MRT = AUMC/AUC (2.2) 
and the volume of distribution at steady state (V ) was calculated from 
the product of clearance and mean residence time: 
V = CL · MRT (2 3) 
ss 
Renal clearance (CLp) was estimated by the total excretion method, 
AURp AURp 
CLp = CL · = — (2 .4) 
R
 D AUG 
where AURp equals the total amount of the compound excreted 
unchanged. 
The renal excretion process of HA was analyzed m detail by fitting the 
renal excretion rate (RR) as a function of the average plasma concentra­
tion (C) over each urine collection period according to the following equa­
tion: 
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R D = (fu · GFR + ) · С (2.5) 
R
 к
т
 + С 
where fu is the fraction of unbound drug in plasma, GFR is the glomeru­
lar filtration rate determined by inulin clearance, T M is the tubular 
transport maximum and K™ is the Michaclis-Menten constant of the secre­
tion system [8,9]. 
Curve fitting was done by least-squares nonlinear regression analysis in 
which all data were equally weighted, using the computer program 
NONLIN [10] . All values are expressed as mean ± standard deviation 
(SD). 
2.3 RESULTS 
The use of the urinary catheter in clearance experiments is shown 
schematically in Fig. 2.1. To prevent injury of the urethra the hard 
inner cannula was pulled back in the outer cannula while the catheter was 
brought into the bladder. After the catheter was placed in the bladder, 
the inner cannula was pushed forward to allow unhindered rinsing of the 
bladder. This flushing procedure takes not more than 90 sec, namely 
about 30 sec to bring in 15 ml of physiological salt and at most 60 sec to 
recover the saline and residual urine completely from the bladder. Until 
recently the double-walled catheter, which is easy to construct, was made 
by ourselves from the cannulas described. In the meanwhile, the 
catheter has become also commercially available from Talas (Ommen, The 
Netherlands). 
To demonstrate the value of the catheter in clearance studies, the renal 
clearance of hippuric acid (HA) was studied in four dogs. Fig. 2.2 shows 
a representative example of the course of plasma concentration and renal 
excretion rate of HA after i.v. injection in one of the animals. The mea­
sured plasma and urine curves could be described well mathematically by 
a two-compartment open model. All curves were fitted separately to this 
model by nonlinear regression analysis. The relevant pharmacokinetic 
parameters obtained from these fits are given in Table 2.1. The HA was 
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Fig. 2.2 Renal excretion rate and plasma concentration as a function of 
time after rapid i .v. injection of 0.93 g sodium hippurate into dog 1. The 
curves through the experimental data were obtained by f i t t ing the plasma 
and urine data separately to a linear open two compartment model. 
rapidly cleared from the circulation and excreted almost completely (92.0 ± 
7.0%) into the urine. Endogenous HA levels were negligible compared to 
the concentrations obtained in plasma and urine after administration of 
exogenous HA. Deconjugation of the glycine moiety, as was described by 
Quick [11] in the nephrectomized dog, was not observed. Neither in plas­
ma nor in urine could the uncoupled product benzoic acid be detected. 
The glomerular filtration rate (GFR) of each dog was estimated by 
steady state [3H]inulin clearance directly after the HA experiment (Table 
2.1). Preliminary studies, in which the inulin clearance was monitored 
iretion rate-
) Na-hippurate 
75 mg / kg i.v. 
dog 1 
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Table 2.1 Pharmacokinetic parameters characterizing the renal handling of 
hippuric acid. 
Dog 
1 
2 
3 
4 
Mean 
S.D. 
Weight 
(kg) 
12.4 
16.5 
12.0 
13.0 
13.5 
2.1 
Dose 
(g) 
0.93 
0.93 
0.93 
0.94 
0.93 
0.01 
Urine flowa 
(ml/min) 
0.87 
1.11 
0.89 
0.81 
0.92 
0.13 
Urine pH 
7.0 
6.6 
7.0 
7.3 
7.0 
0.3 
GFRb 
(ml/min) 
42 
65 
31 
33 
43 
16 
fub 
0.66 
0.74 
0.79 
0.75 
0.74 
0.05 
MRTb 
(min) 
50 
36 
63 
52 
50 
11 
CLb 
(ml/min) 
60 
100 
54 
63 
69 
21 
•V 
(ml/min) 
59 
88 
52 
53 
63 
17 
V b 
(ml) 
3000 
3600 
3400 
3300 
3300 
300 
Weighted average of all urine samples. 
GFR = glomerular filtration rate determined by inulin clearance; fu = free 
fraction of the drug in plasma; MRT = mean residence time; CL = total plasma 
clearance; CLj, = overall renal clearance; and V = volume of distribution at 
steady state. 
αϊ 
ел 
during the entire experiment, revealed that the GFR remained constant 
throughout the experiment and was not different from the GFR determined 
after the last samples for HA analysis had been taken (Rüssel et a l . , 
unpublished resul ts) . Measurement of plasma protein binding demonstrated 
that the fraction of unbound HA was virtually constant over the concen-
tration range of 5 - 450 yg/ml with an average value of 0.74 (Table 2.1) . 
Urine flow and urine pH were kept as constant as possible throughout the 
experiment. Average values of each experiment are given in Table 2 .1 . 
Fig. 2.3 shows a representative example of the course of urine flow and 
pH during one of the experiments. 
urine flow (m l /m in ) -
2.0-1 
1.5 
1.0 
0.5-
dog 1 
• f l o w 
•pH 
-urine pH 
-8.0 
7.5 
L
"! г — J 
7.0 
6.5 
5 0 100 150 
t ime (min) 
6.0 
Fig. 2.3 Course of the urine flow and urine pH during the experiment shown 
in Fig. 2.2. 
A plot of the renal excretion rate against the plasma concentration, the 
so-called tubular titration curve, is one of the best ways to examine the 
processes that determine the renal clearance of a drug. In Fig. 2.4 such 
a plot is shown for HA in one of the dogs. If only glomerular filtration 
would occur, the plot should yield a straight line representing the prod­
uct of the inulin clearance and the fraction of unbound drug in plasma. 
However, It is clear from Fig. 2.4 that the renal excretion of HA exceeds 
by far the amount that enters the urine by glomerular filtration, which 
also indicates that tubular secretion occurs. The observed excretion pro­
files could be described by the summation of glomerular filtration and 
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Ί 
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75 m g / kg ¡.v. 
dog 1 
10000 
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100 2 0 0 300 
plasma cone. (>ig / ml ) 
Fig. 2.A Relationship between the renal excretion rate and the plasma con-
centration of sodium hippurate after i .v . administration of 0.93 g to dog 
1. The renal excretion process can be described by a combination of 
glomerular f i l t r a t i o n (GF) and tubular secretion (TS). The solid l ine rep-
resents the curve calculated after f i t t i ng the data to Eq. 2 .5 , the dotted 
line ref lects the glomerular f i l t r a t i on of the drug. 
active tubular secretion. Assuming that the tubular secretion of HA con-
forms Michaelis-Menten kinetics and is dependent on the total plasma drug 
concentration, the tubular titration curves were analyzed with NONLIN 
according to Eq. 2 .5 . The results of these fits are summarized in Table 
2.2. 
2.4 DISCUSSION 
In studying the renal handling of drugs , it is of crucial importance that 
the urinary excretion of a drug be measured accurately. Errors may 
arise from incomplete emptying of the bladder after a collection period, or 
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Table 2.2 Tubular transport maximuro (TM) and Michaelis-Menten constant 
(К-) characterizing the active renal secretion of hippuric acid. 
Dog T M ICj. 
(yg/min) (Ug/ml) 
1 6800 ± 500 80 ± 14 
2 4900 ± 300 22 ± 4 
3 3800 ± 400 39 ± 13 
4 11600 ± 1300 190 ± 33 
Data are presented as means + SD 
from too large collection intervals with relation to the changes in renal 
excretion ra te . In this paper a double-walled catheter is described that 
makes it possible to collect urine quantitatively at short intervals in dog 
clearance experiments. The method appears to be highly reproducible 
and allows a very detailed study of the mechanisms that govern renal 
drug clearance. The dog was chosen for the in vivo model because of 
the good physiological resemblance between the human and dog kidney 
[12] . Also, a somewhat larger animal makes it possible to collect a rela­
tively large amount of blood and urine samples. An additional advantage 
of the model is that because of the noninvasive methods the dogs can be 
used several times for different clearance experiments, so that, if 
desired, interindividual variations can be eliminated. 
To illustrate the abilities of the in vivo model, the renal clearance of 
HA was studied. It can be concluded from the experiments that the 
excretion of HA is composed of at least two processes, i . e . , glomerular 
filtration and active tubular secretion. These results are in good agree­
ment with previous studies [13-15]. Passive reabsorption by nonionic 
diffusion is very unlikely under the experimental circumstances, because 
of the high urine flow and the high urinary pH compared to the dissocia­
tion constant of HA (pK = 3.80). The HA is cleared almost completely 
via the kidney without further metabolism. A small part of the dose is 
eliminated extrarenally, presumably via the liver. A possible deglycina-
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tion reaction could not be detected and will be also very improbable, 
because such a reaction was only described to occur under very unphysi-
ological conditions [11]. 
Quantitative analysis of the active tubular secretion of HA revealed that 
there is a considerable interindividual variability in affinity and transport 
capacity. The tubular transport maximum (T..) ranged from 3800 to 11600 
Vg/min (21 - 65 ymol/min) and the Michaelis-Menten constant (K~,) from 22 
to 190 pg/ml (0.12 - 1.06 mM). Comparable intersubject variations were 
also observed by Knoefel and Huang [13] . In this context, it should be 
emphasized that the characterization of the excretion process of HA by 
Eq. 2.5 is merely an operational one. Several factors that are of influ­
ence on the carrier-mediated transport, e .g . , protein binding, actual 
drug concentration at the site of transport, cellular retention e t c . , are 
not taken into consideration in this approach [16]. Therefore, the 
parameters T M and K^ found in this way have to be looked upon as 
apparent constants. In order to account for all the typical features con­
cerning the renal handling of drugs, more physiologically based pharma­
cokinetic models are required [17,18]. In a forthcoming paper attention 
will be paid to the use of these models to come to a comprehensive under­
standing of renal transport mechanisms of drugs in the described dog 
model. 
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PART II 
PHYSIOLOGICALLY BASED KIDNEY MODEL 
A picture of reality drawn in a few 
sharp lines cannot be expected to be 
adequate to the variety of all its shades. 
Yet even so the draftsman must have the 
courage to draw the lines firm. 
Hermann Weyl 

CHAPTER 3 
RENAL CLEARANCE OF PHENOLSULFONPHTHALEIN AND THE 
INTERACTION WITH PROBENECID AND SALICYLURIC ACID1 
Frans G.M. Rüssel, Alfons С. Wouterse, and Cees A.M. van Ginneken 
Abstract - Plasma kinetics and renal excretion of intravenous phenolsul-
fonphthalein (PSP, 1.0 g), with and without concomitant administration of 
probenecid or salicyluric acid (SUA), were studied in the Beagle dog. 
Pharmacokinetic analysis revealed that tubular secretion is the predomi­
nant route of excretion, and that secretion is inhibited by probenecid and 
SUA. A physiologically based kidney model was developed that incorpo­
rates the functional characteristics of the kidney that determine the 
excretion of PSP, i . e . , renal plasma flow, urine flow, nonlinear protein 
binding, glomerular filtration, tubular secretion and tubular accumulation. 
The model enabled an accurate description and analysis of the measured 
plasma levels and renal excretion rates. The interaction with probenecid 
and SUA could be adequately described with the model by inhibition of 
the carrier-mediated uptake of PSP into the proximal tubular cells. How­
ever, both compounds clearly differed in their inhibitory action. Whereas 
probenecid showed simple competitive inhibition, for SUA a considerably 
more complex interaction (two-site competitive system) had to be taken 
into consideration. Especially in the interaction experiments, only satis­
factory fits to the model were obtained when secretion was assumed to be 
dependent on unbound PSP concentrations. Model calculations showed that 
in the control experiments tubular secretion was accompanied by a pro­
nounced accumulation of PSP within the proximal tubular cells, which was 
Published in: J . Pharmacokinet. Biopharm. 15, 349-368 (1987). 
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clearly diminished in presence of probenecid or SUA. The predicted accu-
mulation ratios were in good agreement with previous studies. 
3.1 INTRODUCTION 
Phenolsulfonphthalein (PSP) is an indicator dye that is actively secreted 
by the proximal tubules of the kidney. Ever since evidence was obtained 
for its tubular secretion [1], PSP has been studied extensively as a model 
substrate for the renal organic anion transport system. The first step in 
secretion involves active transport at the basolateral membrane into the 
tubule cell, followed by a less efficient transport across the brush-border 
membrane into the tubular fluid. The slower transfer to the lumen conse-
quently contributes to transient intracellular accumulation and retention of 
the compound. 
Binding of PSP to plasma albumin has been reported to limit the extent 
of secretion [2-4] . This is one reason that, compared to p-aminohippurate 
(PAH), a smaller fraction of PSP is extracted at low concentrations from 
renal plasma during a single passage through the kidney. Also a less 
efficient interaction with the tubular secretory system and a possible 
reabsorptive component, observed in experiments with rabbits [5], may 
contribute to the lower extractability of the dye. 
Renal excretion of PSP is susceptible to inhibition by other organic 
anions such as PAH [6], iodopyracet [7], and probenecid [8] . On the 
other hand, PSP has little influence on the tubular secretion of PAH and 
iodopyracet [6] . How these findings should be interpreted is still not 
clear, but they certainly suggest a functional heterogeneity of the organic 
anion transport system. This hypothesis is further supported by the 
observation that kidney tubules of Necturus are unable to transport PSP 
whereas they readily excrete PAH [9]. 
It is well established that the primary site of inhibition of secretion of 
one organic acid by another is at the level of active uptake across the 
basolateral membrane. But detailed information on the precise nature of 
inhibition is scarce and not always in common agreement. For instance, 
probenecid is generally regarded as a competitive inhibitor of organic 
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anion secretion [10]. However, for its effect on PSP excretion competi­
tive [8] as well as noncompetitive inhibition [11] was reported. Further­
more, in a previous study on the effect of probenecid on the secretion of 
salicyluric acid (SUA) we observed also a noncompetitive type of interac­
tion [12]. 
The purpose of the present study was twofold. First, to develop a 
physiologically based model, as accurate but also as simple as possible, 
that is able to quantify the relevant processes of renal PSP excretion. 
This kidney model, based on previous described models [12,13], incorpo­
rates the important features of transtubular transport and nonlinear pro­
tein binding. Second, to characterize the interaction of probenecid and 
salicyluric acid on PSP excretion with the aid of this model. 
3.2 MATERIALS AND METHODS 
Materials 
The Braunule Τ cannulas were obtained from Braun (Melsungen, FRG), 
the double-walled urinary catheter (URO 90.009) from Talas (Ommen, The 
Netherlands). Blood was withdrawn into heparinized 10 ml Monovettes 
from Sarstedt (Eindhoven, The Netherlands). Phenolsulfonphthalein, sali­
cyluric acid, indo]e-3-acetic acid, and LiChrosorb RP18 were from Merck 
(Darmstadt, FRG), probenecid from Sigma (St. Louis, Mo.,USA), sodium 
pentobarbital from Apharma (Arnhem, The Netherlands), heparin from 
Organon (Oss, The Netherlands), atropine sulphate, mannitol, and inulin 
from O.P.G. (Utrecht, The Netherlands). Albipen from Gist Brocades 
(Delft, The Netherlands), and Visking 8 dialysis tubing from Instru­
mentenhandel Z.H. (Den Haag, The Netherlands). All other chemicals 
were of analytical grade and were purchased from Merck (Darmstadt, 
FRG). 
Clearance Experiments 
Male Beagle dogs, weighing 10 to 16 kg, were fasted overnight and 
anesthetized by intravenous administration of 30 mg/kg of pentobarbital 
sodium. As premedication atropine sulphate (0.5%, 1 ml i .v .) was given. 
The dogs were intubated and ventilated using a Harvard (model G07) ven-
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tilator. The cephalic vein of both forelegs was cannulated (Braunule T, 
length 50 mm, φ 1.0 χ 1.5 mm) for blood sampling and drug administration 
purposes. A constant infusion of 50o mannitol and 0.5oo inulin (2 ml/min) 
was administered throughout the experiment in order to obtain a suffi­
ciently high and constant urine flow. In this way the pH of the voided 
urine remained fairly constant at a level of 7.0 ± 0.8. Each dog received 
as an i.v. bolus a sterile solution of 1.0 g PSP dissolved in 15 ml water 
containing an equimolar amount of sodium bicarbonate. In a second exper­
iment, using the same dogs, 1.0 g PSP was given after SUA or 
probenecid preadministration. In case of SUA treatment the dogs 
received 30 min prior to injection of PSP a priming dose of 300 mg (59o in 
aqueous sodium bicarbonate, 6 ml i .v.) followed by a constant infusion of 
a 2.5% solution at a rate of 3 ml/hr (dogs 2 and 3) or a 5% solution at 5 
ml/hr (dog 1). Probenecid treatment (dogs 4, 5, and 6) involved a prim­
ing dose of 75 mg (2.b0ó in aqueous sodium bicarbonate, 3 ml i .v . ) at 
t=-30 min, followed by constant infusion of a 0.5oo solution at a rate of 5 
ml/hr. At regular times throughout the experiment blood samples were 
taken into heparinized tubes. Plasma was separated by centrifugation for 
20 min at 2000g and stored at -20°C until analysis. Urine was collected 
quantitatively with a double-walled urinary catheter [14] at 5 min inter-
vals during the first 100 min of the experiment, and afterwards at 10 min 
intervals. The diluted urine samples were stored at -20°С until analysis. 
At the end of the experiment the cannulas and the urinary catheter were 
® removed, and the dog was allowed to recover. Ampicillin (Albipen 15%, 
0.1 mg/kg) was given subcutaneously to protect against infections. Before 
the dog was used for the second experiment at least 3 weeks of recovery 
were observed. 
Spectrophotometric Assay 
Concentrations of PSP were determined in plasma and urine according to 
the method of Ochwadt and Pitts [2] . Plasma samples (500 μΐ) were 
extracted with 2.0 ml acetone by shaking for 15 min. After centrifugation 
for 10 min at 2000g, 0.2 ml IN sodium hydroxide solution was added to 
2.0 ml of the clear supernatant, and absorbance was read at 54G nm. The 
diluted urine samples could be measured directly after alkalinization with 
sodium hydroxide as described above. Inulin was assayed according to the 
G8 
method of Heyrovski [15]. After hydrolysis to fructose and reaction with 
indole-3-acetic acid in hydrochloric acid (32co w/w) absorbance was mea­
sured at 515 nm. 
HPLC Assay 
SUA and probenecid were determined by high-performance liquid chro­
matography (HPLC). Both procedures were described in detail previously 
[12,16]. A Hewlett Packard 1084B was used equipped with a variable 
wavelength detector, autosampler and terminal (HP 7850 LC). The 
stainless-steel column (150 χ 4.6 mm I .D.) was packed with LiChrosorb 
RP-18, particle size 5 μπι. Peak area ratios using an internal standard 
were calculated for calibration and quantification purposes. 
Protein Binding 
Plasma protein binding of PSP was determined by ultrafiltration using 
Visking dialysis tubing (flat width 10 mm, average pore size 2.4 nm). 
Plasma (2.0 ml) was pipetted into the tubes that were folded in a U-shape 
into a centrifuge tube. Membrane-bound water was removed by preccn-
trifugation for 10 min at lOOOg. After that, the bags were transferred to 
another tube and centrifuged at lOOOg for 60 min, yielding about 150 μΐ 
ultrafiltrate. Binding of PSP to the dialysis membrane was negligible. 
The ultrafiltrates were treated and analyzed in the same way as the urine 
samples. Assuming one class of binding site plasma protein binding was 
analyzed with the aid of the computer program NONLIN [17] according to 
the following equations, derived from the mass-action law: 
С = Cu + P«Cu/(Kd + Cu) (3.1) 
Cu = fuC (3.2) 
where С is the total plasma drug concentration, Cu the unbound drug 
concentration in plasma, fu is the fraction of drug in plasma unbound, Ρ 
is the total concentration of protein binding sites, and Κ , is the dissocia­
tion constant of the drug-protein complex. Average values are expressed 
as mean ± standard deviation (SD). 
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Pharmacokinet ic Analysis 
Plasma c o n c e n t r a t i o n time c u r v e s could be f i t ted well to t h e sum of two 
exponent ia l equat ions (NONLIN), whereas r e n a l e x c r e t i o n r a t e - t u n e c u r v e s 
were analyzed employing t h e log-trapezoidal ru le [18] Applying s ta t i s t ica l 
moments t h e o r y , bas ic pharmacokinet ic p a r a m e t e r s were calculated 
[19,20] T h e a r e a u n d e r t h e plasma curve (AUG) was calculated by d i r e c t 
i n t e g r a t i o n T h e a r e a u n d e r t h e rena l e x c r e t i o n r a t e c u r v e ( A U R ^ ) , a n d 
the a r e a u n d e r the f irst moment of th is c u r v e (AUMR-n) were es t imated 
from 0 to tune t by means of t h e log-trapezoidal r u l e a n d ext rapolat ion to 
infinity u s i n g t h e terminal p h a s e of t h e plot 
t R R ( t ) A U R R = / R R d t • (3 3) 
z , u r 
t - I U , ( t ) R R ( t ) 
A U M R T , = rt'R-o d t + — + — , (3 4) 
ζ,иг
 (z,ur> 
w h e r e R ^ f t ) is t h e las t m e a s u r e d rena l e x c r e t i o n r a t e at tune t a n d λ 
R v ' z , u r 
is t h e terminal elimination c o n s t a n t determined by leas t s q u a r e s r e g r e s s i o n 
analys i s from t h e log-l inear terminal p h a s e of t h e c u r v e Half-lives of 
PSP in plasma ( t , ) a n d u r i n e (t i ) were obta ined from t h e i r r e s p e c -
tive terminal elimination r a t e c o n s t a n t s Total plasma c learance (CL) a n d 
initial volume of d i s t r i b u t i o n (V-) were calculated u s i n g s t a n d a r d e q u a ­
t ions [21] T h e mean r e s i d e n c e tune was d e t e r m i n e d from t h e moments of 
the r e n a l e x c r e t i o n r a t e c u r v e as 
M R T R = AUMR R /AUR R (3 5) 
Renal c learance (CL,,) was est imated by t h e tota l e x c r e t i o n method, 
n. 
AURp AURp 
CLp = CL · = — (3 G) J R D AUG 
where AUR^ r e p r e s e n t s t h e tota l amount of PSP e x c r e t e d in infinite tune it 
into u r i n e 
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F i g . 3.1 P h y s i o l o g i c a l l y based pharmacokinet ic model for t h e r e n a l c l e a r ­
ance of PSP. See M a t e r i a l s and Methods for exp lanat ion of symbols. 
Kidney Model 
T h e physiologically b a s e d model for t h e r e n a l excre t ion of PSP is Illus­
t r a t e d by t h e diagram in Fig. 3 . 1 . T r a n s p o r t p r o c e s s e s and compartmental 
c o n c e n t r a t i o n s of t h e d r u g can be d e s c r i b e d by t h e following set of e q u a ­
t i o n s : 
Centra l plasma 
d C , 
V l -37 = ( Q R - Q u r > C 2 + k 5 1 V 5 C 5 " « R + C L N R + k 1 5 V l ) C l ^ 3 ^ 
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Renal plasma 
d C 2 T M C u 2 
V 9 — = Q p C i - Qr .pCu, - ( Q B - Q)C 2
 d t - - R - l ^ G F - 1 ^ R " « и г ' - г ^ + C u 2 
(3.8) 
T u b u l a r u r i n e 
d C 3 
^З -^ = Q G F C U 1 + k 4 3 V 4 C 4 - < 5 u r C 3 (3.9) 
T u b u l a r cells 
d C 4 T M C u 
V ? = — -— - к V C 
4
 d t K T • C u 2
 k
«
V 4 C 4 
(3.10) 
P e r i p h e r a l t i s s u e s 
dCn 
V 5 -£ - k 1 5 V l C l - k 5 1 V 5 C 5 (3.11) 
w h e r e , 
V. 
ι 
С. 
ι 
Си. 
1 
к.. 
U 
Q 
Q 
Q n i r 
CL. 
R 
GF 
NR 
M 
Kn 
volume of compartment i (ml) 
total d r u g c o n c e n t r a t i o n in compartment i (ug/ml) 
u n b o u n d d r u g c o n c e n t r a t i o n in compartment i (ug/ml) 
f i r s t - o r d e r r a t e c o n s t a n t associated with movement of d r u g 
from compartment i to compartment j ( m i n - 1 ) 
r e n a l plasma flow (ml/min) 
glomerular f i l tration (ml/min) 
u r i n e flow (ml/min) 
n o n r e n a l plasma c learance (ml/min) 
maximum t r a n s p o r t capaci ty of t h e t u b u l a r 
secret ion mechanism (pg/min) 
Michaelis-Menten c o n s t a n t of t h e t u b u l a r 
secre t ion mechanism (vig/ml) 
T h e r e n a l e x c r e t i o n r a t e (yg/min) in t h i s model is r e p r e s e n t e d by 
H - сз (3.12) 
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and the unbound drug concentration in compartment i can be calculated 
after rearrangement of equations 3.1 and 3.2: 
Cu. - i [ - ( P + Kd - C.) • / ( ( P • Kd - C.)2 + 4KdC.)] (3.13) 
The experimentally observed plasma concentration and renal excretion rate 
curves were simultaneously analyzed with the model described above with 
the aid of the computer program NONLIN. Several weighting factors were 
tested, in most cases 1/C2 gave the best fits. The goodness of fit to the 
plasma concentration and renal excretion rate data was evaluated through 
the deviations between observations and model-predicted values expressed 
as R2 = l-Z(Obs)2 /Z(Dev)2 , where I(Obs)2 is the corrected sum of 
squared observations and I(Dev)2 the sum of squared deviations. 
3.3 RESULTS 
Protein Binding 
Over the concentration range measured (5 - 450 ug/ml) nonlinear plasma 
protein binding of PSP was observed, the fraction unbound increasing 
from 15 - 40% (Fig. 3.2) . Neither probenecid (40 - 120 ug/ml) nor SUA 
(20 - 125 pg/ml) interfered with the binding of PSP. Interindividual 
variation in binding was very small. Therefore, all data (n=74) were 
pooled and analyzed according to Eq. 3 .1 . The binding parameters 
obtained from this fit were 441 ± 31 yg/ml and 123 ± 14 pg/ml for total 
concentration of protein binding sites (P) and dissociation constant (K, ) , 
respectively. 
Pharmacokinetic Analysis 
Representative examples of plasma disappearance and renal excretion 
rate of intravenous administered PSP with or without simultaneous infusion 
of SUA or probenecid are shown in Fig. 3.3. Plasma and urinary data 
were analyzed separately by statistical moment theory. The results of 
these calculations are summarized in Table 3 .1 . Steady-state concentra-
tions of the inhibitors are given in Table 3.2. 
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Fig. 3.2 Effect of probenecid and sa l icy lur ic acid on the plasma protein 
binding of PSP. The line through the data is calculated by Eq. 3.1. 
In the control experiments GG ± 10OÓ of the administered dose was 
excreted unchanged into urine at a renal clearance of 40 ± 7 ml/min. 
Assuming an average protein binding of about 30oo it could be calculated 
from the product with glomerular filtration (Table 3.2) that the contribu-
tion of drug filtration to the total renal clearance was about 9 ml/min. 
Hence, it was obvious that active tubular secretion was the predominant 
route of renal excretion at the given dose. Treatment with probenecid or 
with SUA resulted in a clear reduction of renal clearance. Because 
glomerular filtration and protein binding remained unaffected this effect 
could be fully accounted for by inhibition of tubular secretion. The 
extraction ratio of PSP at low plasma concentrations as calculated from the 
ratio of CLR and renal plasma flow (Table 3.2) was 0.46 ± 0.08. This val-
ue reduced in presence of SUA or probenecid to 0.12 ± 0.05 or 0.20 ± 
0.03, respectively. 
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renal excr rate 
(jug/min) 
2 0 0 0 0 
phenolsulfonphthalein 
dog 6 10 g ι ν 
control 
» probenecid 
1 5 0 2 0 0 250 
time (mm ) 
Fig. 3.3A Renal excretion rate and plasma concentration as function of 
time after rapid i .v. administration of 1.0 gram PSP with or without con­
comitant infusion of probenecid. The solid and broken lines in the fig­
ures represent the results of data analysis according to the kidney model. 
The terminal half-lives in plasma and urine were both clearly extended 
under influence of probenecid or SUA. The MRTR, calculated from the 
renal excretion rate curve, was also increased, although less pronounced. 
It is important to notice that under conditions of nonlinear kinetics, which 
is obviously the case for PSP, the MRTR only represents the mean resi­
dence time of those drug molecules that are excreted via the kidney. 
Although the MRT^ can be calculated irrespective of whether the drug 
has nonlinear disposition kinetics or is eliminated peripherally, it is only 
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renal excr rate 
(,ug /mm ) 
200OO n phenolsulfonphthalein 
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1 4 
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time ( mm ) 
F i g . 3.3B Renal e x c r e t i o n r a t e and plasma c o n c e n t r a t i o n as funct ion of 
time a f t e r rap id i . v . a d m i n i s t r a t i o n of 1.0 gram PSP with or without con­
comitant in fus ion of SUA. The s o l i d and broken l i n e s in t h e f igures r e p r e ­
sent t h e r e s u l t s of d a t a a n a l y s i s according t o t h e kidney model. 
for l inear pharmacokinet ic sys tems t h a t it e q u a l s t h e total mean r e s i d e n c e 
time in t h e b o d y . 
Kidney Model 
In o r d e r to come to a comprehensive u n d e r s t a n d i n g of t h e re lat ion 
between plasma a n d r e n a l e x c r e t i o n kinet ics of PSP a physiologically b a s e d 
pharmacokinet ic model was p r o p o s e d . S t a r t i n g from prev ious ly d e s c r i b e d 
models for t h e act ive r e n a l secret ion of iodopyracet [13] and SUA [12] 
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Table 3.1 Basic pharmacokinet ic parameters of PSP a f t e r rap id i .V. 
i n j e c t i o n of 1.0 gram with or wi thout concomitant a d m i n i s t r a t i o n of 
s a l i c y l u r i c acid (SUA) or probenecid (Prob) . 
plasma u r i n e 
Dog I n h i b i t o r t CL 
(min) (ml/min) 
"1 
(1) 
S.« 
(min) 
60 
78 
60 
90 
58 
83 
54 
47 
38 
60 
52 
61 
MRTR 
(min) 
87 
86 
84 
112 
86 
108 
70 
67 
56 
76 
80 
83 
CLR 
(ml/min) 
32 
14 
32 
27 
41 
24 
39 
37 
44 
26 
49 
30 
SUA 
SUA 
SUA 
Prob 
Prob 
Prob 
40 
99 
46 
66 
46 
83 
44 
54 
42 
66 
48 
54 
42 
27 
46 
44 
55 
36 
75 
62 
78 
52 
74 
67 
1.2 
1.4 
1.5 
1.6 
1.9 
1.7 
2.5 
2.4 
2 .5 
2.0 
2.6 
1.4 
the fea tu res of nonl inear p ro te in b ind ing and t u b u l a r d r u g re ten t ion were 
incorpora ted . A schematic r e p r e s e n t a t i o n of the model is given in 
Fig. 3 . 1 . The k idney is set a p a r t as a subsys t em cons is t ing of a plasma, 
tubu la r cell and t u b u l a r u r ine compar tment . Active t r a n s p o r t of u n b o u n d 
PSP t akes place from rena l plasma into t h e t u b u l a r cell compartment 
accord ing to Michaelis-Menten k ine t i c s , s u b s e q u e n t l y followed b y f i r s t -
o r d e r t r a n s p o r t into the t u b u l a r u r ine compar tment . Al though in the 
control expe r imen t s ac t ive t r a n s p o r t was also propor t iona l to total PSP 
concen t ra t ions , u n b o u n d concen t ra t ions were used because in the i n t e r a c -
tion exper iments with p robenec id and SUA only sa t i s fac tory fits were 
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Table 3.2 Physiological and experimentally found parameters used as 
constants in the kidney model. 
V, Dog Weight Inhibitor Cj Q G F Q u r QR .3
(kg) (Vg/ml) (ml/min) (ml/min) (ml/min) (ml) 
10.0 
13.6 SUA 
12.2 
13.0 
13.7 
13.6 
SUA 
13.9 
15.0 SUA 
Prob 
122±6 
32±9 
22±5 
59±3 
28±4 
32±4 
26±3 
28±2 
30±2 
34±4 
41+3 
43±4 
0.77±0.05 
1.14±0.25 
0.83±0.05 
0.79±0.10 
0.95+0.10 
1.25±0.20 
0.92±0.38 
1.05±0.39 
110 
150 
134 
143 
153 
165 
151 
150 
1.16±0.08 
1.71І0.38 
1.24±0.07 
1.18±0.15 
1.42+0.15 
1.88±0.30 
1.38±0.57 
1.58±0.59 
5 13.2 - - 33±4 0.84±0.26 145 1.26±0.39 
12.5 Prob 120±5 35±5 0.93±0.93 138 1.40+0.29 
6 15.4 
15.7 Prob 45±4 
32±2 0.68±0.19 169 1.02±0.28 
33±3 0.98±0.19 173 1.47±0.28 
Q„ is directly estimated from the body weight (see text), therefore no SD. 
obtained when the tubular secretion was assumed to be dependent on 
unbound concentrations. Glomerular filtration was considered to be 
dependent on unbound drug concentration in the central plasma compart­
ment. To describe the plasma kinetics of PSP completely a tissue compart­
ment was allocated to the central compartment and a first-order clearance 
constant was introduced which represented the extra-renal clearance 
pathway. 
Table 3.2 lists some of the parameters used as constants in the model. 
Q--, was determined by steady-state inulin clearance. For Q_ a value of 
11 ml/min,kg was taken [22]. The volume of the tubular urine compart­
ment (V„) was considered to be dependent on urine flow and renal delay 
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time [23]. Assuming a constant renal delay time (At) of 1.5 min _ was 
calculated as follows: 
V3 = Qu r .At (3.14) 
The values for V1 wore taken from Table 3.1 and for V- an arbitrary 
value of 1 1 was chosen. The remaining constants were estimated from lit-
erature, e . g . , for V? a value of 10 ml [24] and for V. a value of 30 ml 
[25]. 
The model was fitted to the experimental data of the control experiments 
using NONLIN. The results of these calculations are listed in Table 3.3 
and are also represented by the solid lines through the datapoints in 
Figs. 3.3, 3.4 and 3.5. R2 was better than 0.95 in most cases. Figs. 
3.4 and 3.5 are so-called tubular titration curves, in which a direct rep-
resentation of the relationship between renal excretion rate and plasma 
concentration at the midpoint of a urine collection period is given. There 
were no indications for passive reabsorption of PSP, probably due to the 
relatively high urine flows resulting from the infusion with mannitol. 
Effect of Probenecid 
Administration of probenecid resulted in a clear reduction of PSP clear-
ance (Table 3 .1 , Fig. 3.4). As was mentioned before, this could be 
attributed to inhibition of tubular secretion. In accordance with the find-
ings of Sheikh [8] the effect of probenecid was adequately described by 
competitive inhibition of the active uptake of PSP into the tubular cells. 
To quantify this interaction the Michaelis-Menten term in the kidney mod-
el, which describes the carrier-mediated transport from renal plasma into 
the tubular cell compartment, was modified as follows: 
T M C u 2 
(3.15) 
KT(1 + C J / K J ) + Cu2 
where CT is the plasma concentration of the inhibitor, in this case 
probenecid, and KT the inhibition constant for probenecid. Steady-state 
probenecid plasma concentrations that were reached are given in Table 
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Table 3.3 Model parameters characterizing the renal handling of PSP and the 
effect of probenecid and SUA . 
Dog Inhibitor TM 
(mg/min) 
4.4±0.5 
6.5±2.5 
5.3±0.7 
5.3±3.5 
6.3І1.1 
6.513.6 
7.4±1.2 
9.6±5.6 
7.7±1.4 
12.0±4.0 
8.5±1.6 
8.7±4.3 
(Ug/ml) 
8±3 
16±5 
18±6 
30±27 
15±7 
18±12 
19±7 
25±20 
17±7 
26±10 
18±7 
18±13 
KI 
(Vg/ml) 
-
3±2 
-
14±12 
— 
5±3 
_ 
29±23 
-
25±10 
— 
17±12 
CLNR 
(ml/min) 
10±2 
14±2 
14±2 
22±3 
14±2 
12±3 
31±2 
31±2 
40±2 
33±2 
24±2 
37±2 
Чз 
(min-1) 
П 5 
(min-1) 
k51 
(min-1) 
SUA 
SUA 
SUA 
Prob 
Prob 
Prob 
0.19±0.13 0.069І0.004 0.054±0.005 
0.19±0.24 0.071±0.009 0.05710.003 
0.22+0.11 0.04710.003 0.045+0.004 
0.23+0.21 0.111+0.009 0.077+0.008 
0.19+0.10 0.049+0.004 0.05010.007 
0.20+0.15 0.079+0.004 0.06310.005 
0.18+0.06 0.020+0.002 0.031+0.002 
0.17+0.09 0.028+0.002 0.042+0.003 
0.20+0.08 0.014+0.002 0.030+0.002 
0.2010.14 0.062+0.007 0.050+0.002 
0.17+0.06 0.033+0.002 0.039+0.003 
0.16+0.09 0.187+0.007 0.080+0.004 
Standard deviations were calculated for the situation in which plasma 
concentration data were reciprocally weighted (1/C2) and renal excretion rate 
data were equally weighted. 
renal excr. rate 
(jug/min) 
8000-ι phenolsulfonphthalein 
dog 6 1.0g l.v. 
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4 0 0 0 -
2 000-
" Γ 
20 40 60 
unbound plasma cone, ( j u g / m l ) 
Fig. 3.4 Tubular t i t r a t i o n curve representing the relat ionship between the 
renal excretion rate and the unbound plasma concentration after i.V. 
administration of PSP with or without probenecid. The lines through the 
data points are calculated according to the kidney model. GF represents 
the clearance by glomerular f i l t r a t i o n of PSP. 
3.2. Eq. 3.15 was incorporated in the differential equations 3.8 and 3.10 
and the model thus obtained was used to analyze the data of the 
probenecid interaction experiments. Results are summarized in Table 3.3 
and represented by the dotted lines in Figs. 3.3A and 3.4. 
Effect of Salicyluric Acid 
SUA also clearly interfered with tubular secretion of PSP (Table 3.1), 
but the concave tubular titration curves that were observed (Fig. 3.5) 
could not be described in terms of simple inhibition kinetics. A more 
complex type of interaction had to be taken into consideration. A two-site 
competitive system, known from enzyme kinetics as ligand exclusion model 
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[26], was succesfuUy used to describe the interaction of SUA with PSP. 
In this system it is assumed that binding of the inhibitor to a single site 
prevents the substrate from binding to either of two identical sites. 
renal excr rate 
(Ajg/min) 
phenolsulfonphthalein 
dog 1 10g ¡v. 
control 
•salicyluric acid 
8000-, 
6 000-
4 000-
2 000-
40 60 
unbound plasma cone ( jug/ml) 
Fig. 3.5 Tubular titration curve representing the relationship between the 
renal excretion rate and the unbound plasma concentration after i.v. 
administration of PSP with or without SUA. The lines through the data 
points are calculated according to the kidney model. GF represents the 
clearance by glomerular filtration of PSP. 
This interaction is described by the following equation: 
T M ( C U 2 / K T + Cu 2 VK T 2 ) 
1 + 2Cu2 /KT + Cu 2 2 /K T 2 + C J / K J 
(3.16) 
where Cj and Kj are the plasma concentration of SUA (Table 3.2) and the 
inhibition constant, respectively. In absence of the inhibitor Eq. 3.16 
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reduces to the normal Michaelis-Mcnten equation which was also used to 
describe PSP kinetics in the control experiments. Experimental data were 
analyzed after Eq. 3.16 was incorporated into equations 3.8 and 3.10. 
Results are summarized in Table 3.3 and represented by the dotted lines 
in Figs. 3.3B and 3.5. 
3.4 DISCUSSION 
The most important step in the renal clearance of PSP and a wide 
variety of other organic anions is the transepithelial transport from renal 
plasma into urine [27] . Several studies have confirmed that the cells of 
the proximal tubules are responsible for the secretion of these compounds 
[28] . Active tubular secretion is almost always accompanied with transient 
accumulation and retention of the substrate in the cells [29,30]. The 
degree of accumulation is determined by the extent at which these com-
pounds are actively transported across the basolateral membrane into the 
cells and the ease at which they can be transported out of the cells into 
the tubular lumen. 
The separate pharmacokinetic analyses of plasma and renal excretion 
data provide an overall impression of the renal clearance of PSP. The 
results clearly show that active secretion is the predominant route of 
renal elimination and that this transport step can be inhibited by 
probenecid and SUA. However, the parameters obtained from this analy-
sis are mainly of qualitative merit. Because of the nonlinear kinetics of 
PSP all parameters are a function of the administered dose and are depen-
dent on factors that influence the nonlinearity of the system. 
In order to account for the processes that govern the renal excretion of 
PSP in a quantitative and more meaningful manner, a physiologically based 
kidney model was used. New features of the present model are that it 
incorporates nonlinear protein binding and a compartment that represents 
the cells of the proximal tubules. The use of this model enables us to 
describe and analyze the plasma kinetics and renal excretion process of 
PSP in a comprehensive way. Furthermore, the model appears to be very 
useful in the characterization of drug interactions at the level of tubular 
secretion. 
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It is a striking observation that in the interaction experiments only sat­
isfactory fits were obtained when tubular secretion was considered to be 
proportional to unbound PSP concentrations, whereas in control experi­
ments it did not seem to matter much whether bound or unbound concen­
trations were used. The role of protein binding in renal secretion is still 
poorly understood. For several compounds, including PSP, it was report­
ed that protein binding retards tubular secretion to a certain extent 
[2-4,31-33]. On the other hand, there are examples of other compounds 
for which protein binding is not a limitation in secretion [7,34,35]. The 
determining factors in this respect are the rate of dissociation of the 
drug-protein complex, the transit time through the peritubular capillaries, 
diffusion into the cortical interstitium, and the affinity for the transport 
system. Apparently, the affinity of PSP for the secretory system relative 
to the other factors is not large enough to give a complete extraction 
from the plasma in a single passage through the kidney. The extraction 
ratio of PSP at low plasma concentrations was about 0.5. This is in 
agreement with previously reported values of 0.7 [36] and 0.5 [37] in the 
dog. Although the extraction is not complete it seems likely that the 
affinity is sufficient to clear more than only the unbound fraction of PSP, 
which explains why in the control experiments comparable fits were 
obtained for bound and unbound concentrations. However, in the inter­
action experiments the apparent affinity of the transport system is, due 
to competitive inhibition by probenecid and SUA, thus far decreased that 
dissociation of bound PSP becomes very unlikely. Under those conditions 
it is understandable that secretion is proportional to the unbound plasma 
concentration. 
It can be concluded from the results in Table 3.3 that in the control 
experiments a considerable accumulation of PSP within the tubular cells 
takes place. The cellular uptake of PSP, expressed as the intrinsic 
unbound secretion clearance CLu. . = Τ,./Κ™ is 430 ± 86 ml/min, whereas 
int Μ Τ 
the clearance out of the cells into the lumen, represented by V . ' k . . , is 
only 5.8 ± 0.5 ml/min. In Fig. 3.6 the cellular concentration of PSP is 
simulated, using the model parameters calculated from the experiments in 
dog 1 (Table 3.3). The course of the simulated curves can be explained 
as follows: In the beginning of the experiment PSP concentrations in renal 
plasma are so high that the active uptake system is saturated and oper-
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tubular cell concentration 
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IOOOT 
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Fig. 3.6 Course of the proximal tubular ce l l concentration of PSP with or 
without the presence of SUA. The parameters used for th i s simulation were 
obtained from the analysis of plasma and urine curves of dog 1 according 
to the kidney model. 
ates at its transport maximum. Since TV. is not affected by SUA the initial 
uptake rate into the cells is the same as in the control experiment. As 
the plasma concentration gradually falls, the rate of uptake into the cells 
in presence of SUA eventually lags behind as a result of the reduced 
apparent affinity of the transport system. Because the clearance out of 
the cells was not influenced by SUA, cellular concentrations were lower 
and decreased more rapidly. Comparison of Fig. 3.3B and Fig. 3.6 shows 
that the concentration in the control substantially exceeds the plasma con­
centration, the concentration ratio tubular cells to plasma ranging from 
approximately 4 at high plasma concentrations to approximately 10 at lower 
concentrations. In presence of SUA PSP accumulation is substantially 
decreased. In this situation the cell to plasma ratio does not exceed a 
phenolsulfonphthalein 
dog 1 simulation 
control ( 1.0 g i.v.) 
-f salicyluric acid 
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value of 1.5. A similar pattern was observed for the interaction with 
probenecid (not shown). These simulated accumulation values are in good 
agreement with in vitro observations [30]. 
The interaction with probenecid could be described well with the model 
when a competitive inhibition of active uptake of PSP into the tubular 
cells was assumed (Eq. 3.15). Studies with isolated membrane vesicles 
have shown that the transport step from cell to lumen is also a potential 
site of interaction [38], but no evidence for such an interference was 
obtained. The interaction with SUA is considerably more complicated. 
The pronounced concave shape of the tubular titration curves (Fig. 3.5) 
pointed to a special kind of interaction. The possibilities for such an 
interaction are limited because without inhibitor active PSP transport has 
to obey straightforward Michaolis-Menten kinetics. A type of interaction 
that meets this requirement is when the inhibitor reacts directly with the 
substrate, thus preventing it from being transported. However, binding 
between PSP and SUA is very unlikely. The most attractive explanation is 
to consider a system for PSP consisting of two identical transport sites, 
in which SUA can act as a pure competitive inhibitor (Eq. 3.16). The 
special thing about this interaction is that competition of SUA for a single 
site prevents transport of PSP via either of the two sites. SUA may over-
lap or utilize part of each PSP binding site or may cause steric hindrance 
or distortion in both sites by binding to one of the sites. Although this 
explanation is somewhat tentative it provides a useful operational relation 
for the characterization of the interaction between PSP and SUA. Further 
studies, for instance, with isolated membrane vesicles, are necessary to 
clarify the precise mechanism of this interaction. Anyway, the clear dif-
ference in inhibitory action between SUA and probenecid furnishes sup-
porting evidence for a supposed heterogeneity of the organic anion t rans-
port system. 
In conclusion, the kidney model described in this paper is able to ade-
quately describe and account for the plasma kinetics and renal excretion 
of PSP and the interaction with two competing drugs . The model incorpo-
rates the functional characteristics of the kidney that are of importance in 
the renal handling of PSP. In future, other mechanisms such as passive 
or active reabsorption, urine flow and pH dependency, and renal effects 
of drugs that are cleared by the kidney ( e . g . , diuretics, uricosuric 
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agents, anti-inflammatory analgesics) have to be incorporated to make the 
model applicable to different types of drugs and several clinically relevant 
situations. However, much fundamental research is still needed to fit in 
all these features in a sound way. 
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CHAPTER 4 
RENAL CLEARANCE OF SALICYLURIC ACID AND THE INTERACTION 
WITH PHENOLSULFONPHTHALEIN1 
Frans G.M. Rüssel, Alfons С. Wouterse, and Cees A.M. van Ginneken 
Abstract - Plasma kinetics and renal excretion of salicyluric acid (SUA, 
0.8 g) administered iv, with and without concomitant administration of 
phenolsulfonphthalein (PSP), wore studied in the beagle dog. Pharmacoki­
netic analysis revealed that tubular secretion is the predominant route of 
excretion, and that secretion is inhibited by PSP. A physiologically based 
kidney model is presented comprising all the functional characteristics of 
the kidney that determine the excretion of SUA, i . e . , renal plasma flow, 
urine flow, nonlinear protein binding, glomerular filtration, tubular secre­
tion and tubular accumulation. The model enabled an accurate description 
and analysis of the measured plasma levels and renal excretion rates . 
The interaction with PSP could be adequately described with the model by 
noncompetitive inhibition of the carrier-mediated uptake of SUA into the 
tubular cells. Furthermore, a small but significant reduction in nonrenal 
SUA clearance was observed. Model calculations showed that, in the con­
trol experiments tubular secretion was accompanied by a pronounced accu­
mulation of SUA within the cells, which was clearly diminished in the 
presence of PSP. The predicted accumulation ratios were in good agree­
ment with previously reported in vitro values. 
Published in: Drug Metab. Dispos. 15, 695-701 (1987). 
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4.1 INTRODUCTION 
Active renal secretion is an important elimination route for a wide 
variety of organic anionic drugs and metabolites. Several studies have 
confirmed that the cells of the proximal tubules are responsible for the 
transport of these compounds. The initial step in tubular secretion 
involves active uptake at the basolateral membrane, resulting in intracel-
lular accumulation of the drug and subsequent, probably facilitated, dif-
fusion across the brush-border membrane into the luminal fluid [1,2]. 
Most of the characteristics of this system have been determined by 
studying the tubular transport of compounds like phenolsulfonphthalein 
(PSP), iodopyracet, and, in particular, p-aminohippurate (PAH). Espe-
cially from competition experiments, there is now increasing evidence sug-
gesting that the renal secretory system consists of several overlapping 
subsystems with different affinities for the large diversity of compounds 
transported [1,3] . 
The present study concerns the renal clearance of salicyluric acid 
(SUA), the major metabolite of salicylic acid. SUA is largely eliminated 
from the general circulation via the kidney by glomerular filtration and 
active tubular secretion. Despite its considerable binding to plasma pro-
teins, renal clearance at low plasma concentrations is the same as PAH 
clearance [4] . The lipophilic nature of SUA, as a result of internal 
hydrogen bonding, may lead to a substantial passive back diffusion under 
conditions of high tubular load in combination with a low urinary flow and 
pH. Tubular secretion of SUA is, as are almost all organic anions sus-
ceptible to inhibition by probenecid, but whereas probenecid generally 
acts as a competitive inhibitor, a noncompetitive type of interaction with 
SUA was observed [5] . Furthermore, in a study on the effect of 
probenecid and SUA on the renal clearance of PSP, probenecid showed 
simple competitive inhibition, while for SUA a considerably more complex 
type of interaction (two-site competitive system) had to be taken into 
consideration [6] . We therefore wondered what the influence of PSP on 
the renal clearance of SUA would be. 
Previously, we showed the usefulness of physiologically based modeling 
in characterizing renal drug clearance and interactions at the level of 
tubular secretion [5,7] . In this paper, we propose an extension of these 
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models, by incorporating the important features of transtubular transport 
and nonlinear protein binding. The aim of the present study was to quan­
tify all the relevant processes of renal SUA excretion and the effect of 
PSP with the aid of this extended physiologically based kidney model. 
4.2 MATERIALS AND METHODS 
Materials. 
Salicyluric acid, phenolsulfonphthalein, indole-3-acetic acid, and 
LiChrosorb RP18 were from Merck (Darmstadt, FRG). Braunule Τ cannu­
las were obtained from Braun (Melsungen, FRG), the double-walled uri­
nary catheter (URO 90.009) from Talas (Ommen, The Netherlands), and 
Visking 8 dialysis tubing from Instrumentenhandel Z.H. (Den Haag, The 
Netherlands). All other materials and chemicals were described previous-
ly [8]. 
Clearance Experiments. 
The experiments were done in male beagle dogs, weighing 12 to 17 kg, 
as was described in detail previously [8] . In summary, the dogs were 
fasted overnight and anesthetized with sodium pentobarbital (30 mg/kg, 
iv). As premedication, atropine sulfate (0.5%, 1 ml iv) was given. A 
cannula (Braunule T) was inserted into the cephalic vein of each foreleg 
for blood sampling and drug administration. A constant infusion of 5% 
mannitol and 0.5% inulin (2 ml/min) was administered throughout the 
experiment. In this way, a sufficiently high urine flow and constant pH 
(7.0 ± 0.8) were obtained. Each dog received as an iv bolus a sterile 
solution of 0.8 g of SUA dissolved in 15 ml of water containing an 
equimolar amount of sodium bicarbonate. In a second experiment, the same 
dogs received a priming dose of 200 mg of PSP (2.5% in aqueous sodium 
bicarbonate, 8 ml iv) 30 min prior to injection of 0.8 g of SUA, followed 
by a constant infusion of the same solution at a rate of 5 ml/hr. At reg­
ular times throughout the experiment, blood samples were taken into hep-
arinized tubes. Plasma was separated by centrifugation for 20 min at 
2000g. Urine was collected quantitatively with a double-walled urinary 
catheter at 5 min intervals during the first 100 min of the experiment, 
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and afterwards at 10 min intervals. Plasma and urine samples were stored 
at -20°C until analysis. Before the dog was used for the second experi­
ment, at least 3 weeks of recovery were observed. 
Analytical Methods. 
SUA was determined in plasma and urine by HPLC. as was described 
previously [5] . A Hewlett Packard 1084B Chromatograph was used 
equipped with a variable wavelength detector, autosampler and terminal 
(HP 7850 LC). The stainless-steel column (150 χ 4.6 mm I.D.) was 
packed with LiChrosorb RP-18, particle size 5 urn. 
Concentrations of PSP were determined by a spectrophotometric assay 
[9]. Plasma samples (500 μΐ) were treated with 2.0 ml of acetone by 
shaking for 15 min to precipitate plasma proteins. After centrifugation 
for 10 min at 2000g, 0.2 ml of IN NaOH solution was added to 2.0 ml of 
the clear supernatant, and the absorbance was measured at 54G nm. 
Inulin was assayed according to the method of Heyrovski [10] . After 
hydrolysis to fructose and reaction with indole-3-acetic acid in hydrochlo­
ric acid (32t> w/w), the absorbance was measured at 515 nm. 
Protein Binding. 
Plasma protein binding of SUA was determined by ultrafiltration using 
Visking dialysis tubing [8] . The ultrafiltrates were treated and analyzed 
in the same way as urine samples were. Assuming one class of binding 
sites, the plasma protein binding was analyzed according to the following 
equations, derived from the mass-action law: 
С = fuC + P«fuC/(Kd + fuC) (4.1) 
Cu = fuC (4.2) 
where С is the total plasma drug concentration, Cu the unbound drug 
concentration in plasma, fu is the fraction of drug in plasma unbound, Ρ 
is the total concentration of protein binding sites, and K, is the dissocia­
tion constant of the drug-protein complex. 
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Pharmacokinetic Analysis. 
Basic pharmacokinetic parameters were calculated from the plasma 
concentration-time curves and renal excretion rate-time curves, applying 
statistical moments theory [11,12] The data points were interpolated 
using a cubic spline method [13], as it was impossible to fit the typical 
nonlinear semilogarithmic plots to the usual multiexponential equations 
Я he area under the plasma curve was calculated by numerical integration 
after extrapolation of the rapid distribution phase to time 0, and the ter­
minal phase of the plot to infinity In a similar way, the area under the 
renal excretion rate curve and the area under the first moment of this 
curve were estimated after extrapolation to infinity using the terminal 
phase of the plot Using standard equations, total plasma clearance (CL) 
and initial volume of distribution (V.) were calculated [14] The mean 
residence time was determined from the renal excretion rate curve 
(MUT.- ), dividing the area under the first moment curve by the area 
under the curve Renal clearance (CL«) was estimated by the total 
excretion method, in which the total amount of SUA excreted in infinite 
tune into urine was calculated from the area under the renal excretion 
rate curve The nonrenal clearance (CL. „) was determined by subtract­
ing the renal clearance from the total plasma clearance 
Kidney Model. 
The physiologically based model for the renal excretion of SUA is illus­
trated by the diagram in Fig 4 1 Transport processes and compartmental 
concentrations of the drug can be described by the following set of equa­
tions 
Central plasma 
dCj 
V l -£ - « R * Qur>C2 + k51V5C5 " « R + CLNR + k 15 V l> C l (4 3 ) 
Renal plasma 
dC« T M C , 
v2 ^ t - - Q R C I - Q G F C U I - W R - Qur>c2 - ^-TEi ( 4 4 ) 
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Fig. 4.1 Physiologically based pharmacokinetic model for the renal clear­
ance of SUA. See Materials and Methods for explanation of symbols. 
Tubular urine 
d C 3 
V 3 -^ - Q G F C U 1 + k 4 3 V 4 C 4 - Q u r C 3 ( 4 . 5 ) 
Tubular cells 
v
 d 3 - T M C 2 -
 k у С 
4
 dt K T + C 2 «
V 4 C 4 
Peripheral tissues 
( 4 . 6 ) 
d C r 
v. —
?
 = ΐί,.ν,α, - κ.,ν,ο. 
о dt 15 1 1 эі 5 5 
( 4 . 7 ) 
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w h e r e , 
V. = volume of compartment i (ml) 
C. = total d r u g concentrat ion in compartment i (yg/ml) 
C u 1 = u n b o u n d d r u g concentra t ion in compartment 1 (yg/ml) 
k.. = f i r s t - o r d e r r a t e c o n s t a n t as soc ia ted with movement of d r u g 
from compartment i to compartment j ( m i n - 1 ) 
Q^, = r e n a l plasma flow (ml/min) 
л 
Q _ _ = glomerular f i ltration (ml/min) 
Q = u r i n e flow (ml/min) 
CL^-T, = n o n r e n a l plasma c learance (ml/min) 
T M = maximum t r a n s p o r t capacity of t h e t u b u l a r 
K™ = Michaelis-Menten c o n s t a n t of t h e t u b u l a r 
s e c r e t i o n mechanism (yg/min) 
s e c r e t i o n mechanism (yg/ml) 
T h e r e n a l e x c r e t i o n r a t e (yg/min) in t h i s model is r e p r e s e n t e d by 
R R = V C 3 (4·8> 
and t h e u n b o u n d d r u g c o n c e n t r a t i o n in compartment 1 can b e calculated 
a f te r r e a r r a n g e m e n t of equat ions 4 .1 a n d 4 . 2 : 
C u 1 = i [ - ( P + K d - Cj) - / ( ( P + K d - Cj)» + I K j C ^ ) ] (4 .9) 
T h e exper imenta l ly o b s e r v e d plasma c o n c e n t r a t i o n a n d r e n a l e x c r e t i o n r a t e 
c u r v e s were s imultaneously f itted to t h e model d e s c r i b e d a b o v e . 
Data Analysis. 
T h e spl ine funct ions were f itted to t h e equal ly weighted d a t a with t h e 
ra t iona l spl ine interpola t ion r o u t i n e of t h e DISSPLA computer p a c k a g e 
[15] . DISSPLA was also u s e d for drawing t h e f igures p r e s e n t e d in t h i s 
s t u d y . All o t h e r d a t a were analyzed with t h e aid of t h e computer p r o ­
gram NONLIN [ 1 6 ] . Plasma p r o t e i n d a t a were weighted e q u a l l y . For t h e 
k i d n e y model, s e v e r a l we ight ing factors were t e s t e d ; in most c a s e s , t h e 
r e c i p r o c a l we ight ing p r o c e d u r e gave t h e b e s t f i t s . In o r d e r to make t h e 
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standard deviations of experiments in which different weighting factors 
wore used comparable to each other, all standard deviations were calculat­
ed for one set of weighting factors, e g , plasma concentration data were 
reciprocally weighted (1/C2) and renal excretion rate data were equally 
weighted The goodness of fit to the plasma concentration and renal 
excretion rate data was evaluated through the deviations between 
observed and model-predicted values as R2= l-E(Obs) 2 /E(Dev) 2 , where 
Z(Obs)2 is the corrected sum of squared observations and Z(Dev)2 the 
sum of squared deviations Statistical differences between means were 
established using Student's t-test for paired samples Average values are 
expressed as mean ± SD 
4.3 RESULTS 
Protein Binding. 
Concentration-dependent plasma protein binding of SUA was observed, 
the fraction unbound ranging from ЗО-бО^ (Fig Л 2) PSP did not inter­
fere with protein binding of SUA Because intermdividual variation m 
binding was found to be small, data of all experiments (n-^G) were pooled 
and analyzed according to Eq 4 1 The results of this fit were 222 ± 2G 
yg/ml and 9G ± 19 pg/ml for total concentration of protein binding sites 
(P) and dissociation constant ( K . ) , respectively 
Pharmacokinetic Analysis. 
A representative example of plasma disappearance and renal excretion 
rate after intravenous administration of SUA with or without simultaneous 
infusion of PSP is shown in Fig 4 3 The pronounced nonlinear shape of 
these curves indicated that at least one capacity-limited process is 
involved in the kinetics of SUA Plasma and urinary data were analyzed 
separately after cubic spline interpolation of the data points and extrapo­
lation of the terminal phase to infinity, assuming log-linear decline. 
Although linear extrapolation may overestimate the area under the curve 
in cases of nonlinear elimination, the contribution of this residual area 
was only small, not exceeding 5% for any of the curves The parameters 
calculated are summarized in Table 4 1 Steady state concentrations of 
PSP that were reached are given in Table 4 2 
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Fig. 4.2 Plasma protein binding of SUA with or without the presence of 
PSP. The line through the data is calculated by Eq. 4.1. 
Total plasma clearance of SUA was significantly reduced from 56 ± 5 
ml/min to 48 ± 8 ml/min (p<0.05), during PSP administration. The fraction 
of the dose excreted unchanged into the urine (D ) remained unaffected, 
namely 75 ± 6% in the control experiments and 77 ± 60o in presence of 
PSP. As a result, renal clearance, calculated from the product of total 
clearance and the fraction of the dose excreted, decreased from 42 ± 2 
ml/min to 37 ± 6 ml/min in presence of PSP, although the difference failed 
to reach the 5% level of statistical significance. The decrease in renal 
clearance could not account fully for the reduction in total plasma clear­
ance, therefore it is likely that PSP also interferes with the nonrenal 
clearance of SUA. Assuming an average protein binding of approximately 
45%, it could be calculated from the product with glomerular filtration 
(Table 4.2) that the contribution of filtration to the total renal clearance 
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renal excretion rate 
(μς/π-ιιη) 
20000 salicyluric acid 
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control 
PSP 
200 250 
time (mm) 
Fig. 4.3 Renal excretion rate and plasma concentration as function of time 
after rapid i .v. administration of O.ß gram SUA with or without concomi-
tant infusion of PSP. The solid and broken lines in the figure represent 
the resul ts of data analysis according to the kidney model. 
of SUA was about IG ml/min. Obviously, active tubular secretion account-
ed for the greater part of renal clearance. The decrease in renal clear-
ance could be ascribed to an effect of PSP on the tubular secretion of 
SUA, as glomerular filtration and protein binding remained unchanged. 
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Table 4.1 Basic pharmacokinetic parameters of SUA after rapid iv injection 
of 0.8 gram with or without concomitant administration of PSP. 
Dog 
1 
2 
3 
4 
Mean 
±SD 
Mean8 
+SD 
Inhibitor 
-
PSP 
-
PSP 
-
PSP 
-
PSP 
-
PSP 
CL 
(ml/min) 
52 
38 
63 
57 
55 
51 
55 
45 
56 
5 
48* 
8 
plasma 
CLNR 
(ml/min) 
10 
9 
20 
15 
16 
13 
11 
6 
14 
5 
* 
11 
4 
Vl 
(1) 
1.84 
1.71 
1.87 
1.59 
1.71 
1.74 
1.55 
1.86 
1.74 
0.15 
1.73 
0.14 
MRTR 
(min) 
62 
82 
69 
87 
62 
71 
65 
90 
64 
3 
82** 
8 
urine 
CLR 
(ml/min) 
42 
29 
43 
42 
39 
38 
44 
39 
42 
2 
37 
6 
D
ur 
m 
80 
76 
67 
73 
72 
74 
79 
86 
75 
6 
77 
6 
a " 
Mean values compared to control levels (paired t-test; p<0.05, 
*"ρ<0.02). 
The MRT« of SUA, calculated from the renal excretion rate curve, 
increased significantly from 64 ± 4 min to 82 ± 8 min (p<0.02) as a result 
of concomitant PSP infusion (Table 4.1) . It should be noticed that the 
MUT- can be calculated irrespective of whether the drug has nonlinear 
disposition kinetics or is eliminated peripherally. However, due to the 
evident nonlinear renal elimination of SUA, the MRT^ is not equal to the 
total mean residence time in the body, but only represents the mean resi­
dence time of those drug molecules that are excreted via the renal path-
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Table 4.2 Physiological and experimentally found parameters used as 
constants in the kidney model . 
Dog 
1 
2 
3 
4 
Mean 
+SD 
Mean 
+SD 
Weight 
(kg) 
12.0 
12.4 
16.8 
16.9 
14.8 
14.2 
16.5 
15.0 
15.0 
2.2 
14.6a 
1.9 
PSP cone. 
(Vg/ml) 
-
45±5 
_ 
35±4 
— 
40±5 
— 
24±4 
— 
36 
9 
QGF 
(ml/min) 
32±3 
30±4 
32±4 
33±4 
30±2 
50±4 
50±3 
39±3 
36 
9 
38a 
9 
%r 
(ml/min) 
1.13±0.06 
1.43±0.15 
1.08±0.05 
1.02І0.04 
0.83±0.12 
0.81±0.21 
0.85І0.09 
0.81±0.07 
0.97 
0.15 
1.02a 
0.29 
^ 
(ml/min) 
132 
136 
185 
186 
163 
156 
182 
165 
165 
24 
161a 
20 
V3 
(ml) 
1.70±0.09 
2.14±0.22 
1.62±0.08 
1.5310.06 
1.2410.18 
1.2210.32 
1.2810.14 
1.2210.11 
1.46 
0.23 
1.53a 
0.43 
No significant differences with controls (paired t-test; p>0.3). 
The other constants were obtained as follows: V. was taken from table 1, 
for V- an arbitrary value of 1 1 was chosen, V, and V, were estimated 
from literature as 10 ml (20) and 30 ml (21), respectively. 
Q„ was directly estimated from the body weight (see text), therefore no 
SD. 
way. No significant difference was observed for the initial volume of dis­
tribution term V.. 
Kidney Model. 
The physiologically based pharmacokinetic model for the renal clearance 
of SUA presented in this study is an extension of previously described 
models for iodopyracet [7] and SUA (5). New elements of the model are 
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t ha t it a ccoun t s for nonl inear pro te in b ind ing and t ha t it incorpora tes a 
compartment r e p r e s e n t i n g the proximal t u b u l a r cells of the k idney These 
cells a re the main anatomical site for the ac t ive secret ion of a wide 
var ie ty of compounds A schematic r e p r e s e n t a t i o n of the model is given in 
Fig 4 1 The k idney is set a p a r t as a subsys t em divided into a plasma, 
t ubu la r cell , and t u b u l a r ur ine compartment Active t r a n s p o r t of SUA 
takes place from rena l plasma into t h e t u b u l a r cell compartment via a 
capacity-l imited pa thway obeying Michaelis-Monten k ine t i c s , subsequen t ly 
followed b y f i r s t - o r d e r t r a n s p o r t into t h e t ubu l a r u r ine compartment 
The most sa t i s fac tory fits to the model were obta ined when t u b u l a r 
secret ion was assumed to be dependen t on total concen t r a t i ons , r a t h e r 
than on unbound concent ra t ions The a v e r a g e goodness of f i ts , 
R2 . = 0 993±0 008 and R2 = 0 979±0 013 (Table 4 4 ) , were s igmfi-
plasma ur ine " D 
cantly b e t t e r t han the values obtained when unbound concent ra t ions were 
used , e g , R2 . = 0 904+0 044 (p<0 005) and R2 = 0 896 ± 0 034 
'
 &
 ' plasma " ' u r i ne 
(p<0 005) T h e r e f o r e , active t ubu l a r secret ion of SUA was cons idered to 
be dependen t on the total concent ra t ion in r ena l plasma Natura l ly , 
glomerular f i l t rat ion was a function of the unbound d r u g concent ra t ion , 
opera t ing d i rec t ly from the cent ra l compartment into the t ubu l a r ur ine 
compartment 
To desc r ibe the plasma kinet ics of SUA completely, a pe r iphe ra l t i s sue 
compartment was allocated to the cen t r a l compartment and a f i r s t - o r d e r 
c learance cons tan t was in t roduced , r e p r e s e n t i n g the e x t r a r e n a l c learance 
pathway In Table 4 2, t he pa ramete r s used as c o n s t a n t s in the model a re 
l isted Qp-p was de termined by s teady s t a t e inul in c learance For Q-p a 
value of 11 m l / m m / k g was taken [17] T h e volume of the tubu la r u r ine 
compartment (V„) was cons idered to be d e p e n d e n t on u r ine flow and rena l 
delay time [18] Assuming a cons tan t rena l delay time (At) of 1 5 mm 
[19], V , was calculated as V , = Q · at L J
 ' 3 3 u r 
Plasma concent ra t ion and renal excre t ion r a t e da ta of each exper iment 
were s imultaneously f i t ted to the model us ing NONLIN The r e s u l t s of 
these calculat ions a re l is ted in Tables 4 3 and 4 4 and a re also r e p r e s e n t -
ed by the solid and b roken l ines t h r o u g h the da ta po in t s in Figs 4 3 and 
4 4 The t u b u l a r t i t ra t ion c u r v e s in Fig 4 4 a r e l inear plots of renal 
excre t ion r a t e aga ins t plasma concent ra t ion a t the midpoint of a u r ine col-
lection in t e rva l T h e y give a good impression of t h e p roces se s tha t d e t e r -
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Table 4.3 Model parameters characterizing the renal handling of SUA and the 
effect of PSP. 
Dog 
1 
2 
3 
4 
Mean 
±SD 
Meana 
ISD 
Inhibitor 
— 
PSP 
-
PSP 
— 
PSP 
— 
PSP 
-
1
 PSP 
TM 
(mg/min) 
4.110.4 
2.310.3 
3.6+0.4 
3.2+0.6 
4.8+0.5 
3.8+0.3 
4.7+0.9 
3.9+1.7 
4.3 
0.6 
Vf 
3.3 
0.7 
«τ 
(Vg/ml) 
19+7 
20+4 
28+10 
28+15 
29+8 
3116 
47+15 
48+32 
31 
5 
32 
12 
C L N R 
(ml/min) 
1114 
912 
2011 
1414 
1614 
1312 
1013 
816 
14 
3 
11* 
3 
k43 
(min-1) 
0.3310.30 
0.38+0.71 
0.3110.15 
0.29+0.30 
0.10+0.03 
0.1010.04 
0.07+0.03 
0.08+0.09 
0.20 
0.14 
0.21 
0.15 
k15 
(min-1) 
0.05810.031 
0.04610.008 
0.045+0.003 
0.06110.011 
0.065+0.022 
0.070+0.010 
0.088+0.013 
0.055+0.019 
0.064 
0.018 
0.058 
0.010 
k51 
(min-1) 
0.118+0.051 
0.08210.012 
0.055+0.008 
0.05210.010 
0.121+0.033 
0.10810.014 
0.10910.015 
0.086+0.029 
0.101 
0.031 
0.082 
0.023 
Mean values compared to control levels (paired t-test; p<0.05). 
Table Α.4 Goodness of fit of the kidney model to the observed plasma 
concentration and renal excretion rate data of SUA. 
Dog Inhibitor R2 R2 
urine 
0.995 
0.977 
0.969 
0.961 
0.992 
0.987 
0.988 
0.965 
-
PSP 
-
PSP 
_ 
PSP 
-
PSP 
 
plasma 
0.999 
0.998 
0.978 
0.982 
0.998 
0.997 
0.996 
0.997 
mine the renal clearance of SUA and the effect of PSP. It appears from 
Fig. 4.4 that SUA undergoes net tubular secretion which becomes saturat­
ed at high plasma levels. In that situation, the final part of the titration 
curve parallels the glomerular filtration (GF) curve. Because of 
concentration-dependent protein binding, this line is not straight but has 
a somewhat concave shape, for glomerular filtration always operates on 
the fraction of the drug that is not protein bound. The effect of PSP 
manifests itself in a decreased renal excretion rate of SUA over the whole 
plasma concentration range measured. Evaluation of the curves with the 
kidney model revealed that this effect could be characterized consistently 
by a noncompetitive inhibition of the active transport step from renal 
plasma into the tubular cells (Table 4.3) . The maximum transport rate 
(T M ) was significantly reduced from 4.3 ± O.G mg/min to 3.3 ± 0.7 mg/ 
min (p<0.05) ) whereas the Michaelis-Menten constant (K T ) remained unal­
tered (31 ± 5 vg/ml vs. 32 ± 12 yg/ml). Furthermore, a small but signif-
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renal excretion rate 
(Mg/mm) 
ЮООО-і 
7500 
5 0 0 0 -
2500 
1 Γ 
300 
plasma cone, (μς/τηΐ) 
Fig. 4.A Tubular t i t r a t i o n curves representing the relationship between 
the renal excretion rate and the plasma concentration after i .v. adminis­
t r a t i o n of SUA with or without PSP. The lines through the data points are 
calculated according to the kidney model. GF represents the clearance by 
glomerular f i l t r a t i o n of SUA. 
icant effect on the nonrenal clearance (CL,™) of SUA was calculated (14 
± 3 ml/min vs. 11 ± 3 ml/min; p<0.05). Under the experimental condi­
tions, passive reabsorption appeared to be negligible, presumably due to 
the mannitol induced diuresis and the high urinary pH (7.0 ± 0.8) as 
compared to the dissociation constant of SUA (pK = 3.6) [22]. 
4.4 DISCUSSION 
The physiologically based model presented provides an overall represen­
tation of the renal secretory system, comprising all the functional charac­
teristics of the kidney that are involved in the excretion of SUA. New 
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renal excretion rate 
( д д / т ш ) 
10000 
7500 -
5000 
2500 
1 1 Γ 
200 300 
plasma cone, (¿¿g/ml) 
Fig. A.4 Continued. 
features of the model are that it accounts for nonlinear plasma protein 
binding and carrier-mediated transport through the cells of the proximal 
tubules. The latter process plays an important role in the renal clear-
ance of SUA and a large number of other organic anions. 
The role of plasma protein binding is appreciably less understood. It 
has been suggested that for compounds cleared with a high affinity for 
the secretory system, protein binding does not limit the extent of tubular 
secretion, whereas for drugs that are secreted with a relatively low affin-
ity renal clearance will be dependent on the fraction unbound [23] . 
Obviously, there will be more determining factors in this respect, like the 
rate of dissociation of the drug-protein complex, the transit time through 
the peritubular capillaries and diffusion into the cortical interstitium. 
Since the renal clearance of SUA equals the PAH clearance at low plasma 
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concentrations [4], the affinity for the secretory system appears to be 
large enough, relative to other factors, to give a complete extraction from 
the plasma in a single passage through the kidney This is in agreement 
with our findings that the best fits to the model were obtained when 
tubular secretion was considered to be proportional to the total plasma 
concentration of SUA 
Active secretion of organic anions is usually associated with accumula-
tion and retention of the drug within the proximal tubular cells [24] 
From the results m Table 4 3, it can be concluded that SUA substantially 
accumulates within the tubular cells The cellular uptake of SUA in the 
control experiments, expressed as the intrinsic secretion clearance CI . = 
T-j/K™ is 152 ± 50 ml/min This value surpasses many times the clearance 
out of the cells into the lumen, represented by V.^k. - , being 6 ± 4 ml/ 
min In Fig 4 5, the cellular concentration of SUA is simulated, using 
the model parameters calculated from the experiments in dog 1 (Table 
4 3) The cellular SUA concentration without PSP exceeds the plasma 
concentration considerably, the concentration ratio of tubular cells to 
plasma ranging from approximately 2 at high plasma concentrations to 
approximately 8 at lower concentrations These simulated accumulation val-
ues are in close accordance with observations m the isolated perfused rat 
kidney [25] In the presence of PSP, accumulation of SUA was reduced 
as a result of interference with the active cellular uptake In this situa-
tion, the cell to plasma ratio ranged from approximately 0 8 at high plas-
ma concentrations to 4 5 at lower concentrations Although uptake was 
decreased, the extent of retention within the cells was apparently not 
influenced by PSP, as judged from the profile of the cellular concentra-
tion curve (Fig 4 5) 
SUA is known to have a renal clearance considerably less than that of 
PAH at high plasma concentrations [26] This was attributed to passive 
tubular reabsorption occurring to an Increasing extent with increased 
tubular loading Dependent on urine flow and urinary pH, even transition 
from net secretion to net reabsorption was observed, resulting from the 
fact that tubular secretion is saturable while back-diffusion is a passive 
process without limitations [4,27] However, our results clearly show 
that , under conditions where passive back-diffusion is negligible the max-
imal rate of tubular transport of SUA, 4 3 ± 0 G mg/min (Table 4 3), is 
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tubular cell concentration 
(¿¿g/ml) 
500 η 
salicyluric acid 
dog 1 simulation 
control (0 8 g ι ν ) 
400 - + PSP 
300 - ^ Ч 
200 - \ 
100 -
0 50 100 150 200 250 
time (mm) 
Fig. 4.5 Course of the proximal tubular cel l concentration of SUA with or 
without the presence of PSP. The parameters used for th i s simulation were 
obtained from the analysis of plasma and urine curves of dog 1 according 
to the kidney model. 
still much lower than the value of 15 ± 2 mg/min reported for PAH [28]. 
It can be concluded that, although passive reabsorption may contribute 
under certain conditions to a less efficient clearance, the limited capacity 
of the secretory system for SUA is the main reason for the restricted 
excretion at high plasma concentrations. 
Analysis with the kidney model showed that PSP behaved like a noncom­
petitive inhibitor of the active uptake of SUA into the tubular cells. A 
similar type of interaction was described previously for the effect of 
probenecid on SUA secretion [5] . PSP reduced to a lesser degree the 
extrarenal clearance of SUA, presumably by interfering with hepatic elimi­
nation, a transport pathway that bears a certain resemblance with the 
renal secretory system [29] . The question of how the mechanism of the 
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PSP interaction should be interpreted at a molecular level cannot be 
answered directly from this study. In view of the hypothesis of multiple 
transport systems, it can be speculated that PSP and SUA bind to dis-
tinct transport sites in which binding of PSP to its site prevents SUA 
from binding to the other site by steric hindrance or distortion. When 
SUA has little or no affinity for the "PSP"-site, the interaction will mani-
fest itself as noncompetitive. Clearly, detailed in vitro work focused on 
the concept of multiplicity of the organic anion transport system win be 
necessary to elucidate the actual mechanism of this interaction. 
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CHAPTER 5 
RENAL CLEARANCE OF IODOPYRACET AND THE INTERACTION WITH 
PROBENECID1 
Frans G.M. Rüssel, Alfons С. Wouterse and Cees A.M. van Ginneken 
Abstract - Plasma kinetics and renal excretion of iodopyracet (3.0 g, 
administered i .v .) with and without concomitant administration of 
probenecid were studied in the beagle dog. Pharmacokinetic analysis 
revealed that tubular secretion is the predominant route of excretion, and 
that secretion is inhibited by probenecid. A physiologically based kidney 
model is proposed comprising all the functional characteristics of the kid­
ney that determine the excretion of iodopyracet, i .e. renal plasma flow, 
urine flow, protein binding, glomerular filtration, tubular secretion and 
tubular accumulation. The model enabled an accurate description and 
analysis of the measured plasma levels and renal excretion rates . Renal 
clearance of iodopyracet is characterized by supply-limited elimination at 
low plasma concentrations and capacity-limited elimination at high plasma 
levels. The interaction with probenecid could be adequately described 
with the model by competitive inhibition of the carrier-mediated uptake of 
iodopyracet into the tubular cells. Model calculations showed that in the 
control experiments tubular secretion was accompanied by a pronounced 
accumulation of iodopyracet within the cells, which was clearly diminished 
in presence of probenecid. 
Biopharm. Drug Dispos., in press 
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5.1 INTRODUCTION 
The renal clearance of iodopyracet (Diodrast), a radiographic contrast 
agent, has historically received a lot of attention as a means to estimate 
tubular function and plasma flow through the kidney. Its renal excretion 
pattern strongly resembles that of the prototypic anion p-aminohippurate 
(PAH). Transport of iodopyracet into the urine occurs very rapidly by 
glomerular filtration and extensive tubular secretion. At low plasma con­
centrations the rate of excretion is so high that the renal clearance 
approaches the renal plasma flow and becomes flow-limited [1]. Under 
these circumstances extraction from the plasma in a single passage 
through the kidney is virtually complete [2] , implying that plasma protein 
binding of iodopyracet, which amounts to about 30o [3], does not form 
any hindrance to tubular secretion. It also implies that at low plasma lev­
els reabsorption from the tubular urine is negligible. Passive pH-
dependent reabsorption is very unlikely to occur for iodopyracet, even at 
high tubular loading, considering the low pK of 2.7 [Λ], compared with 
the usual urinary pH. 
It has been well documented that the renal secretion of iodopyracet, 
and in general of organic anions, is confined to the proximal tubular 
cells. The sequence of transport through these cells is active uptake 
across the basolateral membrane, intracellular accumulation, followed by 
diffusion (probably facilitated) across the brush-border membrane into the 
tubular fluid. Intracellular accumulation is highly dependent on the effi­
ciency of the active transport step across the basolateral membrane. In 
case of iodopyracet the extent of accumulation in the cells and urine will 
determine its visibility as a renal contrast agent, thus providing an esti­
mate of the functional viability of the proximal tubular cells in health and 
disease. The extent of tubular accumulation may also play an important 
part in the pathogenesis of radiocontrast agent-induced acute renal failure 
[5], as a result of a direct toxic effect on the tubular cells. 
In a previous study we showed the usefulness of physiologically based 
modeling in characterizing the flow-dependent renal kinetics of iodopy­
racet [6] . However, the model described did not account for the phe­
nomenon of intracellular accumulation. The purpose of the present study 
was to incorporate this important feature of transtubular transport, and 
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to quantify the relevant processes of renal iodopyracet excretion with this 
extended model. Furthermore, the kidney model was used to describe the 
interaction with the standard inhibitor probenecid, in order to get more 
insight in the mechanisms and effects of drug interactions at the level of 
tubular secretion. 
5.2 MATERIALS AND METHODS 
Materials 
Iodopyracet was obtained from Dagra NV (Diemen, The Netherlands), 
probenecid from Sigma (St. Louis, Mo., USA), indole-3-acetic acid and 
LiChrosorb RP18 were from Merck (Darmstadt, FRG). Braunule Τ cannu­
las were obtained from Braun (Melsungen, FRG), the double walled uri­
nary catheter (URO 90.009) from Talas (Ommen, The Netherlands), and 
Visking 8 dialysis tubing from Instrumentenhandel Z.H. (Den Haag, The 
Netherlands). All other materials and chemicals were described previous-
ly [7]. 
Clearance Experiments 
The experiments were done in male Beagle dogs, weighing 11 to 15 kg, 
as was described in detail previously [7,8] . In summary, the dogs were 
fasted overnight and anesthetized with sodium pentobarbital (30 mg/kg, 
i .V.). As premedication atropine sulfate (0.5%, 1 ml i .v .) was given. A 
cannula (Braunule T) was inserted into the cephalic veins of both 
forelegs for blood sampling and drug administration. A constant infusion 
of 5% mannitol and 0.5% inulin (2 ml/min) was administered throughout the 
experiment. In this way, a sufficiently high urine flow and constant pH 
(7.0 ± 0.8) was obtained. Each dog received as an i.v. bolus a sterile 
solution of 3.0 g iodopyracet dissolved in 20 ml water containing an 
equimolar amount of sodium bicarbonate. In case of probenecid treatment 
the dogs received 30 min prior to injection of iodopyracet a priming dose 
of 75 mg probenecid (2.5% in aqueous sodium bicarbonate, 3 ml i.V.), fol­
lowed by a constant infusion of a 0.5% solution at a rate of 2.5 ml/hr 
(dogs 1 and 3) or 5 ml/hr (dogs 2 and 4) . At regular times throughout 
the experiment blood samples were taken into heparinized tubes. Plasma 
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was separated by centrifugation for 20 mm at 2000g Urine was collected 
quantitatively with a double wallpd urinary catheter at 5 mm intervals 
during the first 100 mm of the expeimient, and afterwards at 10 mm 
intervals Plasma and urine samples were stored at -200C until analysis 
Before the dog was used for the second experiment at least three weeks 
of recovery were observed 
Analytical Methods 
lodopyracet was determined in plasma and urine and probenecid was 
determined m plasma by high-performance liquid chromatography (HPLC) 
Both procedures were described previously [9,10] A Hewlett Packard 
1084B Chromatograph was used equipped with a variable wavelength detec­
tor, autosampler and terminal (HP 7850 LC) The stainless-steel column 
(150 χ 4 G mm I D ) was packed with LiChrosorb R.P-18, particle size 5 
lim 
Inulin was assayed by a spectrophotometnc method [11] After hydrol­
ysis to fructose and reaction with indole-3-acetic acid in hydrochloric acid 
(32'o w/w) absorbance was measured at 515 nm 
Protein Binding 
Plasma protein binding of lodopyracet was determined by ultrafiltration 
[6] using Visking dialysis tubing (flat width 10 mm, average pore size 
2 4 mm) Plasma (2 0 ml) was pipetted into the tubes, precentnfuged 
(10 mm at 1000g) to remove membrane bound water, and subsequently 
centrifuged for 60 mm at 1000g yielding about 150 yl ultrafiltrate Binding 
of lodopyracet to the dialysis membrane was found to be negligible The 
ultrafiltrates were treated and analyzed in the same way as urine samples 
were 
Pharmacokinetic Analysis 
Plasma concentration-time curves and renal excretion rate-time curves 
were fitted separately to the usual multiexponential equations Basic phar­
macokinetic parameters were calculated from these fits applying statistical 
moments theory [12,13] The area under the plasma curve was calculated 
by direct integration after extrapolation of the terminal phase of the plot 
to infinity In the same way the area under the renal excretion rate 
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c u r v e as well as t h e a r e a u n d e r the f i rs t moment of th i s c u r v e were cal­
culated. Half-lives of iodopyracet in plasma ( t , ) and u r i n e (t^ ) 
were obta ined from t h e i r r e s p e c t i v e terminal elimination r a t e c o n s t a n t s . 
Using s t a n d a r d e q u a t i o n s [14], total plasma c learance (CL) was calculated 
as the dose divided by t h e a r e a u n d e r t h e plasma c u r v e , and t h e initial 
volume of d i s t r i b u t i o n (V-) as t h e dose divided by t h e e x t r a p o l a t e d zero-
time plasma c o n c e n t r a t i o n . T h e moan r e s i d e n c e time was determined from 
the rena l e x c r e t i o n r a t e c u r v e ( M R T ^ ) , div iding the area u n d e r t h e f irst 
К 
moment c u r v e by t h e a r e a u n d e r t h e c u r v e . T h e total amount of iodopy­
racet e x c r e t e d in infinite time into u r i n e was d i rec t ly obta ined from the 
area u n d e r t h e r e n a l e x c r e t i o n r a t e c u r v e . Renal c learance (CL^,) was 
calculated as t h e p r o d u c t of total plasma c learance and fract ion of the 
dose e x c r e t e d u n c h a n g e d in t h e u r i n e (D ) , and t h e n o n r e n a l c learance 
(CL^-TJ) was determined by s u b t r a c t i n g t h e r e n a l c learance from the total 
plasma c l e a r a n c e . 
Kidney Model 
The physiologically b a s e d model for t h e r e n a l excre t ion of iodopyracet is 
i l lus t rated by t h e d iagram in Fig. 5 . 1 . T r a n s p o r t p r o c e s s e s and compart-
montal c o n c e n t r a t i o n s of t h e d r u g can be descr ibed by the following set 
of e q u a t i o n s : 
Centra l plasma 
dC-
V l I T = ( Q R " Q u r ) C 2 + k 5 1 V 5 C 5 - W R + C L N R + k 1 5 V l ) C l ^ 1 ) 
Renal plasma 
d C 2 T M C 2 
V 2 -^ = Q R C 1 * Q G F C U 1 - ' S R - Q u r > C 2 - £ - r F 2 ( 5 - 2 ) 
Tubula r u r ine 
d C 3 
V 3 -£ = Q G F C U 1 + k 4 3 V 4 C 4 - Q u r C 3 <5·3> 
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Fig. 5.1 Physiologically based pharmacokinetic model for the renal clear­
ance of iodopyracet. See Materials and Methods for explanation of symbols. 
where, 
V. 
ι 
C. 
C
" l 
k.. 
4 
'H. 
u r 
volume of compartment i (ml) 
total drug concentration in compartment i (ug/ml) 
unbound drug concentration in compartment 1 (ug/ml) 
first-order rate constant associated with movement of drug 
from compartment i to compartment j (min-1) 
renal plasma flow (ml/min) 
glomerular filtration (ml/min) 
urine flow (ml/min) 
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n o n r e n a l plasma clearance (ml/min) 
maximum t r a n s p o r t capaci ty of t h e t u b u l a r 
secre t ion mechanism (yg/min) 
Michaelis-Menten c o n s t a n t of t h e t u b u l a r 
secre t ion mechanism (yg/ml) 
The renal e x c r e t i o n r a t e (yg/min) is r e p r e s e n t e d by 
R R = Q u r - C 3 (5.6) 
The exper imental ly o b s e r v e d plasma c o n c e n t r a t i o n and r e n a l e x c r e t i o n r a t e 
c u r v e s were s imultaneously analyzed with t h e model d e s c r i b e d above . 
Data Analysis 
Curve- f i t t ing was done with t h e aid of t h e computer p r o g r a m NONLIN 
[ 1 5 ] . In t h e e x p o n e n t i a l fits d a t a were weighted r e c i p r o c a l l y . For the 
k idney model s e v e r a l weight ing factors were t e s t e d , in most cases best 
fits were obta ined when plasma data were weighted reciprocal ly ( 1 / C 2 ) 
and r e n a l e x c r e t i o n r a t e data were weighted equal ly . In o r d e r to make 
the s t a n d a r d dev ia t ions (SD) obta ined from fits in which di f ferent weight­
ing factors were u s e d comparable to each o t h e r , all SD were calculated 
for t h e above-ment ioned set of weight ing f a c t o r s . T h e goodness of fit to 
the plasma c o n c e n t r a t i o n and r e n a l e x c r e t i o n r a t e d a t a was evaluated 
t h r o u g h t h e dev ia t ions between o b s e r v e d and m o d e l - p r e d i c t e d values as 
R 2= 1 - Σ (Obs) 2 / Z ( D e v ) 2 , where Σ ( O b s ) 2 is t h e c o r r e c t e d sum of s q u a r e d 
o b s e r v a t i o n s a n d Z ( D e v ) 2 the sum of s q u a r e d d e v i a t i o n s . Stat i s t ical dif­
ferences between means were e s tab l i shed us ing S t u d e n t ' s t - t e s t for pa i red 
samples. Average va lues are e x p r e s s e d as mean ± SD. T h e f igures p r e ­
s e n t e d in t h i s s t u d y were d r a w n with t h e DISSPLA computer package 
[16] . 
C L N R = 
Τ = M 
Krp = 
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5.3 RESULTS 
Protein Binding 
Plasma protein binding of iodopyracet was determined in each experi-
ment in at least five different samples. Over the concentration range 
measured (10-1000 ug/ml) binding was virtually constant. Therefore, 
binding data of each experiment were averaged. Results are presented in 
Table 5.2. The mean fraction unbound in the control experiments was 
0.72 ± 0.03. Probenecid (14-58 yg/ml) had no effect on the protein bind-
ing of iodopyracet, the fraction unbound remaining 0.74 ± 0.04 (p>0.3). 
Pharmacokinetic Analysis 
Fig. 5.2 depicts a representative example of plasma disappearance and 
renal excretion rate of intravenous administered iodopyracet with or with-
out simultaneous infusion of probenecid. Pharmacokinetic parameters were 
determined from plasma and urinary data separately and the results of 
these calculations are summarized in Table 5 .1 . 
Total plasma clearance of iodopyracet was significantly reduced from 88 
± 23 ml/min to 73 ± 14 ml/min (p<0.02), while the fraction of the dose 
excreted unchanged into the urine remained unaffected (89 ± 8 % vs . 88 
± G %, p>0.8). As a result , renal clearance, calculated from the product 
of plasma clearance and fraction of the dose excreted, decreased from 79 
± 25 ml/min to 62 ± 15 ml/min (p<0.05). The decrease in renal clearance 
fully accounted for the reduction in total plasma clearance, indicating that 
probenecid had no effect on the nonrenal clearance of iodopyracet (Table 
5.1). The contribution of glomerular filtration to the total renal clearance 
of iodopyracet in the controls was 25 ± 7 ml/min, as calculated from the 
product of the fraction unbound and the glomerular filtration rate (Table 
5.2). From these results it is clear that tubular secretion of iodopyracet 
is the most important route of renal excretion at the given dose. The 
decrease in renal clearance by probenecid could be fully ascribed to inhi-
bition of tubular secretion, since glomerular filtration and protein binding 
remained unchanged (Table 5.2). 
Administration of probenecid resulted in a significant increase of the 
MRT_ and the terminal half-lives of iodopyracet in plasma and urine, 
whereas no significant difference was observed for the initial volume of 
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Fig. 5.2 Renal excretion rate and plasma concentration as function of time 
after rapid i.V. administration of 3.0 gram lodopyracet with or without 
concomitant infusion of probenecid. The solid and broken lines in the 
figure represent the resul ts of data analysis according to the kidney mod­
el . 
distribution term V 1 . The mean residence time was calculated from the 
renal excretion rate curve as this parameter, contrary to the mean resi­
dence time obtained from the moments of the plasma concentration curve, 
does not suffer from the assumptions of linear disposition kinetics and 
elimination from the central compartment. However, it should be empha-
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Table 5.1 Basic pharmacokinetic parameters of IP after rapid i.V. injection of 
3.0 gram with or without concomitant administration of probenecid (Prob). 
Dog 
1 
2 
3 
4 
Mean 
±SD 
Mean3 
±SD 
Inhibitor 
-
Prob 
— 
Prob 
-
Prob 
-
Prob 
-
Prob 
(min) 
30 
40 
37 
51 
44 
55 
43 
48 
38 
6 
48 
6 
plasma 
CL CLNR 
(ml/min) (ml/min) 
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94 
81 
68 
80 
67 
71 
63 
88 
23 
73 
14 
7 
11 
2 
9 
15 
14 
9 
6 
9 
6 
12 
2 
Vl 
(1) 
2.25 
2.05 
1.99 
2.26 
2.92 
2.42 
2.11 
2.18 
2.32 
0.42 
2.23 
0.15 
(min) 
52 
57 
44 
53 
58 
62 
59 
67 
53 
7 
60 
6 
urine 
MRTR 
(min) 
56 
68 
58 
67 
66 
70 
78 
86 
66 
8 
73** 
9 
CLR 
(ml/min) 
115 
83 
79 
59 
65 
53 
58 
51 
79 
25 
62* 
15 
Dur 
(%) 
94 
88 
98 
87 
81 
95 
82 
81 
89 
8 
88 
6 
Mean values compared to control levels (paired t-test; p<0.05, p<0.02). 
Table 5.2 Physiological and experimentally found parameters used as 
constants in the kidney model . 
Dog 
1 
2 
3 
4 
Mean 
±SD 
Mean 
±SD 
Weight 
(kg) 
14.5 
13.6 
12.3 
13.0 
12.2 
12.3 
11.3 
11.3 
12.6 
1.4 
12.6a 
1.0 
Prob cone. 
(Ug/ml) 
-
14±2 
— 
54±4 
-
19±3 
— 
58±4 
— 
36 
23 
fu 
0.72І0.07 
0.74±0.02 
0.68+0.04 
0.71±0.04 
0.74±0.03 
0.72±0.02 
0.76±0.08 
0.80±0.04 
0.72 
0.03 
0.74a 
0.04 
QGF 
(ml/min) 
44±4 
32±2 
31±2 
34±2 
32±2 
38±3 
21±2 
32±3 
32 
9 
34a 
3 
Our 
(ml/min) 
0.61±0.16 
1.09±0.27 
0.92+0.14 
0.85±0.09 
1.4010.28 
0.88±0.12 
0.7210.15 
0.8610.13 
0.91 
0.35 
0.92a 
0.11 
V3 
(ml) 
0.92+0.24 
1.6410.41 
1.3810.21 
1.28+0.14 
2.10+0.42 
1.3210.18 
1.08+0.22 
1.2910.19 
1.37 
0.52 
1.38a 
0.17 
No significant differences with controls (paired t-test; p>0.3). 
The other constants were obtained as follows: V, and CL.Tr, were taken from 
1 NR 
Table 1, for V,- an a r b i t r a r y value of 1 1 was chosen, V« and V, were 
es t imated from l i t e r a t u r e as 10 ml [17] and 30 ml [ 1 8 ] , r e s p e c t i v e l y . 
sized t h a t only for l inear pharmacokinet ics t h e MRTp equa l s t h e tota l 
mean r e s i d e n c e time in t h e b o d y . Due to t h e obvious nonl inear r e n a l elim­
ination of i o d o p y r a c e t t h e MRTp merely r e p r e s e n t s t h e mean r e s i d e n c e 
time of t h o s e d r u g molecules t h a t a re e x c r e t e d by t h e k i d n e y . 
Kidney Model 
A schematic r e p r e s e n t a t i o n of t h e physiological ly b a s e d k i d n e y model is 
given in Fig . 5 . 1 . In t h e model the k i d n e y is set a p a r t as a s u b s y s t e m 
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divided into a renal plasma, tubular cell and tubular urine compartment. 
Active transport of iodopyracet takes place from renal plasma into the 
tubular cell compartment via a capacity-limited pathway obeying Michaelis-
Menten kinetics, subsequently followed by first-order transport into the 
tubular urine compartment. Active tubular secretion was assumed to be 
dependent on the total iodopyracet concentration in renal plasma. 
Glomerular filtration was considered to be a function of the unbound drug 
concentration, operating directly from the central compartment into the 
tubular urine compartment. For a complete description of iodopyracet 
kinetics a peripheral tissue compartment was allocated to the central com­
partment and a nonrenal clearance pathway was introduced. In Table 5.2 
the parameters used as constants in the model are listed. Qpp was deter­
mined by steady-state inulin clearance. The volume of the tubular urine 
compartment ( „) was considered to be dependent on urine flow and renal 
delay time [19]. Assuming a constant renal delay time (At) of 1.5 min 
[201, V0 was calculated as V0 = Q ·Δί. 1
 ' ' 3 3 ^ u r 
The kidney model was fitted to the plasma concentration and renal 
excretion rate data of the control experiments using NONL1N. Estimates of 
the model parameters are given in Table 5.3 and the results are also rep­
resented by the solid lines through the datapoints in Figs. 5.2 and 5.3. 
The average goodness of fit between the observed and model-predicted 
plasma concentration and renal excretion rate data were R2 , = 0.993 ± 
plasma 0.005 and R2 . = 0.984 ± 0.012, respectively. The tubular titration 
urine ' ^ J 
curves in Fig. 5.3 give a direct representation of the relationship 
between renal excretion rate and plasma concentration at the midpoint of a 
urine collection interval. It appears from these plots that iodopyracet 
undergoes net tubular secretion which becomes saturated at high plasma 
levels. In that situation the titration curve parallels the glomerular filtra­
tion curve, indicating that passive reabsorption was negligible under the 
experimental conditions. Fig. 5.3 also shows that in the controls the ini­
tial part of the titration curve is almost a straight line which clearly dif­
fers from the usual Michaelis-Menten profile. The reason for this deviation 
is that iodopyracet is cleared so rapidly by tubular secretion that at low 
plasma concentrations extraction from the renal plasma is almost complete 
and the rate of excretion becomes flow-limited [2,6]. This means that the 
renal clearance of iodopyracet at low plasma levels practically approaches 
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Table 5.3 Model parameters characterizing the renal handling of IP and the 
effect of probenecid (Prob). 
Dog Inhibitor T. M Krp KT 43 
(mg/min) (vg/ml) (yg/ml) (mi/min) (min-1) 
15 
(min-1) (min-1) 
Prob 
39±2 
38±7 
31±4 
32±13 4±2 
160±6 0.27±0.05 0.063±0.004 0.05710.003 
150±24 0.29±0.10 0.063±0.005 0.046±0.004 
Prob 
32±2 
33±11 
26±9 
28±17 7±4 
109110 0.29+0.05 0.055+0.003 0.046+0.002 
109+29 0.28+0.14 0.027+0.003 0.031+0.002 
Prob 
31110 
33111 
41121 
38+31 816 
83+23 0.29+0.14 0.018+0.002 0.026+0.002 
92+12 0.29+0.14 0.024+0.003 0.031+0.003 
Prob 
2414 
25+14 
44+32 
40+35 11+9 
88+13 0.3310.20 0.055+0.004 0.052+0.003 
88+17 0.3210.21 0.060+0.015 0.06210.005 
Mean 
ISD 
32 
6 
36 
8 
110 
35 
0.30 
0.03 
0.048 
0.020 
0.045 
0.014 
Mean 
ISD 
Prob 32° 34a 110 
28 
a 0.30° 
0.02 
0.044 
0.021 
a 0.042 
0.015 
a 
ел 
No significant differences with controls (paired t-test; p>0.2). 
the renal plasma flow Indeed, the extraction ratio of lodopyracet as 
determined from the ratio of the renal clearance at low plasma concentra­
tions (<100 yg/ml) and the model-calculated Q,, (Table 5 3) was 1 01 ± 
0 02 Administration of probenecid resulted in a significant reduction of 
this value to 0 74 ± 0 10 (p<0 02) 
renal excretion rate 
(mg/min 
6 0 -
200 
1 1 Γ 
600 800 
plasma cone (дд/т і ) 
Fig. 5.3 Tubular t i t r a t i o n curves representing the relationship between 
the renal excretion rate and the plasma concentration after ι ν adminis­
t r a t i o n of lodopyracet with or without probenecid The lines through the 
data points are calculated according to the kidney model. GF represents 
the clearance by glomerular f i l t r a t i o n of lodopyracet 
The effect of probenecid could be adequately described with the kidney 
model by competitive inhibition of the carrier-mediated transport of 
lodopyracet from renal plasma into the tubular cell compartment To quan­
tify this interaction the Michaelis-Menten constant of the tubular secretion 
mechanism (K™) in Eq 5 2 and 5 4 was substituted by the following 
expression for competitive inhibition Κ„(1 + С./КИ, where C. represents 
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Fig. 5.3 Continued. 
the plasma concentration of probenecid and K, the inhibition constant of 
probenecid. Steady-state plasma concentrations of probenecid that were 
reached are given in Table 5.2. Results of the model calculations in 
presence of probenecid are summarized in Table 5.3 and represented by 
the dotted lines in Figs. 5.2 and 5.3. 
In order to get an impression of the extent of tubular accumulation of 
iodopyracet, the time course of the concentration in the tubular cell com­
partment was simulated with the model (Fig. 5.4), using the parameters 
obtained from the experiments in dog 2 (Table 5.3). Comparison of the 
simulated concentrations (Fig. 5.4) with the corresponding plasma concen­
trations (Fig. 5.2) shows that in the control the cellular iodopyracet lev­
els are considerably higher than the levels in plasma. The concentration 
ratio tubular cells to plasma increased from 5.4 at the highest cell con-
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centration of 3360 pg/ml (t=14 min) to a constant value of approximately 
10.0 at cell concentrations lower than 1000 vg/nú (t>85 min). In presence 
of probenecid cellular concentrations were lower and accumulation was 
clearly reduced. At the highest cell concentration of 2400 pg/ml (t=ll 
min) the cell to plasma ratio was 3.6, which thereafter slowly increased to 
a value of 5.7 at a cell concentration of 200 yg/ml (t=175 min). 
5.4 DISCUSSION 
The results of the pharmacokinetic analysis of plasma and renal excre-
tion data separately clearly showed that iodopyracet is rapidly cleared 
from the circulation, largely by renal clearance. At the given dose, 
active tubular secretion is the major pathway of renal elimination. This 
transport step can be inhibited by probenecid resulting in a reduced 
renal clearance and a retarded elimination of iodopyracet. 
In order to account for the processes that govern the renal clearance of 
iodopyracet in a more meaningful manner a physiologically based kidney 
model was developed that enabled the simultaneous analysis of both the 
plasma and the renal excretion data. The model incorporates all the func-
tional characteristics of the kidney that are involved in the excretion of 
iodopyracet, including the important feature of carrier-mediated transport 
through the cells of the proximal tubules. 
It appears from the tubular titration curves in Fig. 5.3 that the renal 
clearance of iodopyracet is characterized by supply-limited elimination at 
low plasma concentrations and capacity-limited elimination at high plasma 
levels. It follows directly from the results in Table 5.3 that in the con-
trols the maximum clearance capacity of the secretory system, expressed 
as the intrinsic secretion clearance CL. . = T. . /K„ = 950 ± 350 tnl/min, is 
int M 1 
many times higher than the renal plasma flow (Q- = 110 ± 35 ml/min). 
CL. . is so high that at plasma levels up to the level at which tubular 
secretion begins to be saturated, elimination is perfusion rate-limited, in 
which case the limiting value of clearance is the renal plasma flow. Obvi-
ously, the saturation kinetics of iodopyracet are masked by this flow limi-
tation. As a consequence, the estimates for KT are necessarily rough, 
since the only information on this parameter can be derived from the small 
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Fig. 5.4 Course of the proximal tubular cel l concentration of iodopyracet 
with or without the presence of probenecid. The parameters used for th i s 
simulation were obtained from the analysis of plasma and urine curves of 
dog 2 according to the kidney model. 
part of the tubular titration curve in which the initial linear course 
branches off to the point where the maximum transport rate is reached. 
The flow-dependency of renal clearance practically abolished in presence 
of probenecid. As a result of the competitive inhibition of the secretory 
system the CL. ., now expressed as Tw/[K T (1 + Cj/Kj)] strongly 
decreased to a value of 190 ± 80 ml/min. 
In calculating QT, it is implicitly assumed that any iodopyracet present 
in erythrocytes is not available for filtration or secretion in the kidney. 
This assumption is based on experiments which have shown that, although 
some iodopyracet penetrates the erythrocytes, extraction from erythro­
cytes during passage through the kidney is negligible [2,21]. It must be 
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recognized that the value obtained for Q^ is only an approximation of the 
true renal plasma flow. Q^ is merely an operational parameter, character­
izing the plasma flow that perfuses the functional parts of the kidney 
tubules. Because iodopyracet is secreted by the proximal tubules it seems 
certain that virtually all extraction occurs in the cortex and that plasma 
directly entering the medulla (5-10 "о of total renal plasma flow) [22] does 
not contribute to excretion. Therefore, it is likely that Q^ reflects the 
cortical plasma flow and as such underestimates the total renal plasma 
flow. 
In accordance with in vitro observations [23], the simulation study with 
the kidney model showed that iodopyracet substantially accumulates within 
the proximal tubular cells prior to excretion (Fig. 5.4). It can be con­
cluded from the results in Table 5.3 that cellular accumulation results 
directly from the very efficient active uptake across the basolateral mem­
brane into the cells compared with the much slower transport out of the 
cells into the tubular lumen. The cellular uptake of iodopyracet in the 
control experiments, which as mentioned before practically approaches the 
renal plasma flow (110 ± 35 ml/min), strongly exceeds the clearance out of 
the cells, represented by the term V. 'k .» , being only 9 ± 1 ml/min. In 
presence of probenecid accumulation of iodopyracet was reduced as a 
result of interference with the active cellular uptake. 
In summary, the physiologically based kidney model enabled a compre­
hensive description of the flow-dependent and capacity-limited renal clear­
ance of iodopyracet. The interaction with probenecid could be adequately 
described with the model by competitive inhibition of the active uptake of 
iodopyracet into the tubular cells. Model simulation predicted a pro­
nounced cellular accumulation within the proximal tubules, which was 
reduced in presence of probenecid. Finally, the kidney model described 
in this paper has also proven to be useful in a study on the renal clear­
ance of phenolsulfonphthalein [8] . The physiologically based modeling 
approach may serve to get further insight in the mechanisms and implica­
tions of carrier-mediated drug transport in the kidney. Future work has 
to be focused on incorporating the mechanisms of active and passive drug 
reabsorption and on scaling-up the model to the human situation. 
130 
5.5 REFERENCES 
1. I.M. Weiner, in The Kidney: Physiology and Pathophysiology, D.W. 
Seldin and G. Giobisch ( E d s . ) , Raven P r e s s , New York, 1985, p p . 
1703-1724. 
2. H.W. Smith, The Kidney: Structure and Function in Health and Dis-
ease , Oxford Univers i ty P r e s s , New York, 1951, p p . 148-162. 
3 . W.W. Smith and H.W. Smith, J. Biol. Chem., 124, 107 (1938). 
4 . H.W. Smith, N. Finkels te in , L. Aliminosa, B . Crawford and M. 
G r a b e r , J . Clin. I n v e s t . , 24, 388 (1945). 
5. H . B . Humes and J .M. Weinberg, in The Kidney, t h i rd e d . , vol . II, 
B.M. B r e n n e r and F . C . Rector ( E d s . ) , S a u n d e r s , Phi ladelphia, 
1986, p p . 1491-1532. 
6. P . Hekman and C.A.M. van Ginneken, J. Pharmacokinet. Biopharm., 
10, 77 (1982). 
7. F .G .M. Rüsse l , A . C . Wouterse and C.A.M. van Ginneken, J. Phar-
macol. Methods, 17, 125 (1987). 
8 . F .G .M. Rüsse l , A . C . Wouterse and C.A.M. van Ginneken, J. Phar-
macokinet. Biopharm., 15, 349 (1987). 
9. P . Hekman and C.A.M. van Ginneken , J. Chromatogr. Biomed. 
A p p i . , 182, 492 (1980). 
10. P . Hekman P . Α . T . W . P o r s k a m p , H . C . J . Kete laars a n d C.A.M. van 
G i n n e k e n , J. Chromatogr. Biomed. Appi., 182, 252 (1980). 
11. A. H e y r o v s k i , Clin. Chim. Acta., 1, 470 (1956). 
12. K. Yamaoka, T . Nakagawa and T . Uno, J. Pharmacokinet. Bio­
pharm., 6, 547 (1978). 
13. L . Z . Benet a n d R . L . Galeazzi, J. Pharm. S c i . , 68, 1071 (1979). 
14. M. Gibaldi a n d D. Регг іег , Pharmacokinetics, Marceli D e c k e r , New 
York, 1982. 
15. C M . Metzler, G . L . Elf r i n g and A . J . McEwen, Biometrics, 30, 562 
(1974). 
16. DISSPLA u s e r ' s manual, Display Integrated Software System and 
Plotting Language, Version 9.2, I n t e g r a t e d Software Systems Corpo­
r a t i o n , San Diego C a . , 1984. 
17. F . P . C h i n a r d , Am. J. Physiol . , 180, 617 (1955). 
18. M.S. Dunnil l a n d W. Halley, J. Pathol., 110, 113 (1973). 
19. E. Bojesen, Scand. J. Clin. Lab. I n v e s t . , 1, 290 (1949). 
131 
20. P .A . Morales, C .H. Crowder , A . P . Fishman, M.H. Maxwell and D.M. 
Gomez, Am. J. Phys io l . , 163, 454 (1950). 
21 . H.A. Fozzard , Am. J . Phys io l . , 206, 309 (1964). 
22. G.D. T h o r b u r n , H .H. Kopald, J . A . Herd , M. HoUenberg, C . C . C . 
O'Morchoe and A . C . B a r g e r , Circ. R e s . , 8, 290 (1963). 
23. M.B. B u r g and P . F . Weiler, Am. J. Phys io l . , 217, 1053 (1969). 
132 
PART III 
SUBSTITUTED HIPPURATES 
Models are to be used, 
but not to be believed 
Henri Theil 

CHAPTER 6 
RENAL CLEARANCE OF SUBSTITUTED HIPPURATES. 
I. BENZOYLGLYCINE (HIPPURATE) AND METHYL-SUBSTITUTED 
BENZOYLGLYCINES1 
Frans G M Rüssel, Alfons С Wouterse, and Cees A M van Ginneken 
Abstract - Plasma kinetics and renal excretion of benzoylglycine (hippu-
rate) and methyl-substituted benzoylglycinos were studied in three Beagle 
dogs, after rapid intravenous administration of about 1 gram of glycine 
conjugate Benzoylglycine and the 3- and 4-methyl analogs showed non­
linear plasma protein binding varying between 20 <md 80oo over a concen­
tration range of 5 - 450 yg/ml For 2-methylbenzoylglycme an extremely 
high protein binding, practically approaching 100o, was observed at low 
plasma levels (<50 yg/ml) All conjugates were largely cleared via the kid­
ney (>80oo of the dose) and, except for the 2-methyl analog, rapidly elimi­
nated from plasma Plasma concentration and renal excretion rate data 
were analyzed simultaneously with a previously developed physiologically 
based kidney model Tubular secretion appeared to be a function of the 
total drug concentration in renal plasma, except for 2-methylbenzoyl-
gycine, presumably due to its tight protein binding The average values 
of the parameters characterizing the tubular transport maximum ( Т „ in 
mg/min) and the apparent affinity for the secretory system (K T in yg/ml) 
were benzoylglycine Τ = 5 5 ± 0 8, KT= 40 ± 5, 3-methylbenzoylglycine 
TM= 7 1 + 3 3 , KT= 49 ± 1, 4-methylbenzoylglycine TM= 8 0 + 1 6 , KT= 
14 ± 6 Secretion of 2-methylbenzoylglycine was not saturated According­
ly, only the ratio T../K = 163 ± 54 ml/mm could be calculated An inter-
J Pharmacol Exp Ther , submitted Partly published as an abstract 
in· Naunyn-Schmiedeberg's Arch Pharmacol 330, R32 (1985) 
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esting Observation was the partial doconjugation of 4-methylbenzoylglycine 
to its corresponding benzoate. 4-Methylbenzoate was only found in plasma 
and not in urine, indicating that the benzoate was either cleared 
extrarenally, or completely metabolized during transfer through the kid-
ney. 
6.1 INTRODUCTION 
Because of their high renal clearance, hippurate analogs traditionally 
are considered as prototypical substrates of the organic anion transport 
system present in the proximal tubules of the kidney [Miller and Sheikh, 
1983]. Hippurate (bonzoylglycine) itself is an endogenous substance that 
is excreted in large amounts in normal urine [Grantham and Chenko, 
1986]. Well-known exogenous hippurates are salicylurate 
(2-hydroxybenzoylglycine), the major metabolite of salicylic acid, 
o-iodohippurate (Hippuran), a renal contrast agent, and p-aminohippurate 
(PAH). The latter two have been primarily used as a means to estimate 
renal plasma flow and tubular function in normal and disease states 
[Smith, 1951] . Hippuran is still used for clinical purposes, whereas PAH 
has become the anion of choice in the experimental characterization of the 
renal organic anion system in vivo and in vitro [Miller and Sheikh, 1983; 
Grantham and Chenko, 1986] . 
Studies with PAH have shown that the principal step in transtubular 
secretion of organic anions is active carrier-mediated transport from per-
itubular fluid to cytoplasma across the basolateral membrane, resulting in 
high intracellular concentrations. The anion is subsequently transported 
down its concentration gradient into the tubular lumen by a mediated pro-
cess in the brush border membrane [Weiner, 1985] . 
The substrate specificity of the renal organic anion system has been the 
subject of many investigations. In the fifties and early sixties extensive 
analyses were performed on structure analogs of hippurate to determine 
the minimal requirements for carrier-mediated t ransport . Despopoulos 
[1965] concluded that the carbonyl and carboxylate group are essential in 
the secretion of hippurates. Later on, attention was shifted from the 
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hippurates to other classes of organic anions in an attempt to come to a 
comprehensive characterization of the chemical s tructures required for 
mediated transport . Recently, it has been proposed that the great 
variety of secreted anions, having in common only a negative charge and 
a hydrophobic backbone, are not transported by a single uniform carrier 
system but by several parallel systems with overlapping specificities 
[Haberle, 1981; Miller and Sheikh, 1983]. 
In this, and two accompanying papers we examined the renal clearance 
of a series of mono-substituted benzoylglycines (hippurates) in the dog. 
The purpose of these studies was to determine systematically the influence 
of ring substitution on the excretory characteristics of benzoylglycine. 
Previously, we proposed a physiologically based pharmacokinetic model for 
the saturable renal clearance of organic anions [Rüssel et a l . , 1987a,b]. 
This kidney model was applied to quantify the relevant processes that are 
involved in the renal excretion of the benzoylglycines. In the present 
study plasma and renal excretion kinetics of benzoylglycine and methyl-
substituted benzoylglycines were investigated. The renal handling of 
these compounds is of special interest as they are the major metabolites of 
toluene and xylenes. These organic solvents are widely used in industry 
and concentrations of the metabolites in urine of workers are generally 
regarded as a quantitative measure of exposure to these solvents [Ogata 
et a l . , 1986] . 
6.2 MATERIALS AND METHODS 
Chemicals 
Benzoylglycine (hippurate) and salicyluric acid were commercially avail-
able from British Drug Houses Ltd. (Poole, England) and Merck (Darm-
stadt, FRG), respectively. The methyl-substituted benzoylglycines were 
prepared by chemical synthesis as described below. Glycine was obtained 
from Merck, o-, m- and p-toluylchloride were from Aldrich (Brussel, Bel-
gium), sodium pentobarbital from Apharma (Arnhem, The Netherlands), 
atropine sulfate, mannitol and inulin from O.P.G. (Utrecht, The Nether-
lands). [3H]inulin (2.03 Ci/mmol) was from Amersham (Buckinghamshire, 
England). All other chemicals were purchased from Merck. 
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Preparation of the Methyl-Benzoylglycines 
The methyl-substituted benzoylglycines were prepared according to the 
Schotten-Baumann method from the corresponding acylchlorides by reac-
tion with glycine in the presence of a slight excess of sodium hydroxide 
[Vogel, 1978] . The compounds were purified by recrystallization from 
boiling water. The identy and purity were checked by comparing melting 
points with available literature values [Beilstein, 1926] and by TLC and 
HPLC. TLC was performed on silicagel GF„-. plates (Merck, Darmstadt, 
FRG) with a mobile phase of chloroform:methanol:acetic acid (80:20:3). 
Spots were detected under UV light and by immersing the plates in a sat-
urated iodine solution in carbon tetrachloride. The HPLC method is 
described under analytical methods. 
Clearance Experiments 
The experiments were done in three male beagle dogs, weighing 11 to 
15 kg, as was described in detail previously [Rüssel et a l . , 1987c]. The 
dogs were fasted overnight and anesthetized by intravenous administration 
of sodium pentobarbital (30 mg/kg) . As premedication atropine sulfate 
(0.5%, 1 ml i .v . ) was given. After anesthesia occurred, the dogs were 
artificially respirated with room air using a Harvard (model 607) ventila-
tor. The cephalic vein of both forelegs was provided with a Braunule Τ 
cannula (Braun, Melsungen, FRG) for blood sampling and drug adminis­
tration. A constant infusion of 5% mannitol and 0.5% inulin was adminis­
tered at a rate of 2 ml/min throughout the experiment to obtain a suffi­
ciently high and constant urine flow. The urinary pH was controlled by 
an infusion of 8.4% sodium bicarbonate at a rate (3-8 ml/min) such that 
the pH remained at a level of 7.0 ± 0.6. 
Each dog received as an intravenous bolus a sterile solution of the sub­
stituted benzoylglycine dissolved in about 15 ml of water containing an 
equimolar amount of sodium bicarbonate. At regular times throughout the 
experiment, blood samples were taken into heparinized tubes. Plasma was 
separated by centrifugation for 20 min at 2000g. Urine was collected 
quantitatively with a double-walled urinary catheter (URO 90.009 from 
Talas, Ommen, The Netherlands) by rinsing the bladder with 15 ml phys­
iological saline. During the first 50 min of the experiment urine was col­
lected every 5 min and afterwards every 10 min. The plasma and diluted 
urine samples were stored at - 2 0 ^ until analysis. 
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At the end of the experiment, the glomerular filtration rate was estimat­
ed by steady-state [3H]inulin clearance. The [3H]inulin was added to 
the mannitol-inulin infusion (0.04 yCi/ml) and concomitantly 1 ml of this 
solution, but with an activity of 3.3 цСі/тІ, was rapidly injected. During 
the following 40 min, six blood samples were taken and urine was collect­
ed every 5 min. Before the dog was used for the next experiment, at 
least three weeks of recovery were observed. 
Analytical Methods 
The substituted benzoylglycines were determined in plasma and urine by 
reversed phase HPLC, according to a previously described method [Rüssel 
et a l . , 1987c]. A Hewlett Packard 1084B was used equipped with a vari-
able wavelength detector, autosampler, and terminal (HP 7850 LC). The 
stainless-steel column (150 χ 4.6 mm I .D.) was packed with LiChrosorb 
RP-18, particle size 5 щп (Merck, Darmstadt, FRG). The mobile phase 
consisted of a mixture of methanol and twice-distilled water (30:70) con­
taining 0.01 M citrate (pH 2.6). The column temperature was 35°C and 
the eluent was delivered at a flow rate of 1.0 ml/min. Operating values 
of the wavelength detector (λ) and retention times ( t ^ ) of the compounds 
a. 
were: benzoylglycine λ = 245 nm, t = 4.1 min; 2-methylbenzoylglycine 
λ = 228 nm, t = 5.5 min; 3-methylbenzoylglycine λ = 235 nm, t = 8.3 
min; 4-methylbenzoylglycine λ = 238 nm, 1^ ,= 7.9 min. Salicyluric acid 
(2-hydroxybenzoylglycine, t^ 6.2 min) was used as internal standard in 
the assay of benzoylglycine, 2-methylbenzoylglycine as internal standard 
of 3-methylbenzoylglycine and benzoylglycine as internal standard of 3-
and 4-methylbenzoylglycine. 
Concentrations in plasma and urine were determined by comparing the 
peak area ratio of compound and internal standard with a calibration 
curve of peak area ratio versus compound concentrations spiked to blank 
plasma and urine. Linear correlations ( r J > 0.98) were found over the 
compound concentration range 1 - 700 μg/ml for plasma and 10 - 7000 
Vg/ml for urine. The coefficient of variation over the examined concentra­
tion ranges for plasma and urine was less than 5%. 
Plasma and urine were checked for the presence of the corresponding 
acid derivative, resulting from a possible In vivo deglycination reaction. 
For this purpose the samples were run in a mobile phase consisting of 
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methanol:water (0.01 M citrate pH 2.G) in a ratio of 50:50, with the 
detector wavelength set at 254 nm. In the experiments with 
4-methylbenzoylglycine, 4-methylbenzoic acid (t = 5.4 min) was found in 
ti. 
plasma and concentrations were quantified in the same way as described 
above. 
Concentrations of [3H]inulin in plasma and urine were estimated using 
standard liquid scintillation techniques after dissolution of 0.5 ml plasma 
or urine in 10 ml Aqualuma plus (Lumac, Schaesberg, The Netherlands). 
Protein Binding 
Plasma protein binding of the substituted benzoylglycines was deter-
mined by ultrafiltration [Rüssel et al . , 1987c], using Visking 8 dialysis 
tubing (Instrumcntenhandel Z.H., Den Haag, The Netherlands). The 
ultrafliltrates were treated and analyzed in the same way as urine samples 
were. No significant binding of any of the benzoylglycines to the dialysis 
membrane was found. Assuming one class of binding site, plasma protein 
binding was analyzed according to the following equations 
С = Cu + P»Cu/(Kd + Cu) (6.1) 
Cu = fuC (6.2) 
where С is the total plasma drug concentration, Cu the unbound drug 
concentration in plasma, fu is the fraction of drug in plasma unbound, Ρ 
is the total concentration of protein binding sites and Κ , is the dissocia­
tion constant of the drug-protein complex. 
Pharmacokinetic Analysis 
Basic pharmacokinetic parameters were calculated from the plasma-
concentration time curves and renal excretion rate-time curves, applying 
statistical moments theory [Yamaoka et al . , 1978]. Plasma curves could 
be fitted well to the sum of two exponential equations, while renal excre­
tion rate curves were analyzed using a cubic spline interpolation method 
[Yeh and Kwan, 1978], as it was often impossible to fit the typical non­
linear semilogarithmic plots to the usual multiexponential equations. The 
area under the plasma curve was calculated by direct integration after 
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extrapolation of the terminal phase of the plot to infinity. The area 
under the renal excretion rate curve and the area under the first moment 
of this curve were estimated by numerical integration of the interpolated 
data points from time 0 to the last measured excretion rate and by subse-
quent extrapolation of the log-linear terminal phase of the curve to infini-
ty . 
Half-lives in plasma (t, ) and urine (t, ) wore obtained from the 
^ î , p ' v ? , u r ' 
respective terminal elimination rate constants. Using standard equations, 
total plasma clearance (CL) and initial volume of distribution (V..) were 
calculated [Gibaldi and Perrier, 1982]. The mean residence time was 
determined from the renal excretion rate curve (MRTf l), dividing the area 
under the first moment curve by the area under the curve. The total 
amount excreted in infinite time into urine was directly obtained from the 
area under the renal excretion rate curve. Renal clearance (CLp) was 
calculated as the product of total plasma clearance and the fraction of the 
dose excreted unchanged in the urine (D ) . 
Kidney Model 
The physiologically based model that was used to analyze the renal 
excretion of the substituted benzoylglycinos is shown in Fig. 6 .1 . The 
model was described in detail earlier [Rüssel et a l . , 1987a,b], therefore 
only a brief description is given. 
Transport processes and compartmental concentrations of the drug are 
described by the following set of equations : 
dC. 
V l υ " = « R - Qur) C 2 + k 5 1 V 5 C 5 " « R + C L N R + k 1 5 V l ) C l ( 6 · 3 > 
d C , T M C 2 
V 2 -£ - Q R C 1 - Q G F C U 1 - ( Q R - Qur>C2 - І ^ Г Г ^ ( 6 · 4 ) 
d C 3 
V 3 -£ -- Q G F C U 1 + k43V4C4 - QurC3 (6·5> 
141 
peripheral 
tissues 5 
^ 5 1 
U . E 
ι — " 
1 
1 
1 r » . . 
1 
1 
Our 
* 
1 
1 
L 
—Ol-
-
' 
tubular 
urine 
-
-
-
3 
-
• 
C L N R 
central 
plasma 
Q R Q 
* к4з 
k i d n e y — 
4 
R-QGF 
1 
\ 
r e n a l 
p l a s m a 
T M 
K T *C 
t u b u l a r 
cel ls 
-
г | 
_J 
urine 
collection 
Fig. 6.1 Physiologically based pharmacokinetic model for the renal clear­
ance of substituted benzoylglycines. See Materials and Methods for expla­
nation of symbols. 
d C 4 T M C 2 (6.6) 
dCc-
V 5 -£ - k 1 5 V l C l - k51V5C5 (6.7) 
R R = «u r * C 3 (6.8) 
where V. = volume of compartment i (ml) ; C. = total drug concentration in 
compartment i (yg/ml); Cu, = unbound drug concentration in compartment 
1 (yg/ml); k.. = first-order rate constant associated with movement of 
drug from compartment i to compartment j (min-1); Q_ = renal plasma 
flow (tnl/min) ; Q^p = glomerular filtration (ml/min); Q = urine flow 
(ml/min) ; CL™ = nonrenal plasma clearance (ml/min) ; T. . = maximum 
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transport capacity of the tubular secretion mechanism (vg/min); K„ = 
Michaelis-Menten constant of the tubular secretion mechanism (ug/ml); RR 
= renal excretion rate (ug/min). 
The unbound drug concentration (Cu) can be expressed as a function 
of С after rearrangement of equations 6.1 and 6.2. The parameters Q_, 
Qpp., Q and all compartmental volumes (V.) were used as constants in 
the model. They were either experimentally found or taken from literature 
[Rüssel et a l . , 1987b] . Qpp. Q a n d V- were experimentally deter-
mined. For QT. a value of 11 ml/min per kg body weight was taken. 
Under the assumption of a constant renal delay time (At) of 1.5 min, V« 
was calculated as V,, = Q · At. For V„ and V. literature values of 10 3 ur 2 4 
ml and 30 ml, respectively, were taken, while an arbitrary value of 1 lit-
er was chosen for _. The remaining parameters, viz . , TM , KT , CL^jp, 
к . , , к-- and к,., were estimated by fitting the experimentally observed 
plasma concentration and renal excretion rate curves simultaneously to the 
kidney model. 
Data Analysis 
The spline functions were fitted to the equally weighted renal excretion 
rate data with the rational spline interpolation routine of the DISSPLA 
computer package [DISSPLA, 1984]. DISSPLA was also used for drawing 
the figures presented in this study. All other data were analyzed with 
the aid of the computer program NONLIN [Metzler et a l . , 1974]. Plasma 
protein data were weighted equally and in the exponential fits data were 
weighted reciprocally ( 1 / C 2 ) . In most cases best fits to the kidney model 
were obtained when plasma data were reciprocally weighted and renal 
excretion rate data were weighted equally. The goodness of fit was evalu­
ated through the deviations between observed and model-predicted values 
as R2 = 1 - Z(Obs) 2 /Z(Dev) 2 , where I (Obs) 2 is the corrected sum of 
squared observations and X(Dev)2 the sum of squared deviations. Aver­
age values are expressed as mean ± SD. 
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6.3 RESULTS 
Experimental Conditions and Protein Binding 
The experimental conditions of the clearance studies are given in Table 
6.1. The glomerular filtration was determined by measuring the steady 
state [3H]inulin clearance and ranged from 17 to 43 ml/min. The urine 
flow, induced by mannitol, varied between 0.8 and 1.3 ml/min and the 
urinary pH was controlled with sodium bicarbonate between pH 6.9 and 
7.6. 
Table 6.1 Experimental conditions of the clearance studies with 
methyl-substituted benzoylglycines. 
Dog 
1 
2 
3 
Weight 
( k g ) 
1 2 . 4 
1 2 . 3 
1 2 . 5 
1 2 . 8 
1 2 . 0 
1 1 . 5 
1 1 . 5 
1 2 . 0 
1 3 . 0 
1 3 . 3 
1 4 . 8 
1 3 . 3 
S u b s t i t u e n t 
H 
2-CH 3 
з-сн3 
4-СН 3 
H 
2-СН 3 
з-сн3 
4-СН 3 
H 
2-СН 3 
з-сн3 
4-СН 3 
Dose 
(mg) 
930 
1000 
860 
990 
930 
990 
860 
990 
940 
1010 
1880 
990 
%F 
( m l / m i n ) 
42 
25 
42 
27 
31 
23 
17 
24 
33 
23 
43 
29 
+ 
± 
+ 
+ 
+ 
± 
± 
± 
+ 
+ 
+ 
± 
2 
2 
2 
1 
2 
1 
1 
1 
2 
1 
2 
2 
%r 
( m l / m i n ) 
0 . 8 7 
1.33 
0 . 9 7 
1.17 
0 . 8 9 
0 . 7 6 
1.19 
0 . 9 2 
0 . 8 1 
0 . 8 5 
0 . 9 7 
0 . 8 5 
+ 
+ 
+ 
+ 
± 
+ 
± 
± 
+ 
+ 
+ 
± 
0 . 1 1 
0 . 6 5 
0 . 1 7 
0 . 3 7 
0 . 2 6 
0 . 4 0 
0 . 2 8 
0 . 2 2 
0 . 3 3 
0 . 2 3 
0 . 5 2 
0 . 2 6 
P H u r 
6 . 9 5 
7 .54 
6 . 9 5 
7 .35 
7 . 0 1 
7 .49 
7 . 5 8 
7 .22 
7 .30 
7.27 
7.09 
7 . 2 0 
+ 
+ 
+ 
+ 
+ 
± 
+ 
± 
+ 
± 
± 
± 
0 . 2 6 
0 . 1 5 
0 . 2 2 
0 . 0 6 
0 . 1 5 
0 . 2 1 
0 . 0 8 
0 . 1 5 
0 . 2 5 
0 . 1 1 
0 . 2 3 
0 . 1 8 
Plasma protein binding of benzoylglycine and the methyl-substituted 
analogs is shown in Fig. 6.2. Interindividual variation in protein binding 
was small, therefore for each compound data of all three dogs were pooled 
and analyzed according to Eq. 6 .1. The results of these calculations are 
given in Table 6.2. The plasma protein binding of benzoylglycine was 
fairly constant (0.68 - 0.82) over the concentration range measured, 
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whereas the methyl-substituted analogs clearly showed concentration-
dependent protein binding. An unusual binding profile was observed for 
2-methylbenzoylglycine. At plasma concentrations below 100 ug/ml the 
fraction unbound decreased dramatically, which is expressed by the very 
low dissociation constant (Table 6.2). Extrapolation of the binding curve 
predicted a fraction unbound of practically zero for concentrations lower 
than 30 vg/ml (Fig. 6.2). 
fraction unbound 
10 
0 * -
0 2 
benzoylglycine 
(hippurate) 
I 1 1 1 1 — I 1 1 Γ 
100 200 300 400 
total plasma cone (дд/ті) 
fraction unbound 
10 
τ 1 1 1 1 1 - 1 г 
100 200 300 400 
total plasma cone (мд/ті) 
fraction unbound 
10 
0 8 
06 -
0 4 
02 -
3-methyl-
benzoylglyeine 
τ 1 1 - 1 1 1 1 1 Г 
100 200 300 400 
loto! plasmo cone (μς/ml) 
10 -, 
OB -
06 -
04 -
02 -
0 -
• / 
• 
ι τ 
^ - ^ ^
Γ
· * 
4-methyl-
benzoylglydne 
— ι 1 1 1 1 1 r-1 
100 200 300 400 
tola! plasma cone (мд/ті) 
Fig. 6.2 Plasma protein binding of benzoylglycine and methyl-substituted 
benzoylglycines. 
145 
Table 6.2 Plasma protein binding of methyl-substituted benzoylglycines. 
Substituent 
H 
2-CH3 
з-сн3 
4-СН3 
η 
13 
17 
25 
18 
Ρ 
(Vg/ml) 
92 ± 16 
43 ± 5 
167 ± 31 
126 ± 10 
Kd 
(Vg/ml) 
187 ± 46 
0.01 ± 4 
103 ± 30 
36 ± 7 
Pharmacokinetic Analysis 
Representative examples of the plasma concentration and renal excretion 
rate after intravenous administration of benzoylglycine and methyl-
substituted benzoylglycines are shown in Fig. 6.3. Basic pharmacokinetic 
parameters were determined from plasma and urinary data separately by 
statistical moment analysis and the results are presented in Table 6.3. 
At the given doses, all conjugates were largely eliminated from the gen­
eral circulation by renal clearance (D > 80"). Taking the plasma protein 
binding into consideration, it is apparent that the total renal clearance 
(CLp) of each of the benzoylglycines exceeded the clearance of the 
unbound fraction by glomerular filtration, indicating that all compounds 
were actively secreted by the kidney. All conjugates were rapidly elimi­
nated from plasma, except for the 2-methyl analog. Compared to the oth­
ers, 2-methylbenzoylglycine had a low plasma clearance (43 ± 3 ml/min) 
and a long terminal half-life in plasma (149 ± 48 min), which was more 
than two times higher than the corresponding value in urine (61 ± 28 
min). It seems likely that the extremely high protein binding at low 
plasma concentrations accounted for the slow terminal elimination of this 
compound. It should be noticed that all parameters listed in Table 6.3 
are not of absolute value but, due to the evident nonlinear processes of 
saturable protein binding and active renal secretion, they are dependent 
on the administered dose. 
In all experiments plasma and urine samples were checked for the pres­
ence of the corresponding benzoate derivative, as it has been reported 
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Fig. 6.3 Renal excretion rate and plasma concentration of benzoylglycine 
and methyl-substituted benzoylglycines. The solid lines through the data 
points represent the results of data analysis according to the kidney mod­
el. 
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μ- Table 6.3 Basic pharmacokinetic parameters of methyl-substituted benzoylglycines 
00
 after rapid intravenous injection. 
Substituent 
H 
2-CH3 
з-сн3 
4-СН3 
Dog 
1 
2 
3 
Mean(SD) 
1 
2 
3 
Mean(SD) 
1 
2 
3 
Mean(SD) 
1 
2 
3 
Mean(SD) 
^.P 
(min) 
40 
46 
49 
45(5) 
186 
95 
167 
149(48) 
28 
48 
34 
37(10) 
27 
37 
32 
32(5) 
plasma 
CL 
(mi/min) 
60 
54 
63 
59(5) 
45 
43 
40 
43(3) 
67 
36 
71 
58(19) 
83 
62 
80 
75(11) 
Vl 
(D 
1.97 
2.17 
2.02 
2.05(0.10) 
2.74 
2.65 
2.77 
2.72(0.06) 
1.76 
1.29 
1.62 
1.56(0.24) 
1.79 
1.90 
2.06 
1.92(0.14) 
S.ur 
(min) 
50 
69 
48 
56(12) 
92 
50 
40 
61(28) 
40 
75 
46 
54(19) 
31 
50 
39 
40(10) 
urine 
MRTR 
(min) 
73 
101 
72 
82(16) 
59 
73 
58 
63(8) 
65 
109 
68 
81(25) 
49 
78 
57 
61(15) 
CLR 
(mi/min) 
59 
52 
56 
56(4) 
40 
40 
35 
38(3) 
56 
31 
57 
48(15) 
72 
52 
66 
63(10) 
D 
ur (%) 
98 
97 
89 
95(5) 
88 
92 
88 
89(2) 
83 
85 
80 
83(3) 
87 
83 
82 
84(3) 
that some benzoylglycines may be deglycinated in the organism [Quick, 
1932; Mályusz et a l . , 1972; Bekersky et a l . , 1980]. Only in the experi-
ments with 4-methylbenzoylglycine deconjugation could be detected. The 
deconjugation product, 4-methylbenzoate, was found in plasma and not in 
urine (Fig. 6.3), indicating that the acid either is metabolized completely 
within the kidney, or is reabsorbed unchanged into the general circula-
tion and cleared or metabolized elsewhere. Metabolism in the kidney may 
involve reconjugation with glycine or other routes, of which glucuronida-
tion is most likely. The voided urine was not examined for the presence 
of glucuronides. Plasma concentration data of 4-methylbenzoate were fit-
ted to two exponentials; the half-life of the ascending phase was 23 ± 10 
min and of the descending phase 33 ± 10 min. The maximum plasma con-
centration (± 10 yg/ml) was reached in about 30 min, after which concen-
trations up to 25% of the parent compound were observed. Since the vol-
ume of distribution of 4-methylbenzoate is not known, no information can 
be obtained on clearance values and absolute quantities formed. 
Kidney Model 
The physiologically based kidney model for the renal excretion of the 
glycine conjugates is depicted in Fig. 6 .1 . The model is composed of a 
series of lumped compartments representing the kidney, the central plas-
ma pool and the peripheral tissues. The drug is introduced in the cen-
tral plasma compartment by i .v. injection and can be distributed from 
there to the kidney and peripheral tissues or be eliminated by nonrenal 
clearance. The kidney compartment is subdivided into a renal plasma, 
tubular cell and tubular urine compartment. Clearance by glomerular fil-
tration is considered to be dependent on unbound drug concentration in 
the central plasma compartment. Active transport takes place from renal 
plasma into the tubular cell compartment according to Michaelis-Menten 
kinetics, followed by first-order transport into the tubular urine compart-
ment. Tubular secretion was assumed to be a function of total drug con-
centration in renal plasma, except for 2-methylbenzoylglycine. At low 
plasma concentrations, the renal extraction ratio of the 2-methyl analog 
was nearly zero, whereas renal clearance of the other benzoylglycines 
approached the renal plasma flow, indicating that plasma protein binding 
does not hinder the active renal secretion of these compounds. 
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Table 6.A Model parameters characterizing the renal handling of methyl-substituted benzoylglycines. 
ел 
о 
C L N R k43 k15 k51 Substituent Dog T M K-
(mg/min) (vg/ml) (mi/min) (min-1) (min-1) (min-1) 
H 1 5.8 ± 2.1 46 ± 38 0 ± 2 0.07 ± 0.03 0.033 ± 0.020 0.043 ± 0.006 
2 4.6 ± 0.7 38 ± 12 4 ± 2 0.08 ± 0.04 0.047 ± 0.003 0.063 ± 0.006 
3 6.2 ±1.1 37 ± 20 5 ± 3 0.27 ± 0.17 0.027 ± 0.002 0.026 ± 0.002 
Mean(SD) 5.5(0.8) 40(5) 3(3) 0.14(0.11) 0.036(0.010) 0.044(0.019) 
2-CH3
a
 1 216b 1 ± 5 0.31 ± 0.17 0.023 ± 0.005 0.035 ± 0.003 
2 109 10 ± 6 0.33 ± 0.39 0.026 ± 0.004 0.046 ± 0.006 
3 164 1 0 + 7 0.16 ± 0.12 0.026 ± 0.007 0.033 ± 0.003 
Mean(SD) 163(54) 7(5) 0 .27(0 .09) 0.025(0.002) 0.038(0.007) 
3-CH3 1 8.2 ±1.9 48 ± 25 7 ± 2 0.05 ± 0.01 0.053 ± 0.007 0.083 ± 0.014 
2 3.4 ± 1.2 49 ± 21 10 ± 4 0.16 ± 0.23 0.071 ± 0.007 0.070 ± 0.008 
3 9.6 ± 1.6 50 ± 20 11 ± 4 0.07 ± 0.04 0.084 ± 0.008 0.071 ± 0.008 
Mean(SD) 7.1(3.3) 49(1) 9(2) 0.09(0.06) 0.069(0.016) 0.075(0.007) 
4-CH3 1 9.5 ± 0.3 8 ± 2 10 ± 3 0.53 ± 0.20 0.054 ± 0.004 0.053 ± 0.003 
2 6.3 ± 1.6 18 ± 19 7 + 5 0.14 ± 0.12 0.042 ± 0.005 0.043 ± 0.009 
3 8.2 ±0.5 17 ± 4 13 ± 2 0.37 ± 0.12 0.041 ± 0.003 0.043 + 0.002 
Mean(SD) 8.0(1.6) 14(6) 10(3) 0.35(0.20) 0.046(0.007) 0.046(0.006) 
Tubular secretion was considered dependent on unbound plasma concentrations. 
Since secretion was not saturated estimates of T M and K-, were very inaccurate 
(SD > 200%), therefore only the ratio Τ,,/Κ™ (ml/min) is given. 
Plasma concentration and renal excretion rate data of each experiment 
were simultaneously fitted to the model and the results are listed in Table 
6.4 and are also represented by the solid lines through the data points in 
Figs. 6.3 and 6.4. The goodness of fit between the observed and model-
predicted plasma concentration and renal excretion rate data was in all 
cases: R2 . > 0.990 and R2 . > 0.982. In Fig. 6.4, the renal 
plasma urine β 
excretion rate is plotted linearly against the plasma concentration at the 
midpoint of a urine collection interval. These so-called tubular titration 
curves clearly show that all compounds undergo net tubular secretion 
over the concentration range measured. The lines representing the 
glomerular filtration are slightly curved as a result of the nonlinear pro­
tein binding. With the exception of 2-methylbenzoylglycine, the titration 
curves paralleled the glomerular filtration line at high concentrations, 
indicating that tubular secretion was saturated. Because saturation was 
not reached for 2-methylbenzoylglycine, the estimates of the parameters 
describing active transport (T.. and K T ) were inevitably crude and high­
ly correlated, therefore only the ratio T../K™,, the intrinsic unbound 
ivi 1 
secretion clearance (CLu ), is given (Table 6.4). 
There were no indications to suggest that active or passive reabsorption 
were involved in the renal clearance of the benzoylglycines. Non-ionic 
back-diffusion is very unlikely to occur, considering the high urine flow 
and the high urinary pH as compared to the dissociation constants of the 
compounds (pK < 4.5) . 
6.4 DISCUSSION 
The results of the present study show that the renal excretion of ben-
zoylglycine and methyl-substituted derivatives is dominated by tubular 
secretion. The plasma concentration and renal excretion rate curves could 
be adequately described with the physiologically based kidney model in 
terms of concomitant glomerular filtration and active secretion, despite the 
considerable differences in kinetics. 
All substances showed concentration-dependent plasma protein binding 
which affected their renal clearance to a greater or lesser degree. Obvi­
ously, the excretion by glomerular filtration was influenced in all cases, 
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Fig. 6.4 Tubular t i t r a t i o n curves representing the relationship between 
renal excretion rate and plasma concentration of benzoylglycine and 
methyl-substituted benzoylglycines. The solid lines through the data 
points are calculated according to the kidney model. GF represents the 
clearance by glomerular f i l t r a t i o n . 
for only the unbound concentration in plasma is available for filtration. 
Plasma protein binding did not directly affect the tubular secretion of 
benzoylglycine and 3- and 4-methylbenzoylglycine, presumably due to a 
rapid dissociation of the drug-protein complex relative to the affinity for 
the secretory system. However, in case of 2-methylbenzoylglycine the 
very low dissociation constant of the complex apparently prevented the 
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protein bound fraction from being secreted. As a result of the extremely 
high protein binding at low plasma concentrations, elimination from plasma 
was strongly retarded and renal excretion was almost completely inhibited 
at concentrations below 30 pg/ml. However, it should be mentioned that 
although evidence for the inhibitory effect of tight protein binding on 
tubular secretion of 2-methylbenzoylglycine is plausible, there remains a 
theoretical possibility of saturable tubular reabsorption being responsible 
for the lack of renal excretion at plasma levels below 30 yg/ml. 
Apart from the variable effects of protein binding on renal clearance, 
the excretory profiles of the benzoylglycines varied also as a result of 
differences in their kinetic interaction with the tubular secretory system. 
The lowest tubular transport maximum (T M ) was observed for benzoyl-
glycine, followed by 3- and 4-methylbenzoylglycme, while the clearance 
capacity of 2-methylbenzoylglycine was apparently too high to estimate its 
T M at the given dose (Table 6.4). This hampered also the calculation of 
the apparent affinity constant for tubular secretion (K™) of the 2-methyl 
analog. The K™ of benzoylglycine and 3-methylbenzoylglycine were about 
the same value and the lowest value was found for the 4-methyl isomer. 
Taken these results together, it follows that the maximum clearance 
capacity of the secretory system, expressed as the intrinsic secretion 
clearance CL. . = Tw/K™, was largest for 4-methylbenzoylglycme (CL. .= 
570 ± 180 ml/min). As this value surpasses the renal plasma flow several 
times, renal elimination is perfusion-rate limited up to plasma concentra­
tions at which tubular secretion starts to get saturated. This is 
expressed by the initial linear part in the tubular titration curve of 
4-methylbenzoylglycine, the slope of which is an estimate of the renal 
plasma flow. The rate constants describing transport from tubular cell to 
lumen (кд~) were in the same range for all compounds (Table G.4). 
Although this transport step is in principle also saturable, it is known 
from in vitro studies with PAH [Kinsella et a l . , 1979] that it is character­
ized by a very high capacity and low affinity (K > 3.5 mM), thus it 
seems justified to approximate the transfer from cell to lumen by a first-
order process. 
An interesting finding of the present study is the conversion of 
4-methylbenzoylglycine into 4-methylbenzoate. The absence of 
4-methylbenzoate from urine indicated that the compound was either 
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cleared extrarenally, or completely metabolized during transit through the 
kidney. It is important to notice that the renal clearance of 
4-methylbenzoylglycine may have been influenced by the presence of 
4-methylbenzoate. If both compounds share the same secretory transport 
system, it is possible that tubular secretion was partially inhibited. On 
the other hand, renewed glycine conjugation within the kidney and subse-
quent excretion could lead to an overestimation of tubular secretion. 
A commonly used test of exposure to toluene and xylenes is based on 
the excretion of benzoylglycine and methyl-benzoylglycines in urine 
[Ogata et a l . , 1986]. It is generally assumed that the tubular secretory 
capacity for benzoylglycines is so high that it precludes renal excretion 
as the rate-limiting step in disposition [Riihimkki and Hänninen, 1987]. 
However, if the results of the present study may be extrapolated to the 
human situation, the differences in excretory profiles demonstrate that 
this assumption may not always hold t rue . For instance, exposure to 
o-xylene is not noticed until plasma levels of its metabolite have exceeded 
a certain treshold value. Clearly, an adequate evaluation of biological 
exposure to xenobiotics by monitoring the urinary excretion of their final 
metabolites is not possible without a thorough knowledge of the basic pro-
cesses that determine the renal excretion of the metabolites involved. 
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CHAPTER 7 
RENAL CLEARANCE OF SUBSTITUTED HIPPURATES. 
LGLYCINE AND HYD 
BENZOYLGLYCINES1 
II. 4-AMINOBENZOY YDROXY-SUBSTITUTED 
Л
Frans G.M. Rüssel, Alf ons С. Wouterse, and Cees A.M. van Ginneken 
Abstract - Plasma kinetics and renal excretion of 4-aminobenzoylglycine 
(p-aminohippurate) and hydroxy-substituted bonzoylglycines were studied 
in three Beagle dogs after rapid intravenous administration of about 1 
gram. Plasma protein binding of 4-amino-, 3-hydroxy-, and 
4-hydroxybenzoylglycine was low (<150o) and practically constant over a 
concentration range of 5 - 450 ug/ml, while the 2-hydroxy analog showed 
concentration-dependent protein binding ranging from 40 - 80%. The 
excretory patterns of the 4-amino, 3- and 4-hydroxy analogs were essen­
tially the same; rapid elimination from plasma into urine (>80% of the 
dose), mainly by very efficient supply-limited tubular secretion. Con­
versely, the excretion of 2-hydroxybenzoylglycine was characterized by a 
lower plasma clearance and total renal excretion (G40o of the dose), and a 
limited capacity of the tubular secretory system. Plasma concentration 
and renal excretion rate data were analyzed simultaneously according to a 
physiologically based kidney model. The kinetic parameters characterizing 
the tubular secretion of 2-hydroxybenzoylglycine were, Т
м
= 4.4 ± 0.9 
mg/min and !(_,= 23 ± 8 yg/ml. Since secretion of the other compounds 
was not saturated, only the intrinsic secretion clearance (CL. = T . . / K T ) , 
could be estimated; 4-amino- CL. .= 145 ± 50 ml/min, 3-hydroxy- CL. .= 
194 ± 21 ml/min, and 4-hydroxybenzoylglycine CL. ,= 153 ± 23 ml/min. 
J . Pharmacol. Exp. T h e r . , submitted 
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7.1 INTRODUCTION 
In the present study, the second in a series of three on the renal han-
dling of substituted hippurates, the excretory characteristics of 
4-aminobenzoylglycine (p-aminohippurate) and hydroxy-substituted ben-
zoylglycines were investigated. 4-Aminobenzoylglycine was chosen by 
renal physiologists many years ago as a model compound to study the 
properties of the renal organic anion system [Smith et a l . , 1938; Smith et 
a l . , 1945]. Preference for this compound emanated from its very efficient 
renal clearance, weak binding to plasma proteins, limited reabsorption, 
and convenience to be analyzed chemically in biological fluids. At low 
plasma concentrations, renal clearance of 4-aminobenzoylglycine approach-
es the renal plasma flow, since extraction from plasma during a single 
passage of blood through the kidney is almost complete. In fact, its renal 
clearance was used for a long time as a measure of renal plasma flow, but 
it has been shown that it is not under all conditions a reliable parameter 
[Aukland and L0yning, 1970; Lote et a l . , 1985]. Furthermore, in man 
and some animal species 4-aminobenzoylglycine is metabolized to a certain 
extent during passage through the kidney f room blood to urine [Setchell 
and Blanch, 1961; Mályusz et a l . , 1972; Girndt et a l . , 1974]. 
Among the hydroxy-substituted benzoylglycines, the kinetics and renal 
excretion of the 2-hydroxy analog (salicylurate) have received most atten-
tion, because it is the major metabolite of salicylic acid. Although 
2-hydroxybenzoylglycine is bound considerably to plasma proteins, its 
renal clearance equals the 4-aminobenzoylglycine clearance at low plasma 
concentrations, indicating that protein binding does not limit the extent of 
secretion [Knoefel et a l . , 1962]. At high plasma concentrations, 
2-hydroxybenzoylglycine showed renal excretory transport to a small 
degree in comparison with 4-aminobenzoylglycine [Knoefel and Huang, 
1959] . It was suggested that because of the high hydrophobicity, as a 
result of internal hydrogen bonding, passive reabsorption accounted for 
the lower tubular excretory transport rather than a limited capacity of 
the secretory system [Knoefel et a l . , 1962]. However, recently we showed 
that under circumstances where passive back-diffusion is negligible, the 
maximal rate of tubular transport of 2-hydroxybenzoylglycine is consider-
ably less than that described for 4-aminobenzoylglycine [Rüssel et a l . , 
1987]. 
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The renal excretory characteristics of 4-hydroxybenzoylglycine were 
found to resemble those of its 4-amino analog. At high plasma concentra-
tions (>200 vg/ml) 4-hydroxybenzoylglycine saturated the tubular t rans-
port system and underwent tubular excretory transport at a maximal rate 
such as found with the 4-amino analog. The compound had a low 
hydrophobicity and accordingly little tendency to undergo passive tubular 
reabsorption [Knoefel et a l . , 1962]. 
The renal clearance of 3-hydroxybenzoylglycine has been studied only 
at low plasma concentrations (<5 ug/ml). Under these conditions its renal 
clearance was essentially identical to that of its 4-hydroxy and 4-amino 
analogs [Smith et a l . , 1945]. 
In the foregoing paper wc investigated the renal handling of benzoyl-
glycine and methyl-substituted benzoylglycines in the dog [Rüssel et a l . , 
1988a]. The aim of the present study was to determine under exactly the 
same circumstances the excretory characteristics of 4-amino- and 2-, 3 - , 
and 4-hydroxybenzoylglycine. 
7.2 MATERIALS AND METHODS 
Chemicals 
4-Aminobenzoylglycine (p-aminohippuric acid) and 2-hydroxybenzoyl-
glycine (salicyluric acid) were commercially available from Merck (Darm-
stadt, FRG). The 3- and 4-hydroxy-substitut9d benzoylglycines were 
prepared by chemical synthesis as described below. The preparation of 
4-methoxybenzoylglycine is described elsewhere [Rüssel et al . , 1988b] . 
Glycine, 3- and 4-hydroxybenzoic acid and dioxane were obtained from 
Merck, N-hydroxysuccinimide and N.N'-dicyclohexylcarbodiimide were from 
Janssen Chimica (Beerse, Belgium). All other chemicals are described 
elsewhere [Rüssel et a l . , 1988a]. 
Preparation of 3- and 4-HydroxybenzoyIglycine 
The active ester method, as described by Van Brussel and Van Sumere 
[1978], was used to synthesize 3- and 4-hydroxybenzoylglycine. An acti-
vated ester was prepared by reaction of the corresponding hydroxyben-
zoate with N-hydroxysuccinimide in presence of N,N'-dicyclohexylcarbo-
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diimide in dry dioxane. The ester was separated by filtration and subse-
quently added to a slight alkaline glycine solution to yield the hydroxy-
substituted benzoylglycine. The compounds were purified by recrystal-
lization from boiling water. The identity and purity were checked by com-
paring melting points with available literature values [Van Brussel and 
Van Sumere, 1978] and by TLC and HPLC, the methods of which are 
described elsewhere [Rüssel et al . , 1988a]. 
Clearance Experiments 
The experiments were done in the same three male Beagle dogs that 
were used in the foregoing study, under exactly the same conditions 
[Rüssel et al. , 1988a] . Each dog received as a rapid intravenous injec-
tion a sterile solution of about 1 gram of 4-amino- or hydroxy-substituted 
benzoylglycine dissolved in about 15 ml water containing an equimolar 
amount of sodium bicarbonate. At regular times throughout the experiment 
blood samples were taken and urine was collected quantitatively. At the 
end of each experiment the glomerular filtration rate was estimated by 
measuring the steady-state [3H]inulin clearance. 
Analytical Methods 
The 4-amino- and hydroxy-substituted benzoylglycines were determined 
in plasma and urine according to the elsewhere described HPLC method 
[Rüssel et a l . , 1988a], with slight modifications. The mobile phase con-
sisted of a varying mixture of methanol and twice-distilled water contain-
ing 0.01 M citrate (pH 2.6) . The methanol-water ratio was 10:90 in the 
determination of 4-aminobenzoylglycine, 20:80 for 3-hydroxybenzoyl-
glycine, and 30:70 for 2- and 4-hydroxybenzoylglycine. Operating values 
of the wavelength detector (λ), retention times (t-p) and internal stan­
dards ( I .S . ) were: 4-aminobenzoylglycine λ= 254 nm, t R = 3.0 min, I.S.= 
4-methoxybenzoylglycine (t-r,^ 1G.0 min); 2-hydroxybenzoylglycine λ= 245 
nm, t = G.2 min, I.S.= benzoylglycine (tj,= 4.1 min); 3-hydroxybenzoyl-
glycine λ= 238 nm, t„= 3.4 min, I.S.= 4-methylbenzoylglycine ( t R = 11.0 
min); 4-hydroxybonzoylglycine \= 240 nm, t_= 2.0 min, I.S.= 4-methyl­
benzoylglycine (tp= 7.9 min). 
Plasma and urine samples were checked for the presence of the corre­
sponding acid derivative, resulting from a possible in vivo deglycination 
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reaction. In the plasma samples of the experiments with 
4-hydroxybenzoylglycine, chromatographed under the same conditions as 
described above, a small amount of 4-hydroxybenzoate (t = 5.8 min) was 
found. Concentrations were, however, too low (<1 yg/ml) to be quantified 
accurately. 
The determination of plasma protein binding and [3H]inulin concentra-
tions in plasma and urine were the same as described in the foregoing 
paper. 
Kinetic Analysis 
Plasma concentration and renal excretion rate curves were analyzed sep-
arately by statistical moment theory and basic pharmacokinetic parameters 
were calculated. Plasma curves were fitted to the sum of two exponen-
tials, except for the nonlinear semilogarithmic plots of 
2-hydroxybenzoylglycine. These curves were fitted using a cubic spline 
interpolation method in combination with extrapolation of the initial distri-
bution phase of the plot to time 0, and the terminal phase of the plot to 
infinity. The renal exretion rate curves of all experiments were analyzed 
in the same way. 
In order to come to a comprehensive analysis of the processes that 
determine the renal excretion of the compounds, plasma concentration and 
renal excretion rate data of each experiment were analyzed simultaneously 
according to a physiologically based kidney model. Equations, calculation 
methods and computer programs are described in detail elsewhere [Rüssel 
et al . , 1988a]. Average values are expressed as means ± SD. 
7.3 RESULTS 
Experimental Conditions and Protein Binding 
The parameters describing the experimental circumstances of the clear-
ance studies are given in Table 7 .1 . The glomerular filtration rate 
(Qpp), measured by steady state [3H]inulin clearance, ranged from 22 -
38 ml/min. the mannitol induced urine flow (Q ) varied from 0.6 - 1.3 
'
v
 u r ' 
ml/min and the urinary pH from 7.0 - 7.7. 
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Table 7.1 Experimental conditions of the clearance studies with 4-amino-
and hydroxy-substituted benzoylglycines. 
Dog 
1 
2 
3 
Weight 
(kg) 
13.0 
13.5 
13.0 
13.7 
13.3 
13.5 
12.8 
13.5 
15.0 
14.8 
14.8 
15.2 
Substituent 
4-NH2 
2-OH 
3-OH 
4-OH 
4-NH2 
2-OH 
3-OH 
4-OH 
4-NH2 
2-0H 
3-OH 
4-OH 
Dose 
(mg) 
1060 
970 
980 
1130 
1050 
980 
980 
1160 
1060 
980 
960 
1090 
QGF 
(ml/min) 
27 
38 
30 
31 
22 
27 
28 
28 
34 
30 
34 
32 
+ 
+ 
+ 
+ 
+ 
+ 
± 
+ 
+ 
+ 
+ 
± 
3 
4 
1 
1 
4 
3 
3 
1 
3 
1 
1 
1 
%r 
(ml/min) 
0.83 
0.94 
0.63 
1.21 
1.04 
0.69 
0.64 
0.89 
1.05 
0.83 
0.95 
1.26 
± 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
0.22 
0.31 
0.25 
0.41 
0.22 
0.20 
0.19 
0.51 
0.25 
0.28 
0.28 
0.45 
PHur 
7.67 
7.15 
7.54 
7.53 
7.37 
7.24 
7.35 
7.46 
7.19 
7.05 
7.26 
7.42 
± 
+ 
+ 
+ 
± 
+ 
+ 
+ 
+ 
+ 
+ 
± 
0.16 
0.31 
0.11 
0.12 
0.13 
0.16 
0.12 
0.10 
0.14 
0.24 
0.16 
0.14 
Plasma protein binding of 4-aminobenzoylglycine and the hydroxy-
substituted benzoylglycine is shown in Fig. 7 .1 . Protein binding data of 
all experiments were pooled for each compound, since differences in the 
extent of binding were small between the dogs. Over the plasma concen­
tration range measured (5 - 450 yg/ml), the fraction unbound was virtu­
ally constant for 4-amino- (0.95 ± 0.05, n=13), 3-hydroxy- (0.Θ9 ± 0.06, 
n=9) and 4-hydroxybenzoylglycine (0.91 ± 0.05, n=14). The plasma pro­
tein binding of 2-hydroxybenzoylglycine was concentration-dependent, the 
fraction unbound varying from 0.2 - 0.G, and the data (n=30) were ana­
lyzed according to a one site binding model as described in the foregoing 
paper. The results of these calculations were 218 ± 24 pg/ml for total 
concentration of protein binding sites (P) and 92 ± 18 μg/ml for the dis­
sociation constant (K ,) of the drug-protein complex. 
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Fig. 7.1 Plasma protein binding of 4-aminobenzoylglycinc and hydroxy-
substituted bcnzoylglycines. 
Pharmacokinetic Analysis 
Representative examples of plasma concentration and renal excretion 
rate after intravenous administration of 4-aminobenzoylglycine and 
hydroxy-substituted benzoylglycines are shown in Fig. 7.2. Plasma and 
renal excretion data were analyzed separately and basic pharmacokinetic 
parameters are given in Table 7.2. The results show that 4-amino-, 
3-hydroxy- and 4-hydroxybenzoylglycine were rapidly eliminated from 
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Fig. of 7.2 Renal excretion rate and plasma concentration 
A-aminobenzoylglycine and hydroxy-substituted benzoylglycines. The solid 
lines through the data points represent the results of data analysis 
according to the kidney model. 
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Table 7.2 Basic pharmacokinetic parameters of 4-amino- and hydroxy-substituted 
benzoylglycines after rapid intravenous injection. 
Substituent 
4-NH2 
2-OH 
3-OH 
4-OH 
Dog 
1 
2 
3 
Mean(SD) 
1 
2 
3 
Mean(SD) 
1 
2 
3 
Mean(SD) 
1 
2 
3 
Mean(SD) 
^.P 
(min) 
36 
42 
71 
50(19) 
20 
25 
20 
22(3) 
23 
29 
27 
26(3) 
37 
33 
40 
37(4) 
plasma 
CL 
(ml/min) 
90 
73 
82 
82(9) 
69 
50 
61 
60(10) 
120 
96 
116 
111(13) 
98 
71 
90 
86(14) 
Vl 
CD 
1.45 
1.95 
2.96 
2.12(0.77) 
1.90 
2.11 
1.95 
1.99(0.11) 
1.78 
2.24 
2.31 
2.11(0.30) 
2.38 
1.46 
2.26 
2.03(0.50) 
Ь
і,пг 
(min) 
64 
43 
53 
53(11) 
23 
35 
30 
29(6) 
35 
28 
23 
29(6) 
38 
37 
43 
39(3) 
up 
MRTR 
(min) 
52 
62 
58 
57(5) 
57 
73 
63 
64(8) 
35 
40 
33 
36(4) 
40 
57 
48 
48(9) 
ine 
C LR 
(ml/min) 
79 
67 
70 
72(6) 
46 
31 
39 
39(8) 
97 
79 
91 
89(9) 
92 
62 
87 
80(16) 
D
ur 
« ) 
88 
92 
85 
88(4) 
66 
63 
63 
64(2) 
81 
83 
78 
81(3) 
94 
88 
97 
93(5) 
plasma, largely by renal excretion (D > 80oo). The high total renal clear-
ance of these compounds as compared to the clearance that would be 
observed by glomerular filtration alone, is indicative for avid tubular 
secretion. 
The pharmacokinetic profile of 2-hydroxybenzoylglycine differed clearly 
from its hydroxy isomers and 4-amino analog. Its plasma clearance was 
much lower and only 64 ± 2% of the administered dose was excreted in the 
urine. Accordingly, renal clearance was also substantially lower. How-
ever, taking an average protein binding of 40 - 50oo into account, it can 
be calculated that the total renal clearance was still twice the value 
attributable to glomerular filtration, showing that 2-hydroxybenzoylglycine 
is also cleared by tubular secretion. 
Since splitting of the glycine moiety from 4-amino- and 
2-hydroxybenzoylglycine has been described in the rat [Mályusz et a l . , 
1972; Bekersky et al . , 1980], we checked all plasma and urine samples 
for the presence of the corresponding benzoates. Only in case of 
4-hydroxybenzoylglycine, small amounts of its benzoate (<1 yg/ml) were 
discovered in plasma, while for none of the other compounds deglycination 
products could be detected. 
Kidney Model 
A physiologically based pharmacokinetic model was used to quantify the 
processes that are involved in the renal excretion of the benzoylglycines. 
The model is composed of a series of lumped compartments representing 
the central plasma pool, the peripheral tissues and the kidney. The kid-
ney is divided further into a renal plasma, tubular cell and tubular urine 
compartment. A schematic representation and detailed description of the 
model was given in the foregoing paper. Since the renal extraction of the 
4-amino- and hydroxy-substituted benzoylglycines is virtually complete at 
low plasma concentrations, the process of tubular secretion was consid-
ered to be dependent on the total concentration of compound in renal 
plasma. Plasma and urinary data of each experiment were simultaneously 
fitted to the model and the results are given in Table 7.3 and are also 
represented by the solid lines through the data points in Figs. 7.2 and 
7.3. The goodness of fit between the observed and model-predicted plas-
ma concentration and renal excretion rate data was in all cases: R2 , > 
plasma 0.990 and R2 . > 0.980. 
urine 
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Table 7.3 Model parameters characterizing the renal handling of 4-amino- and 
hydroxy-substituted benzoylglycines. 
Substituent Dog !„ K- CL™ k,, k 1 5 k 5 1 
(mg/min) (vg/ml) (ml/min) (min-1) (min-1) (min-1) 
4-NH2 1 144
a
 10 ± 9 0.14+0.13 0.094 ± 0.023 0.059 ± 0.008 
2 196 10 ± 6 0.23 ± 0.16 0.053 ± 0.007 0.045 ± 0.004 
3 96 7 ± 6 0.31 ± 0.23 0.034 ± 0.004 0.028 ± 0.002 
Mean(SD) 145(50) 9(2) 0.23(0.09) 0.060(0.031) 0.044(0.016) 
2-OH 1 5.0 ± 0.9 1 7 + 1 4 20 ± 3 0.07 ± 0.02 0.024 ± 0.005 0.056 ± 0.012 
2 3.3 ±0.2 20 ± 3 18 ± 2 0.26 ± 0.16 0.042 ± 0.006 0.104 ± 0.014 
3 4.8 ± 0 . 5 3 2 + 9 21 ± 4 0.10 + 0.03 0.060 ± 0.026 0.143 + 0.049 
Mean(SD) 4 . 4 ( 0 . 9 ) 23(8) 20(2) 0 .14(0.10) 0.042(0.018) 0.101(0.044) 
3-OH 1 218a 21 ± 6 0.11 ± 0.07 0.040 ± 0.015 0.060 ± 0.004 
2 179 14 ± 5 0.17 ± 0.11 0.030 ± 0.008 0.056 ± 0.006 
3 186 20 ± 4 0.22 ± 0.07 0.034 ± 0.004 0.058 ± 0.004 
Mean(SD) 194(21) 18(4) 0.17(0.06) 0.035(0.005) 0.058(0.002) 
4-OH 1 180a 10 ± 4 0.19 ± 0.14 0.052 ± 0.006 0.047 ± 0.005 
2 143 3 ± 8 0.11 ± 0.06 0.035 ± 0.012 0.040 ± 0.004 
3 137 4 ± 4 0.20 ± 0.06 0.029 ± 0.004 0.038 ± 0.002 
Mean(SD) 153(23) 6(4) 0.17(0.05) 0.039(0.012) 0.042(0.005) 
Since secretion was not saturated estimates of T., and KT were very inaccurate 
-a (SD > 200%), therefore only the ratio ^/K™ (ml/min) is given. 
renal excretion rate 
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Fig. 7.3 Tubular t i t r a t i o n curves representing the relationship between 
renal excretion rate and plasma concentration of 4-aniinobenzoylglycine and 
hydroxy-substituted benzoylglycines. The solid lines through the data 
points are calculated according to the kidney model. GF represents the 
clearance by glomerular f i l t r a t i o n . 
Fig. 7.3 shows linear plots of the renal excretion rate as a function of 
the plasma concentration at the midpoint of a urine collection interval. 
These tubular titration curves indicate that the clearance characteristics 
of 4-amino-, 3-hydroxy- and 4-hydroxybenzoylgycine were practically the 
same, whereas the profile of the 2-hydroxy analog was clearly different. 
At the given doses, saturation of the secretory system was achieved only 
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for 2-hydroxybenzoylglycine. Renal secretion of the other compounds 
appeared to be a linear function of the plasma concentration up to levels 
of at least 150 yg/ml. Accordingly, the parameters 14, and K T , describ­
ing the active transport of these compounds, could not be calculated 
accurately. Therefore only an estimate of the ratio Τ,./Κ,-ρ, the intrinsic 
secretion clearance (CL. ), was given (Table 7.3). 
Considering the dissociation constants of the glycine conjugates [Smith 
et al., 1945; Knoefel et al . , 19G2], viz., 4-amino- (pK = 3.8), 
2-hydroxy- (pK = 3.6), 3-hydroxy- (pK = 3.6) and 4-hydroxybenzoyl-
glycine (pK = 3.7), in relation with the experimental conditions, it seems 
a 
unlikely that reabsorption by non-ionic diffusion played a role of impor­
tance in total renal clearance. Although the hydrophobic nature of 
2-hydroxybenzoylglycine, due to internal hydrogen bonding, may give 
rise to passive reabsorption, even when the urinary flow and pH are high 
[Knoefel et a l . , 1962], it is clear from the profile of its tubular titration 
curve, in which the total renal clearance parallels the glomerular filtration 
at high concentrations, that reabsorption was negligible under the present 
conditions. 
7.4 DISCUSSION 
The renal disposition of 4-aminobenzoylglycine and the hydroxy-
substituted benzoylglycines can be analyzed in terms of the basic 
intrarenal processes of glomerular filtration and transtubular secretion. 
However, the excretory pattern of 2-hydroxybenzoylglycine contrasted 
clearly with that of the other compounds. Plasma kinetics and renal clear­
ance of the 4-amino and 3- and 4-hydroxy analogs were essentially the 
same and were characterized by a low plasma protein binding, rapid elimi­
nation from plasma and a high renal clearance due to avid tubular secre­
tion. In comparison, the kinetics of the 2-hydroxy analog were character­
ized by a relatively high protein binding, lower plasma and renal 
clearance, and limited capacity of the tubular secretory system. 
It can be calculated from Table 7.3 that the intrinsic secretion clearance 
of 2-hydroxybenzoylglycine, CL. = TM/K™= 203 ± 19 ml/min, was not less 
than that of the other compounds, indicating that at low plasma levels 
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renal clearance was equally efficient and not hindered by the high protein 
binding. But, at increasing plasma concentrations its renal clearance 
decreased rapidly and fell toward the level of glomerular filtration, while 
the renal clearance of the other derivatives remained virtually unaltered. 
Since passive reabsorption by non-ionic diffusion was negligible under the 
experimental conditions, the lower renal excretion can be ascribed to the 
limited capacity of the secretory system (TM) for 2-hydroxybenzoyl-
glycine. 
The clearance capacity of the secretory system with respect to 
4-amino-, 3-hydroxy- and 4-hydroxybenzoylglycine is apparently so high 
that up to plasma concentrations of 150 ug/ml saturation was not reached. 
The almost linear course of the titration curves of these compounds dif-
fers clearly from the usual Michaelis-Menten profile and is typical for 
compounds that are so efficiently excreted that clearance is supply-limited 
up to levels at which the secretory system begins to be saturated. In this 
situation the renal plasma flow is the rate-limiting step in clearance. 
Indeed, the slope of the titration curve is an operational estimate of the 
effective renal plasma flow. Since the active step in secretion is located at 
the basolateral membrane of the proximal tubular cells [Miller and Sheikh, 
1983] , it can be concluded that the cellular uptake of these compounds is 
in the order of magnitude of the renal plasma flow, i . e . , 140 - 170 ml/ 
min. The clearance out of the cells into the tubular lumen ranges from 4 
- 9 ml/min, as calculated from the product of the estimated tubular cell 
volume, being 30 ml [Rüssel et al . , 1988a], and the rate constant k._ 
(Table 7.3) . Thus, according to the kidney model, the active secretion 
of these compounds will be accompanied by a substantial accumulation 
within the tubular cells. This is in accordance with previously reported 
in vitro observations [M0ller and Sheikh, 1983; Forster and Copenhaver, 
1956] 
Deconjugation of the glycine group of 4-amino- and 
2-hydroxybenzoylglycine has been described to occur in rat kidney 
[Mályusz et a l . , 1972; Bekersky et a l . , 1980]. Apparently, this is not a 
significant process in dog as we found no metabolic conversion for any of 
the compounds, except for the small quantities of 4-hydroxybenzoate in 
plasma in the experiments with 4-hydroxybenzoylglycine. Acetylation of 
the amino group of 4-aminobenzoylglycine, which is known to occur in liv-
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er and kidney of man and many animal species, does not occur in rabbit 
and dog [Smith et a l . , 1945; SetcheU and Blanch, 1961]. 
In conclusion, 3- and 4-hydroxybenzoylglycine are very efficiently 
cleared by the kidney in essentially the same way as 4-aminobenzoyl-
glycine. The excretory pattern of 2-hydroxybenzoylglycine is clearly dif-
ferent and is characterized by a limited transport capacity of the secreto-
ry system. It may be suggested that the less efficient interaction of the 
2-hydroxy analog with the renal anion transport system is related to its 
specific property to form an intramolecular hydrogen bond between the 
hydroxy and carbonyl group. 
Acknowledgements 
The authors are indebted to Mr. H. van Deelen and Dr. A.J . Beld for 
the preparation of the glycine conjugates. 
7.5 REFERENCES 
Aukland, K. and L0yning, E.W. : Intrarenal blood flow and para-
aminohippurate (PAH) extraction. Acta Physiol. Scand. 79, 95-108, 
1970. 
Bekersky, I . , Colburn, W.A., Fishman, L. and Kaplan, S.A.: 
Metabolism of salicylic acid in the isolated perfused rat kidney. Inter-
conversion of salicyluric and salicylic acids. Drug Metab. Dispos. 8, 
319-324, 1980. 
Forster, R.P. and Copenhaver, J .V . : Intracellular accumulation as an 
active process in a mammalian renal transport system in vitro. Am. J . 
Physiol. 186, 167-171, 1956. 
Girndt, J . , Mályusz, M., Rumpf, K.W., Neubaur, J . and Sheller, F . : 
Metabolism of p-aminohippurate and its relevance in man. Nephron 13, 
138-144, 1974. 
Knoefel, P.K. and Huang, K.C. : Biochemorphology of renal tubular 
transport: hippuric acid and related substances. J . Pharmacol. Exp. 
Ther. 126, 296-303, 1959. 
171 
Knoefel, Ρ К , Huang, К С and Jai boe, С Η Renal disposal of salicy­
luric acid Am J Physiol 203, G-10, 1962 
Lote, С J , Mc Vicar, A J and Yardley, С Ρ Renal extraction and 
clearance of p-armnohippurate during saline and dextrose infusion in 
the rat J Physiol 363, 303-313, 1985 
Malyusz, M , Girndt, J , Malyus?, G and Ochwadt, В Die 
Metabolisierung von p-Aminohippurat m Nieren von normalen Ratten 
und Ratten mit experimentellen Goldblatt-Hochdruck Pflugers Arch 
333, 156-165, 1972 
Miller, J V and Sheikh, Μ I Renal organic anion transport system 
pharmacological, physiological, and biochemical aspects Pharmacol 
Rev 34, 315-358, 1983 
Rüssel, F G M , Wouterse, А С and van Ginneken, C A M Physiologi­
cally based pharmacokinetic model for the renal clearance of salicyluric 
acid and the interaction with phenolsulfonphthalein in the dog Drug 
Motab Dispos 15, 695-701, 1987 
Rüssel, F G M , Wouterse, A С and van Ginneken, C A M Renal 
clearance of substituted hippurates in the dog I Ben/oylglycine 
(hippurate) and methyl-substituted benzoylglycines J Pharmacol 
Exp Ther submitted, 1988a 
Rüssel, F G M , Wouterse, A С and van Ginneken, C A M Renal 
clearance of substituted hippurates in the dog III Methoxy-
substituted benzoylglycines J Pharmacol Exp Ther submitted, 
1988b 
Setchell, Β Ρ and Blanch, E Conjugation of p-aminohippurate by the 
kidney and effective renal plasma flow Nature (Lond ) 189, 230-231, 
1961 
Smith, Η W , Goldring, W and Chasis, Η The measurement of the 
tubular excretory mass, effective blood flow and filtration rate in the 
normal kidney J Clin Invest 17, 263-278, 1938 
Smith, H W , Finkelstem, N , Aliminosa, L , Crawford, В and Graber, 
M The renal clearances of substituted hippuric acid derivatives and 
other aromatic acids in dog and man J Clin Invest 24, 388-404, 
1945 
Van Brussel, W and Van Sumere, С F N-Acylammo acids and peptides 
VI A simple synthesis of N-acylglycines of the benzoyl and cinnamyl 
type Bull Soc Chim Belg 87, 791-797, 1978 
172 
CHAPTER 8 
RENAL CLEARANCE OF SUBSTITUTED HIPPURATES. 
III. METHOXY-SUBSTITUTED BENZOYLGLYCINES1 
Frans G.M. Hussel, Alfons С. Wouterse, and Cees A.M. van Ginneken 
Abstract - Plasma kinetics and renal excretion of methoxy-substituted 
benzoylglycines were studied in three Beagle dogs after rapid intravenous 
administration of about 1 gram. The methoxybenzoylglycines showed non­
linear plasma protein binding varying between 10 and 70oo over a concen­
tration range of 5 - 450 yg/ml. The compounds were rapidly cleared from 
plasma, largely by renal excretion (72 - 84% of the administered dose). 
Variation between the basic pharmacokinetic parameters was small, except 
for a higher plasma and total renal clearance of the 4-mothoxy isomer. 
At the given dose, tubular secretion of 2- and 3-methoxybenzoylglycine 
was saturated, while the clearance capacity of the secretory system for 
the 4-methoxy isomer was so high that complete saturation was not 
achieved. The kinetic parameters of tubular secretion, obtained from 
data analysis according to a physiologically based kidney model, were: 
2-methoxybenzoylglycine T . = 11.7 ± 4.9 mg/min, KT= 42 ± 9 ug/ml, and 
3-methoxybenzoylglycine TM= 8.8 ± 1.0 mg/min, ! ( = 27 ± 20 yg/ml. Since 
secretion of 4-methoxybenzoylglycine was not saturated only the ratio 
T M /K T = 201 ± 47 ml/min could be calculated. The 4-methoxy isomer was 
metabolized to some extent by deconjugation of the glycine moiety and the 
resulting benzoate was found in plasma but not in urine. 
J. Pharmacol. Exp. T h e r . , submitted 
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8.1 INTRODUCTION 
This paper is the last in a series of three on the influence of ring sub-
stitution on renal clearance of benzoylglycine (hippurate) In the preced-
ing papers the excretory characteristics of benzoylglycine, 
4-aminobenzoylglycine (p-aminohippurate), methyl-substituted and 
hydroxy-substituted benzoylglycines were studied [Rüssel et al , 
1988a, b] The most efficient renal excretion was found with the 3- and 
4-hydroxy- substituted benzoylglycines, and the model compound 
4-aminobenzoylglycine, which were cleared equally well The renal dispo-
sition of the Oiher benzoylglycines varied considerably as a result of dif-
ferences in their intrarenal as well as extrarenal behavior Plasma kinetics 
and renal excretion rate of all compounds could be adequately analyzed 
with the same physiologically based kinetic model, which comprises the 
functional characteristics of the kidney that determine the excretion of 
the benzoylglycines, ι e , renal plasma flow, urine flow, nonlinear protein 
binding, glomerular filtration and transtubular secretion 
The present study is concerned with the renal clearance of methoxy-
substituted benzoylglycines The renal transport of the 2-methoxy isomer 
has been described previously by Knoefel and Huang [1959] in a study in 
the dog They found a protein binding of about 40% at a plasma concen­
tration of 250 pg/ml and net tubular secretion of about 10 mg/min at a 
concentration of 140 ug/ml The extent of secretion was in the same range 
as was found for benzoylglycine As far as we know, there have been no 
reports on the renal clearance of the 3- and 4-methoxy isomers 
8.2 MATERIALS AND METHODS 
Chemicals 
The methoxy-substituted benzoylglycines were prepared according to 
the Schotten-Baumann method from the corresponding acylchlorides as 
described elsewhere [Rüssel et al , 1988a] The identity and purity were 
checked by comparing melting points with available literature values 
[Quick, 1932, Selheun and Sheline, 1973, ApSunon et al , 1978] and by 
TLC and HPLC o-, m-, and p-Anisoylchlonde (methoxybenzoylchlonde) 
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were obtained from Aldrich (Brussel, Belgium) All other chemicals are 
described elsewhere [Rüssel et al , 1988a] 
Clearance Experiments 
The experiments were done in the same three male Beagle dogs that 
were used in the preceding studies, under exactly the same conditions 
[Rüssel et al , 1988a,b] Each dog received as a rapid intravenous 
injection a sterile solution of about 1 gram of 2-, 3- or 
4-methoxyben7oylglycme dissolved in about 15 ml water containing an 
equimolar amount of sodium bicarbonate At regular times throughout the 
experiment blood samples were taken and urine was collected quantitative-
ly At the end of each experiment the glomerular filtration rate was esti-
mated by measuring the steady-state [3H]mulin clearance 
Analytical Methods 
The methoxy-substituted benzoylglycines were determined in plasma and 
urine according to the elsewhere described HPLC method [Rüssel et al , 
1988a], with slight modifications The mobile phase consisted of a mixture 
of methanol and twice-distilled water (30 70) containing 0 01 M citrate (pH 
2 6) Operating values of the wavelength detector (λ), retention times 
(t.-) and internal standards ( I S ) were 2-methoxybenzoylglycine λ= 235 
nm, t f l = 7 2 mm, I S = benzoylglycine (.t-n= 4 1 nun), 3-methoxybenzoyl-
glycine λ= 238 nm, 1-= 6 0 mm, I S = 3-methylbenzoylglycine (tp= 8 3 
mm), 4-methoxybenzoylglycine \= 240 nm, t = 5 2 mm, I S = 4-methyl-
benzoylglycine (t f l = 7 9 mm) 
Plasma and urine samples were checked for the presence of the corre­
sponding acid derivative In the experiments with 4-methoxybenzoyI-
glycine, 4-methoxybenzoic acid ( ΐ = 13 8, methanol water 35 65, 0 01 M 
citrate pH 2 6, λ= 254 nm) was found in plasma and concentrations were 
quantified 
The determination of plasma protein binding and [3H]inulin concentra­
tions in plasma and urine were the same as described in the foregoing 
paper 
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Kinetic Analysis 
Plasma concentration and renal excretion rate curves were analyzed sep-
arately by statistical moment theory and basic pharmacokinetic parameters 
were calculated. Plasma curves could be fitted well to the sum of two 
exponentials, while the nonlinear scmllogarithmic renal excretion rate 
curves were analyzed using a cubic spline interpolation method in combi-
nation with extrapolation of the terminal phase of the curve to infinity. 
In order to come to a comprehensive analysis of the processes that 
determine the renal excretion of the methoxy-substituted benzoylglycines, 
plasma concentration and renal excretion rate data of each experiment 
were analyzed simultaneously according to a physiologically based kidney 
model. Equations, calculation methods and computer programs are 
described in detail elsewhere [Rüssel et a l . , 1988a]. Average values are 
expressed as means ± SD. 
Table 8.1 Experimental conditions of the clearance studies with 
methoxy-substituted benzoylglycines. 
Dog 
1 
2 
3 
Weight 
(kg) 
12.8 
13.0 
12.5 
11.5 
11.5 
11.5 
13.0 
14.5 
14.0 
Substituent 
2-0CH3 
з-осн3 
4-0CH3 
2-0CH3 
з-осн3 
4-0CH3 
2-0CH3 
з-осн3 
4-0CH3 
Dose 
(mg) 
1000 
1010 
980 
1010 
990 
980 
1010 
1000 
990 
QGF 
(ml/min) 
30 
32 
31 
26 
28 
19 
33 
30 
28 
± 
+ 
+ 
+ 
+ 
+ 
± 
+ 
+ 
2 
2 
5 
1 
1 
1 
1 
3 
1 
Q«r 
(ml/min) 
0.97 
1.02 
0.69 
0.64 
0.70 
0.76 
0.87 
0.99 
0.95 
± 
± 
+ 
+ 
+ 
+ 
+ 
+ 
± 
0.45 
0.29 
0.25 
0.11 
0.27 
0.13 
0.31 
0.18 
0.28 
PHur 
7.18 
7.33 
7.53 
6.43 
7.20 
7.34 
7.06 
7.18 
7.44 
±0.26 
± 0.12 
± 0.11 
± 0.42 
±0.07 
± 0.09 
±0.15 
±0.16 
±0.12 
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8.3 RESULTS 
Experimental Conditions and Protein Binding 
The experimental conditions of the clearance studies with the methoxy-
substituted benzoylglycines are given in Table 8.1. The glomerular fil­
tration rate (Qpp), measured by steady state [3H]inulin clearance, 
ranged from 19 - 33 ml/min, the urine flow (Q ) varied from 0.6 - 1.0 
ml/min and the urinary pH from 6.4 - 7.5. 
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Fig. 8.1 Plasma protein binding of methoxy-substituted benzoylglycines. 
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C o n c e n t r a t i o n - d e p e n d e n t plasma prote in b i n d i n g was o b s e r v e d for each 
of t h e methoxy isomers, t h e fraction u n b o u n d r a n g i n g from 10 - 70% (Fig . 
8 . 1 ) . Because in ter indiv idua l var iat ion was small, d a t a of all e x p e r i m e n t s 
were pooled for each compound and analyzed a c c o r d i n g to a one site b ind­
ing model as d e s c r i b e d in t h e foregoing p a p e r [Hussel et a l . , 1988a]. 
T h e r e s u l t s of t h e s e fits a r e given in Table 8 .2 . 
Table 8.2 Plasma p r o t e i n binding of methoxy-subs t i tu ted benzoylg lyc ines . 
S u b s t i t u e n t η Ρ К, 
α 
(Vg/ml) (yg/nil) 
2-0CH3 16 132 ± 9 16 ± 4 
3-0CH3 15 152 ± 9 44 ± 6 
4-0CH3 17 158 ± 4 4 97 ± 41 
Pharmacokinetic Analysis 
R e p r e s e n t a t i v e examples of plasma d i s a p p e a r a n c e a n d renal excre t ion 
r a t e a f te r i n t r a v e n o u s adminis t rat ion of t h e methoxybenzoylg lyc ines a r e 
shown in Fig. 8 .2 . Plasma a n d u r i n a r y data were ana lyzed separate ly by 
s ta t i s t ica l moment t h e o r y . T h e r e s u l t s of t h e s e calculat ions are summarized 
in Table 8 . 3 . T h e r e was l itt le var iat ion between t h e basic pharmacokinet­
ic p a r a m e t e r s of t h e methoxy i somers . Only t h e plasma c learance (CL) a n d 
tota l r e n a l c learance ( C L p ) of the 4-methoxy isomer was h i g h e r t h a n t h e 
va lues for t h e o t h e r compounds . T h e methoxybenzoylg lyc ines a r e r a p i d l y 
removed from t h e body, as can be d e r i v e d from t h e i r shor t mean r e s i ­
d e n c e time (MRT_) a n d half-lives in plasma ( t , ) a n d u r i n e ( t , ) . 
T a k i n g t h e p r o t e i n b inding of the compounds into cons iderat ion it is obvi­
ous t h a t t h e c o n t r i b u t i o n of glomerular f i l t rat ion was only small, demon­
s t r a t i n g t h a t act ive t u b u l a r secre t ion was t h e major r o u t e of rena l e x c r e ­
t ion . 
In t h e e x p e r i m e n t s with 4-methoxybenzoylg lyc ine, i t s deglycinat ion 
p r o d u c t 4-methoxybenzoate was found in plasma b u t not in u r i n e (Fig . 
8 . 2 ) . T h i s s i tuat ion is similar to t h a t observed with 
4-methylbenzoylg lycine [Rüsse l et a l . , 1988a]. Plasma concentra t ion da ta 
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Fig. 8.2 Renal excretion rate and plasma concentration of methoxy-
substituted benzoylglycines. The solid lines through the data points rep­
resent the results of data analysis according to the kidney model. 
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Table 8.3 Basic pharmacokinetic parameters of methoxy-substituted 
benzoylglycines after rapid intravenous injection. 
Substituent 
2-0CH3 
з-осн3 
4-0CH3 
Dog 
1 
2 
3 
Mean(SD) 
1 
2 
3 
Mean(SD) 
1 
2 
3 
Mean(SD) 
Ч.Р 
(min) 
26 
34 
32 
31(4) 
25 
31 
53 
36(15) 
38 
35 
43 
39(4) 
plasma 
CL 
(ml/min) 
101 
57 
82 
80(22) 
94 
66 
84 
81(14) 
120 
75 
104 
100(23) 
Vl 
(1) 
2.20 
1.61 
2.17 
1.99(0.33) 
2.61 
1.51 
2.82 
2.31(0.70) 
2.36 
2.07 
2.65 
2.36(0.29) 
Ч.иг 
(min) 
23 
41 
32 
32(9) 
31 
43 
36 
37(6) 
39 
32 
45 
39(7) 
urine 
MRTR 
(min) 
37 
64 
48 
50(14) 
52 
66 
55 
58(7) 
33 
49 
41 
41(8) 
CLR 
(mi/min) 
77 
42 
59 
59(18) 
79 
49 
60 
63(15) 
101 
62 
85 
83(20) 
D
ur 
(%) 
76 
74 
72 
74(2) 
84 
74 
72 
77(6) 
84 
82 
82 
83(1) 
of 4-methoxybenzoate were fitted to two exponentials: the half-life of the 
ascending phase was 9 ± 5 min, and of the descending phase G3 ± 25 min. 
The maximum plasma concentration (±3 yg/ml) was reached after 30 - 40 
min. In the descending phase of the curve plasma levels up to 7% of the 
parent compound were found. In case of the 2- and 3-methoxy isomers no 
deglycination products were found, neither in plasma nor in urine. 
Kidney Model 
In order to account for the relevant processes that determine the renal 
clearance of the methoxy-substituted benzoylglycines, plasma concentra-
tion and renal excretion rate data of each experiment wore analyzed 
simultaneously with the aid of a physiologically based kidney model. A 
detailed description of the model is given elsewhere [Rüssel et a l . , 
1988a]. The results of the model calculations are listed in Table 8.4 and 
are also represented by the solid lines through the data points in Figs. 
8.2 and 8.3. The goodness of fit between the observed and model-
predicted plasma concentration and renal excretion rate data was in all 
cases: R2 . > 0.990 and R2 . > 0.983. Despite their considerable 
plasma urine 
protein binding, renal clearance of the methoxybenzoylglycines approached 
the renal plasma flow at low plasma levels indicating that the process of 
tubular secretion was dependent on the total drug concentration in renal 
plasma. 
It appears from the tubular titration curves in Fig. 8.3 that renal 
excretion of 2- and 3-methoxybenzoylglycine was saturated over the con-
centration range measured. The kinetic parameters describing the renal 
handling of both compounds were about the same value (Table 8.4). In 
the experiments with 4-methoxybenzoylglycine the level at which satura-
tion begins was hardly reached (Fig. 8.3). As a result, individual esti-
mates of TM and K™ were very inaccurate and only the intrinsic secretion 
clearance CL. .= Т
м
/ К
т
 was calculated (Table 8.4). The profiles of the 
tubular titration curves (Fig. 8.3) gave no reason to suggest that active 
or passive reabsorption occurred. Non-ionic back-diffusion is very unlike­
ly in view of the experimental conditions and physicochemical properties 
of the compounds. 
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Table 8.4 Model parameters characterizing the renal handling of 
methoxy-substituted benzoylglycines. 
Substituent Dog Tw K~ '-'Чл? ^дч ^і1; s^i 
(mg/min) (ug/ml) (ml/min) (min-1) (min-1) (min-1) 
2-0CH- 1 17.0 ± 4.0 32 ± 28 20 ± 5 0.23 ± 0.17 0.017 ± 0.004 0.042 ± 0.002 
2 7.2 ± 1.0 45 ± 19 11 ± 3 0.16 + 0.06 0.056 ± 0.006 0.011 ± 0.003 
3 11.0 ± 1.5 50 ± 19 21 ± 2 0.20 ± 0.07 0.025 ± 0.003 0.021 ± 0.002 
Mean(SD) 11.7(4.9) 42(9) 17(6) 0.20(0.03) 0.033(0.021) 0.025(0.016) 
3-0CH3 1 9.6 ± 0.4 6 ± 2 19 ± 4 0.27 ± 0.06 0.025 ± 0.004 0.050 ± 0.005 
2 7.7 ± 1.3 45 ± 19 16 ± 4 0.10 ± 0.04 0.125 ± 0.022 0.016 ± 0.004 
3 9.0 ± 0.8 30 ± 10 21 ± 3 0.26 ± 0.07 0.010 ± 0.002 0.025 ± 0.002 
Mean(SD) 8.8(1.0) 27(20) 19(3) 0.21(0.09) 0.053(0.063) 0.030(0.018) 
4-0CH3 1 250
a
 20 ± 9 0.19 ± 0.08 0.013 ± 0.003 0.026 ± 0.003 
2 157 11 ± 2 0.15 ± 0.04 0.026 ± 0.003 0.044 ± 0.003 
3 195 18 ± 4 0.32 ± 0.08 0.013 ± 0.002 0.026 ± 0.002 
Mean(SD) 201(47) 16(8) 0.22(0.09) 0.017(0.008) 0.032(0.010) 
Since secretion was not saturated estimates of T M and K_ were very inaccurate 
(SD > 200%), therefore only the ratio Τ,,/Κρ (ml/min) is given. 
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Fig. 8.3 Tubular t i t r a t i o n curves representing the relationship between 
renal excretion rate and plasma concentration of methoxy-substituted ben-
zoylglycines. The solid lines through the data points are calculated 
according to the kidney model. GF represents the clearance by glomerular 
f i l t r a t i on . 
8.4 DISCUSSION 
Compared to the previously studied benzoylglycines, the methoxy-
substituted derivatives are cleared reasonably well by the kidney. The 
variation in excretory patterns between the isomers was considerably less 
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than that observed with the corresponding methyl and hydroxy analogs 
[Rüssel et al., ІЭвва.Ь]. 
The protein binding, plasma kinetics and renal handling of the 2- and 
3-methoxy isomers were practically the same. Tubular secretion of both 
compounds was clearly saturated at the given dose and was not impeded 
by the high binding to plasma proteins. The tubular secretion of 
4-methoxybenzoylglycine was also not influenced by protein binding, but 
it differed from that of the 2- and 3-methoxy isomers by a much higher 
clearance capacity. Saturation of the secretory system was not observed 
until plasma concentrations of about 200 vg/ml were reached. Up to that 
level, renal clearance was perfusion-rate limited as a result of the high 
intrinsic secretion clearance (Fig. 8.3, Table 8.4). 
Similar to its 4-methyl and 4-hydroxy analogs, 4-methoxybenzoylglycine 
was metabolized to some extent by deconjugation of the glycine group and 
the resulting benzoate was found in plasma and not in urine. It seems 
that substitution in the para position favors such a deconjugation reac­
tion. The nature of the substituent must be also of influence, considering 
the variation in metabolite concentrations and the absence of dpconjugation 
of 4-aminobenzoylglycine. Taking the area under the metabolite plasma 
concentration curve as a relative measure of conversion, the extent of 
metabolite formation was in the order of 4-amino- < 4-hydroxy- < 
4-methoxy- < 4-methylbenzoylglycine. This qualitative order corresponded 
well with the electron-donating properties of the substituents as predicted 
by the Hammett relation, viz., a. = - 0 . 6 6 , 0 . , , = 
σ
 ' ' 4-amino ' 4-hydroxy 
-0.37, a. ., = -0.27, a n d o . .. .- -0.17 [Hansch, 1973]. The 
' 4-methoxy ' 4-methyl l ' J 
more strongly a substituent donates electrons, the more negative is its σ 
value. 
However, it should be emphasized that the metabolite concentration in 
plasma is the resultant of its rate of formation and elimination. Therefore, 
the influence of a substituent with a lower о value may just as well be 
explained by a lower metabolic conversion as a faster elimination of the 
metabolite. 
The presence of the deconjugation product in plasma as well as its 
probable intrarenal metabolism may have consequences for the renal clear­
ance of the parent compound as has been discussed elsewhere [Rüssel et 
al., 1988a]. 
184 
Taking the findings of the present and the two preceding studies 
together it can be concluded that introduction of a substituent in the ring 
of benzoylglycine results in general in a substance for which the renal 
secretory system has a higher clearance capacity The most extensive 
tubular secretion was found for the 4 amino, 3-hydroxy, and 4-hydroxy 
substitutes, while the extent of secretion of 2-hydroxybenzoylglycine was 
even less than that of benzoylglycine In between, a largo diversity in 
excretory characteristics were observed In spite of these variations, 
plasma concentration and renal excretion rate curves could be described 
consistently with a physiologically based kidney model This type of 
kinetic modeling may serve to understand and quantify more comprehen­
sively the complexity of processes that determine the renal excretion of 
drugs 
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PART IV 
ISOLATED MEMBRANE VESICLES 
Everything should be made as 
simple as possible but not simpler 
Albert Einstein 

CHAPTER 9 
Na AND H GRADIENT-DEPENDENT TRANSPORT OF p-AMINOHIPPURATE 
IN MEMBRANE VESICLES FROM DOG KIDNEY CORTEX1 
Frans G.M. Russol, Peter E.M. van der Linden, Wim G. Vermeulen, Marc 
Heijn, Carel H. van Os , and Cees A.M. van Ginneken 
Abstract - The transport of p-aminohippurate (PAH) was studied in baso-
lateral (BLMV) and brush border membrane vesicles (BBMV) isolated from 
dog kidney cortex. Imposition of an inwardly directed 100 mM Na gradi­
ent stimulated the uptake of 50 μΜ ['Η]PAH into BLMV, whereas a pH 
gradient (pHout = 6.0, pHin = 7.4) only slightly enhanced uptake. The 
Na gradient-dependent uptake of PAH was electroneutral, saturable and 
sensitive to inhibition by probenecid and several anionic drugs, with 
(apparent) К = 0.79 ± 0.16 mM, V = 0 . 8 0 + 0.05 nmol/mg protein, 15 
sec and Ki for probenecid = 0.08 ± 0.01 mM. Simultaneous imposition of 
the pH gradient (outward OH gradient) and inward Na gradient stimu­
lated PAH uptake significantly over that with a Na gradient alone. These 
results are consistent with a Na gradient-stimulated РАН/ОН exchange 
mechanism in the basolateral membrane. In BBMV, PAH uptake could be 
stimulated by an outwardly directed OH gradient as well as an inward 
Na gradient. Both gradients could drive PAH transport via a mediated 
probenecid-sensitive pathway. Na gradient-stimulated uptake was elec-
trogenic with a (apparent) К = 4.93 ± 0.57 mM, V = 6 . 7 1 + 0.36 
& v
 ^ ' m ' max 
nmol/mg protein, 15 sec and Ki.prob = 0.13 ± 0.01 mM. The kinetic param­
eters for РАН/ОН exchange were virtually the same, (apparent) К = 
Biochem. Pharmacol., submitted. Partly published as an abstract in: Br. 
J . Pharmacol. 89, 513P (1986) 
Department of Physiology, University of Nijmegen 
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5.72 ± 0.49 mM, Vmax - 7.87 ± 0.33 nmol/mg protein, 15 sec and Ki.prob 
= 0.16 ± 0.02 mM. When both the Xa+ and pH (outward ОН ) gradient 
were simultaneously imposed an almost twofold stimulation in uptake was 
observed over that with either a Na or pH gradient alone. These 
results suggested that both gradients stimulate PAH transport in BBMV 
via the same pathway. However, inhibition experiments with various 
organic anions showed that the specificities of Na and pH gradient-
stimulated РЛН uptake do not entirely overlap. Thus, our results are in 
favor of a simple transport mechanism in BBMV, but it cannot be exclud­
ed that two separate pathways are involved. 
9.1 INTRODUCTION 
Most of our present knowledge about the renal handling of organic 
anionic drugs comes from studies with p-aminohippurate (PAH). In the 
mammalian kidney transport of PAH and other organic anions is confined 
to the proximal tubule. PAH is actively secreted by the tubular cells into 
the urine against its electrochemical gradient. The active step in the 
transepithelial transport appears to be the uptake across the basolateral 
membrane into the cells, since PAH is accumulated to much higher concen­
trations in the cells than in the extracellular fluid. The high intracellu­
lar concentration is probably the main driving force for the mediated 
movement across the brush border membrane into the lumen [1,2]. 
In the past ten years the use of isolated membrane vesicles has con­
tributed to a better understanding of the role that each plasma membrane 
plays in the transcellular transport of PAH. However, despite numerous 
vesicle studies there is no general agreement on the mechanisms and the 
driving forces that govern PAH transport across the basolateral and 
brush border membrane. 
Several investigators have demonstrated mediated transport of PAH into 
basolateral membrane vesicles (BLMV) from rat [3-6], rabbit [6-8] and 
dog [9], which was stimulated by a Na gradient and sensitive to 
probenecid inhibition. However, only Sheikh and Miller [7] were able to 
achieve uptake values above equilibrium, using BLMV from rabbit kidney. 
190 
On the other hand Tse et al. [10] observed just a minor stimulating 
+ 2+ 
effect of Na in rabbit BLMV, while Mg and other divalent cations sig-
nificantly enhanced probenecid-sensitive PAH transport . Berner and 
Kinne [3] suggested a nonspecific effect of Na by creating an inside 
positive diffusion potential which stimulated PAH anion uptake, while oth-
ers observed only a small [4] or no effect [5,7] of the membrane potential 
on Na -dependent PAH uptake. Taken these results together most stud-
ies point to a direct coupling of Na with PAH uptake, but they also 
suggest that a Na gradient alone may not be the only driving force for 
the intracellular accumulation of PAH. Kasher et al. [5] found that 
Na -dependent uptake in rat BLMV could be altered to uphill transport in 
the presence of an opposing gradient of unlabeled PAH, and they pro-
posed a Na gradient-stimulated anion exchange mechanism. During the 
preparation of this manuscript a study of Eveloff [11] was published, in 
which it was shown that in rabbit BLMV an outward OH gradient could 
also provide for concentrative uptake in combination with an inward Na 
gradient. 
With regard to PAH transport across the luminal membrane it has been 
questioned for some time whether the downhill movement from cell to 
lumen occurs by unmediated or by mediated diffusion. The first evidence 
for mediated transport in membrane vesicles was demonstrated by Kinsella 
et al. [9], using brush border membrane vesicles (BBMV) from dog kid-
ney. In presence of a Na gradient they found saturable and 
probenecid-sensitive PAH uptake. Na -stimulated transport was also 
described in BBMV from rabbit [8,12] and rat [4]. Others were unable to 
observe a stimulation with Na [3,6,13] and it was shown that uptake is 
stimulated by an inside-positive diffusion potential induced by the Na 
gradient, ra ther than by a direct interaction of Na with a PAH trans-
porter [4,12]. Recently, uphill PAH uptake into BBMV from dog [13-15] 
and rat [IG] was demonstrated in presence of an inwardly directed H 
gradient. Kahn et al. [13,16] showed that stimulation by a pH gradient 
resulted from carrier-mediated PAH/OH exchange. This anion exchanger 
also accepts urate , and it can drive uphill transport of PAH and urate by 
opposing gradients of OH , CI and HCO„ . 
The purpose of the present study was to provide additional information 
on the effects of a Na or H gradient on PAH transport In isolated mem-
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brane vesicles The characteristics and specificity of PAH uptake in 
BLMV and BBMV from dog kidney cortex were studied 
9.2 MATERIALS AND METHODS 
Isolation of Membrane Vesicles 
Brush border (BBMV) and basolateral membrane vesicles (BLMV) were 
isolated from the same cortical tissue preparation according to procedures 
described by Sheikh et al [17] and Wmdus et al [18] with some modifi­
cations Kidneys from Beagle dogs that became available from other, main­
ly surgical, experiments were used as starting material Immediately after 
excision, the kidneys were perfused with ice-cold saline to remove residu­
al blood All subsequent steps of the procedure were carried out at 4°С 
After the kidneys were decapsulated, slices of approximately 5-7 mm thick 
cortex were cut off, weighed, minced and suspended at 10oo w/v in 100 
mM mannitol, 5 mM 4-(2-hydroxyethyl)-1-piperazine ethane sulfonic acid 
(HEPES) buffered to pH 7 4 with Tris and 0 2 mM phenylmethylsul-
fonylfluonde The mixture was homogenized with a loose-fitting dounce 
apparatus (30 strokes) and, subsequently, with a Polytron homogenizer 
on setting 7 for three 30 sec pulses The cortex homogenate was cen-
trifuged at 2,500g for 15 mm in a Heraeus Minifuge GL and the super­
natant was treated with 10 mM CaCl„ during 20 mm After a second cen-
trifugation step of 2,500g for 15 mm the resulting supernatant contained 
the crude BBMV fraction and the pelleted material contained BLMV and 
membranes from other cell organelles The crude BBMV fraction was 
spun at 24,000g for 20 mm in an IEC B-G0 ultracentrifuge (A-169 rotor) 
The supernatant was discarded and the upper fluffy layer of the pellet 
was resuspended in 100 mM mannitol and 5 mM HEPES-Tris pH 7 4, 
homogenized with a tight-fitting dounce apparatus (30 strokes), and 
treated again with 10 mM CaCl. for 20 mm The pellet obtained after 
centrifugation at 2,500g for 15 mm was discarded and the purified BBMV 
were collected at 30,000g for 20 mm The BBMV pellet was washed with 
the appropriate uptake buffer, generally consisting of 100 mM KCl, 100 
mM mannitol and 5 mM HEPES-Tris pH 7 4, to which 0 5 mM 
ethyleneglycol-bis-(|5-aminoethyl ether)N,N'-tetraacetic acid (EGTA) was 
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added, centrifuged at 30,000g for 20 min and finally resuspended in 
uptake buffer through a 23-gauge needle to obtain a final protein concen-
tration of 8-12 mg/ml. 
The pellet obtained after the first CaCl„-precipitation step, containing 
the BLMV fraction, was resuspended in 250 mM sucrose and 5 mM HEPES-
Tris pH 7.4, homogenized using a tight fitting dounce (30 strokes) and 
spun at 24,000g for 20 min. The fluffy upper layer of the pellet was gen-
tly resuspended in the sucrose buffer to a volume of approximately 2 ml/g 
of initial cortex, homogenized with a tight fitting dounce (30 strokes) and 
brought to a concentration of 8% v/v Percoli. BLMV were separated from 
other cellular membranes on the self-orienting Percoli density gradient by 
centrifugation at 50,000g for 30 min in an SB-283 rotor. A density gra-
dient ranging from 1.020 to 1.050 g/ml as measured by a Bausch and 
Lomb refractometer was obtained and the purified BLMV were recovered 
from the second opaque band from the top of the gradient corresponding 
to a density of approximately 1.034 g/ml. The BLMV suspension was 
diluted in a ratio of 1 to 4 ml with the appropriate uptake buffer (gener-
ally 100 mM KCl, 100 mM mannitol and 5 mM HEPES-Tris pH 7.4) and the 
Percoli was removed by centrifugation at 96,000g for 30 min. The fluffy 
layer on top of the glassy Percoli pellet was resuspended in uptake buffer 
by passing it through a 23-gauge needle. The BLMV were resuspended at 
a protein concentration of 8-12 mg/ml in uptake buffer. 
The purity of the membrane preparations was assessed by assaying the 
specific activity of the following marker enzymes according to previously 
published procedures: alkaline phosphatase [19] and maltase [20] for 
brush border membranes, (Na -K )-ATPase [19] for basolateral mem-
branes, succinate dehydrogenase [21] for mitochondria, acid phosphatase 
[22] for lysosomes and NADPII-dependent cytochrome-c reductase [23] for 
smooth endoplasmic reticulum. (Na -K )-ATPase was determined after 
detergent treatment with 0.4 mg/ml deoxychelate, followed by freezing-
thawing, to disrupt membrane vesicles [18] . Protein was assayed with a 
commercial coomassie blue kit (BioRad, München, FRG), with bovine plas-
ma globulin as the standard. Compared to the initial homogenate, BBMV 
were enriched for maltase and alkaline phosphatase 12- to 14-fold, while 
the enrichment factors for the other marker enzymes were all <0.9. The 
results of the enzymatic analysis of BLMV showed a 8- to 10-fold enrich-
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ment in (Na -К )-ATPase, 0.8-fold in maltase, 2.5-fold in alkaline phos­
phatase, 1.2-fold in acid phosphatase and <0.8-fold in succinate dehydro­
genase and NADPH-cytochrome-c reductase. 
The membranes were rapidly frozen in liquid nitrogen and stored at 
-80°C in small aliquote until use. In preliminary experiments, we found no 
difference in transport of glucose and PAH between frozen and freshly 
prepared membrane vesicles. 
Transport Studies 
The uptake of D-[ 3H] glucose, [3H] glycine and [3H]PAH in BBMV and 
BLMV was measured at ЗТ'С by a rapid filtration technique [24] . Mea­
surement of solute uptake in membrane vesicles was initiated by the addi­
tion of 40 yl of solution to 10 μΐ of membrane suspension such that the 
initial content of the extravesicular medium was 100 mM NaCl, 20 mM KCl, 
100 mM mannitol, 5 mM HEPES-Tris, pH 7.4 or 5 mM 
2-(N-morpholino)-ethanesulfonic acid (MES)-Tris pH 6.0; or 100 mM KCl, 
100 mM mannitol, 5 mM HEPES-Tris pH 7.4 or 5mM MES-Tris pH 6.0, and 
radiolabeled solute. The experimental conditions and the exact composi­
tion of the transport buffers are given in the legends. The initial solute 
concentrations were: glucose 25 μΜ, glycine 50 μΜ and PAH 50 μΜ or 100 
μΜ except in concentration-dependence studies. The uptake of solute was 
terminated at appropriate time intervals by diluting the incubation mixture 
with 3 ml ice-cold stop buffer that had the same composition as the incu­
bation medium but without the solute. This sample was immediately filtered 
under vacuum through a prewetted 0.45 μπι cellulose nitrate filter (Schle­
icher and Schüll, Dassel, FRG) and washed twice with 3 ml of ice-cold 
stop buffer. The radioactivity remaining on the filters was counted using 
standard liquid scintillation techniques after dissolution in 10 ml Aqualuma 
plus (Lumac, Schaesberg, The Netherlands). Corrections were made for 
the radioactivity bound to the filters in the absence of vesicles. 
To ascertain whether PAH uptake by the vesicles represented transport 
across the membrane into the vesicles rather than binding to the mem-
brane surface, PAH uptake at equilibrium was measured by increasing the 
extravesicular osmolarity with sucrose. Uptake of PAH was found to 
decrease linearly with the reciprocal medium osmolarity, and binding was 
estimated by extrapolating the uptake to infinite osmolarity, which corre-
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sponded to approximately l-30 0 for BBMV and 10-20 о for BLMV of the 
uptake under standard conditions (± 345 mOsM). 
Data Analysis and Presentation 
Absolute uptake of solute is expressed as picomoles or nanomoles per 
milligram of protein. All experiments were performed on at least three dif­
ferent membrane preparations. Data are expressed as means ± SE. The 
kinetic constants of PAH uptake in BBMV and BLMV were determined from 
the initial linear uptake values (15 sec) at various substrate concentra­
tions. Total PAH uptake could be described as uptake via a Michaelis-
Menten process in parallel with passive diffusion. The carrier-mediated 
or specific component of uptake was defined as the difference between 
uptake in the absence and presence of 5 mM probenecid. Inhibition curves 
of probenecid were analyzed assuming competitive inhibition to a one 
binding site model. Curve fitting was done by least-squares nonlinear 
regression analysis using the computer program NONLIN [25] . Student 's 
t-test was used to determine statistical significance. The figures pre­
sented in this study were drawn with the DISSPLA computer package 
[26]. 
Chemicals 
D-[1-3H] glucose (15 Ci/mmol) was obtained from New England Nuclear 
(Dreieich, FRG) and [2-3H] glycine (10 Ci/mmol) and p-aminopHjhippuric 
acid (254 mCi/mmol) were from Amcrsham (Buckinghamshire, UK). Percoli 
was purchased from Pharmacia Fine Chemicals (Uppsala, Sweden), iodopy-
racet from Dagra NV (Diemen, The Netherlands) and amiloride was a gift 
from Merck Sharp & Dohme (Haarlem, The Netherlands). All other chemi­
cals were purchased from either Sigma (St. Louis, MO, USA) or Merck 
(Darmstadt, FRG) and were of the highest grade available. 
9.3 RESULTS 
Functionality of the Membrane Vesicles 
The isolated membrane vesicles were functionally evaluated by measuring 
the Na gradient-dependent glucose and glycine uptake. Fig. 9.1 shows 
195 
pmol glucose / m g prolei 
?00 
pmol glucose / mg protein 
l ime (minutes) 
100-
75-
50-
25-
0 -
Г 
glucose 25 μΜ 
BLMV »- - Ν 
О К 
__ i 
' ·· ì 
io 15 90 
time (minules) 
Fig . 9 .1 Uptake of 25 μΜ glucose i n t o BBMV ( l e f t pane l ) and BLMV ( r i g h t 
p a n e l ) in t h e presence or absence of a Na g r a d i e n t . The v e s i c l e s were 
suspended in 100 mM KCL, 100 mM manni to l , 5 mM HEPES-Tris pH 7.4. The i n i ­
t i a l content of the e x t r a v e s i c u l a r medium was 100 mM m a n n i t o l , 5 mM HEPES-
T r i s pH 7.4 and e i t h e r 100 mM KCl or 100 mM NaCl and 20 mM KCl. Values are 
expressed as means ± SE of four exper iments . 
t h e time c o u r s e of 25 μΜ glucose u p t a k e into BBMV a n d BLMV in t h e 
p r e s e n c e or absence of an inwardly d i r e c t e d Na g r a d i e n t . In the p r e s ­
ence of a Na g r a d i e n t an o v e r s h o o t above t h e equi l ibr ium value (90 min) 
of the u p t a k e of glucose into BBMV was o b s e r v e d , while t h e replacement 
of NaCl by KCl r e s u l t e d in t h e complete d i s a p p e a r a n c e of t h e overshoot . 
Uptake a t 15 sec in p r e s e n c e of a Na g r a d i e n t was 9.3-fold enhanced 
o v e r t h a t o b s e r v e d without Na (205 ± 19 v s . 22 ± 3 pmol/mg p r o t e i n ; 
p<0.001) . BLMV showed no c o n c e n t r a t i v e glucose u p t a k e in p r e s e n c e of a 
Na g r a d i e n t and t h e initial r a t e of u p t a k e was not di f ferent from u p t a k e 
in a Na -free medium (8.9 ± 0.6 v s . 8.3 ± 2 .1 pmol/mg p r o t e i n , 15 sec; 
p > 0 . 5 ) . T h e r e f o r e , contamination of t h e BLMV p r e p a r a t i o n by BBMV must 
be functionally negl igible. 
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Fig. 9.2 Uptake of 50 μΜ glycine into BBMV (lef t panel) and BLMV (right 
paneli in the presence or absence of a Na gradient. The experimental con­
ditions were the same as in Fig. 9.1. Values are expressed as means ± SE 
of three experiments. 
The functional integrity of the vesicles was further evaluated through 
the Na gradient-dependent transport of glycine. Tig. 9.2 depicts the 
uptake of 50 μΜ glycine into BBMV and BLMV as function of time in pres­
ence or absence of an inwardly directed Na+ gradient. The imposition of a 
Na gradient resulted in a substantial transient accumulation of glycine in 
BBMV and to a lesser extent in BLMV. The initial uptake of glycine mea­
sured at 15 sec, as compared with the values measured under Na+-free 
conditions, was 9.8-fold stimulated in BBMV (161 ± 14 vs. 16.5 ± 1.4 
pmol/mg protein; p<0.001) and 2.3-fold in BLMV (49 ± 4 vs. 21 ± 3 pmol/ 
mg protein; p<0.005). These findings arc in good accordance with previ­
ously reported observations for glycine transport in dog kidney membrane 
vesicles [24] . Together with the glucose uptake data these results indi­
cated the transport capability of our membrane vesicles. 
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F i g . 9.3 Effec t of a Na g rad i en t ( l e f t panel ) or a H+ g rad ien t ( r i g h t 
pane l ) on the uptake of 50 μΜ PAH i n t o BBMV. Left p a n e l : v e s i c l e s were 
suspended in 100 mM KCl, 100 mM manni to l , 5 mM HEPES-Tris pH 7.4. The i n i ­
t i a l c o n t e n t of t h e e x t r a v e s i c u l a r medium was 100 mM m a n n i t o l , 5 mM HEPES-
T r i s pH 7.4 and e i t h e r 100 mM KCl or 100 mM NaCl and 20 mM KCl with or 
without 5 mM probenecid . Values a re expressed as means ± SE of f ive exper­
iments . Right p a n e l : v e s i c l e s were suspended in 100 mM KCl, 100 mM manni­
t o l and e i t h e r 5 mM HEPES-Tris pH 7.4 or 5 mM MES-Tris pH 6.0. The i n i t i a l 
content of t h e e x t r a v e s i c u l a r medium was 100 mM KCl, 100 mM manni to l , 5 mM 
MES-Tris pH 6 . 0 . Uptake in presence of a H+ g r a d i e n t (H+ 6 .0/7.4) was 
measured with or wi thout 5 mM probenecid. Values a re expressed as means + 
SE of four exper iments . 
Na and H Gradient-Dependent PAH Uptake 
T h e effect of imposed Na or H g r a d i e n t s on t h e u p t a k e of 50 vM PAH 
into BBMV is i l l u s t r a t e d in Fig. 9 . 3 . In t h e r i g h t panel it is shown t h a t 
when t h e e x t r a v e s i c u l a r medium was at pH 6.0 a n d t h e i n t r a v e s icular 
medium at pH 7.4 ( 6 . 0 / 7 . 4 ) t h e u p t a k e of PAH was s t imulated a n d a small 
t r a n s i e n t accumulat ion o v e r t h e equil ibrium value was o b s e r v e d at 1 min. 
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The uptake at G.0/6.0 was slightly faster than at 7.4/7.4 (left panel, 
open circles), however, uptake rates were clearly decreased compared to 
the pH gradient situation. To distinguish mediated transport from non­
specific uptake by simple diffusion, H -dependent uptake was measured in 
presence of 5 mM probenecid. This resulted in a marked reduction of the 
uptake rate, the initial (15 sec) uptake of PAH was inhibited 82% by 
probenecid (97 ± 7 vs. 17 + 4 pmol/mg protein; p<0.001). Our results are 
consistent with previous investigations demonstrating that PAH uptake in 
BBMV is driven by an outwardly directed OH gradient via an anion-
exchange transport mechanism [13,14]. 
However, in contrast with these studies we also observed a stimulation 
of PAH uptake into BBMV by an inwardly directed Na gradient as is 
shown in the left panel of Fig. 9.3. Imposition of a Na gradient 
enhanced PAH uptake above that measured under KCl-equilibrated condi­
tions. Similar to H -stimulated transport, maximum uptake was observed 
at 1 min slightly exceeding the equilibrium value. Probenecid also clearly 
interfered with Na -stimulated transport . The PAH uptake measured at 
15 sec was inhibited from 103 ± 7 to 26 ± 3 pmol/mg protein (76%, 
p<0.001). 
It has been supposed that Na -stimulated PAH uptake into BBMV is 
mediated by a non-specific effect on the membrane potential, rather than 
by transport via a Na -PAH cotransport system [13] . To investigate 
this, the effect of valinomycin on PAH uptake in presence of a Na gradi­
ent was measured (Table 9.1). Due to the outwardly directed К gradi­
ent valinomycin renders the intravesicular space more electronegative 
[27]. This resulted in a significant reduction of PAH uptake into BBMV 
at 15 sec, confirming that at least an important part of Na -stimulated 
uptake into BBMV is mediated by an inside-positive membrane potential. 
Fig. 9.4 shows the effect of a Na or H gradient on the uptake of 50 
yM PAH into BLMV. Uptake conditions were the same as described in Fig. 
+ 9.3. An inwardly directed H gradient (6.0/7.4) slightly enhanced PAH 
uptake over that when the extra- and intravesicular pH were equal at 6.0 
(Fig. 9.4, right panel) or at 7.4 (left panel, open circles), and no con-
centrative uptake was observed. Only a small inhibition was observed in 
presence of probenecid (27 ± 5 vs. 18 ± 3 pmol/mg protein, 15 sec; 
p>0.10), indicating that uptake occurred predominantly by simple diffu­
sion. 
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Table 9 .1 Effect of membrane p o t e n t i a l on Na g r a d i e n t - s t i m u l a t e d PAH 
uptake i n t o BLMV and BBMV. 
PAH uptake 
(pmol/irg p r o t e i n ) 
valinomycin 15 sec 90 min 
BLMV 
BBMV 
49 ± 4 
41 ± 2 
94 ± 5 
70 ± 7" 
71 ± 5 
68 ± 6 
117 ± 10 
110 ± 12 
Uptake of 50 μΜ PAH was measured. The v e s i c l e s were suspended in 100 mM 
KCl, 100 mM m a n n i t o l , 5 mM HEPES-Tris pH 7.4. Valinomycin (10 pg/mg 
p r o t e i n ) was added in e t h a n o l (2 yg/y l ) . An equal c o n c e n t r a t i o n of e thanol 
(1 %) was added in t h e c o n t r o l s . The i n i t i a l content of t h e e x t r a v e s i c u l a r 
medium was 100 mM NaCl, 20 mM KCl, 100 mM m a n n i t o l , 5 mM HEPES-Tris pH 
7 . 4 . Values a re expressed as means ± SE of t h r e e exper iments . p<0.05 vs . 
c o n t r o l . 
In t h e left panel of Fig . 9.4 it is i l lus t ra ted t h a t t h e imposition of a 
Na g r a d i e n t r e s u l t e d in a c lear stimulation of PAH u p t a k e into BLMV 
above t h a t m e a s u r e d when no Na was p r e s e n t . A small t r a n s i e n t accumu­
lation o v e r t h e equi l ibr ium value was o b s e r v e d a f te r 15 min. Probenec id 
effectively inhibi ted t h e Na grad ient-s t imula ted u p t a k e from 48 ± 4 to 20 
± 3 pmol/mg p r o t e i n , 15 sec (58%, p<0.005) . Valinomycin did not affect 
PAH u p t a k e in the p r e s e n c e or absence of a Na g r a d i e n t (Table 9 . 1 ) , 
s u g g e s t i n g t h a t Na - d e p e n d e n t PAH u p t a k e into BLMV is e l e c t r o n e u t r a l 
a n d not inf luenced by t h e membrane potent ia l . 
Kinetics of PAH Uptake and Probenecid Inhibition 
T h e concept of c a r r i e r - m e d i a t e d PAH t r a n s p o r t was f u r t h e r s u p p o r t e d 
by t h e s a t u r a b i l i t y of Na - or Η - d e p e n d e n t u p t a k e into BBMV (Fig . 9 . 5 , 
left panel) and Na - d e p e n d e n t t r a n s p o r t into BLMV (Fig . 9 . 5 , r i g h t p a n ­
el) in t h e p r e s e n c e of i n c r e a s i n g PAH c o n c e n t r a t i o n s . In b o t h p r e p a r a -
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Fig. 9.A Effect of a Na gradient ( lef t panel) or a H gradient (right 
panel) on the uptake of 50 μΜ PAH into BLMV. The experimental conditions 
were the same as in Fig. 9.3. Values are expressed as means ± SE of four 
experiments. 
tions concentration-dependent uptake could be described by a combination 
of carrier-mediated uptake following Michaelis-Menten kinetics and nonsat­
urable simple diffusion. The contribution of the non-specific component to 
total uptake was estimated from the amount of PAH uptake that could not 
be inhibited with 5 mM probenecid. The slopes of these linear curves 
were (nmol/mg protein, 15 sec per mM) 0.811 ± 0.010 for BBMV (Na ), 
0.608 ± 0.007 for BBMV (H+) and 0.595 ± 0.009 for BLMV (Na + ). The 
kinetic parameters characterizing the carrier-mediated, probenecid sensi­
tive part of uptake (K and V ) were derived from computer-based fit 
of the individual data and are given in Table 9.2. 
The inhibitory effect of increasing probenecid concentrations on carrier-
mediated PAH uptake into BLMV and BBMV is shown in Fig. 9.6. The 
inhibitory constants for probenecid (K.) were calculated by curve fitting 
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Fig. 9.5 Kinetics of Na or H gradient-dependent PAH uptake into BBMV 
(left panel) and Na gradient-dependent uptake into BLMV (right panel). 
The vesicles were suspended in 100 mM KCl, 100 mM mannitol, 5 mM HEPES-
Tris pH 7.4. The initial content of the extravesicular medium was either 
100 mM NaCl, 20 mM KCl, 100 mM mannitol, 5 mM HEPES-Tris pH 7.4 or 100 mM 
KCl, 100 mM mannitol, 5 mM MES-Tris pH 6.0, in both cases with or without 
5 mM probenecid. Uptake was measured at 15 sec in presence of increasing 
concentrations of PAH (0.05 - 10 mM). Values are expressed as means ± SE 
of three to five experiments. 
Table 9.2 Kinetic parameters for Na gradient-dependent PAH uptake into 
эг H gradient-dependent uptake into 
interaction with probenecid (prob). 
BLMV and Na or BBMV and the 
BLMV 
BBMV 
BBMV 
(Na" 1") 
(Na+) 
(H+) 
K
m 
(mM) 
0.79 ± 0.16 
4.93 ± 0.57 
5.72 ± 0.49 
V 
max 
(nmol/mg p r o t e i n , 1 5 sec) 
0.80 ± 0.05 
6.71 ± 0.36 
7.87 ± 0.33 
K i , p r o b 
(mM) 
0.08 ± 0.01 
0.13 ± 0.01 
0.16 ± 0.02 
The experimental conditions were the same as those given in the legends 
to Figs. 9.5 and 9.6. The results are means ± SE of three experiments. 
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Fig. 9.6 Inhibition of specific Na gradient-dependent PAH uptake into 
BLMV (upper paneli and Na or Η gradient-dependent uptake into BBMV (low­
er panel) by probenecid. The vesicles were suspended in 100 mM KCl, 100 mM 
mannitol, 5 mM HEPES-Tris pH 7.4. The initial content of the extravesicu-
lar medium was 100 μΜ PAH and either 100 mM NaCl, 20 mM KCl, 100 mM manni­
tol, 5 mM HEPES-Tris pH 7.4 or 100 mM KCl, 100 mM mannitol, 5 mM MES-Tris 
pH 6.0, with varying probenecid concentrations (0.1 nM - 5 mM). Uptake 
was measured at 15 sec and values are expressed as means of three experi­
ments. SE were less than 10 % for all values. 
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of individual data according to a one binding site model. Results are 
listed in Table 9.2. The results show that PAH transport in BBMV has a 
lower affinity, but a higher capacity than transport into BLMV. The 
kinetic parameters and probenecid inhibition constants for Na - and 
H -dependent transport are not significantly different from each other 
(p>0.1), suggesting that both gradients stimulate PAH uptake via the 
same transport system. 
Effect of Various Organic Anions on PAH Uptake 
The substrate specificity of PAH transport into BLMV and BBMV was 
tested by cisinhibition experiments with various organic anions (Table 
9.3). Each organic anion (2.5 or 5 mM) was added to the external medium 
and its effect on the 15 sec uptake of 100 цМ PAH in the presence of an 
inward Na+ (BLMV, BBMV) or H+ gradient (BBMV) was measured. The 
strongest inhibition in both preparations was found with probenecid. 
Because PAH is a glycine conjugate the interaction with glycine was 
studied. Glycine had no effect on PAH uptake, and conversely we found 
no effect of concentrations up to 5 mM PAH on Na -dependent uptake of 
50 vM glycine (data not shown), indicating that neither in BLMV nor in 
BBMV PAH and glycine share the same transport system. 
In BLMV iodopyracet and salicylate were good inhibitors, while urate 
only slightly affected PAH uptake. In BBMV some remarkable differences 
between the inhibitory effect on Na - and H -stimulated PAH uptake were 
observed. Phenolsulf onphthalein, iodopyracet and urate had no effect and 
1-naphthyl-glucuronide had only a small effect on Na -stimulated uptake, 
whereas they clearly inhibited H -stimulated uptake. The effect of the 
other anions was virtually the same for both gradients with the exception 
of hydrochlorothiazide, which inhibited Na -stimulated uptake but did not 
interfere with uptake in presence of a H gradient. Although the differ­
ence in pH may play a role by altering the degree of ionization of phenol-
sulfonphthalein (pK = 7.9), urate (pK = 5 . 8 ) and hydrochlorothiazide 
(pK = 7.9), this will hardly be of any influence on the differences in 
inhibitory effect observed for iodopyracet (pK = 2.9) and 
1-naphthyl-glucuronide (pKa< 3). Therefore, these results suggest that 
the pathways of sodium and H gradient-stimulated PAH uptake into BBMV 
do not entirely overlap. 
204 
Table 9.3 Effect of various organic anions on PAH uptake into BLMV and 
BBMV. 
% PAH uptake 
organic anion mM BLMV BBMV BBMV 
(Na+) (Na+) (H+) 
Probenecid 
Glycine 
Hippurate 
Phenolsul fonphthalein 
lodopyracet 
Salicylate 
AcetyIsa1 icylate 
Urate 
Hydrochlorothiazide 
1-Naphthyl-glucuronide 
5.0 
5.0 
5.0 
5.0 
5.0 
5.0 
5.0 
2.5 
2.5 
5.0 
43 
93 
69 
64 
58 
54 
76 
87 
64 
65 
± 
+ 
+ 
+ 
± 
± 
± 
± 
± 
± 
3 
5 
7 
12 
9 
9 
11 
9 
12 
12 
29 
101 
69 
99 
92 
62 
78 
95 
69 
81 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
± 
2 
6 
9 
9 
9 
3 
6 
6 
9 
6 
26 ± 9 
102 ± 7 
7 7 + 9 
44 ± 11 
32 ± 8 
54 ± 8 
88 ± 12 
70 ± 9 
91 ± 13 
57 ± 12 
The 15 sec uptake of 100 μΜ PAH was measured. The exper imental 
c o n d i t i o n s were s i m i l a r t o those given in t h e legend of F i g . 9 . 5 , except 
for t h e presence of 2.5 or 5.0 mM o r g a n i c an ion. R e s u l t s are expressed 
r e l a t i v e t o t h e r e s p e c t i v e c o n t r o l uptakes as means ± SE of t h r e e 
exper iments . Control u p t a k e s , measured in presence of 5 mM g l u c o n a t e , 
were (pmol/mg p r o t e i n , 15 sec) 111 ± 4 for BLMV ( N a + ) , 224 ± 10 for BBMV 
(Na+) and 210 ± 18 for BBMV ( H + ) . 
Effect of pH on Na + -Dependent PAH Uptake 
T h e effect of a H + g r a d i e n t (pH = G.O, p H .
n
= 7.4) on N a + - d e p e n d e n t 
PAH u p t a k e is shown in Table 9.4. When a pH g r a d i e n t was p r e s e n t 
alone u p t a k e in to BLMV was lower compared to Na g r a d i e n t - s t i m u l a t e d 
u p t a k e , as was also noted in Fig. 9 .4 . U n d e r pH g r a d i e n t condi t ions 
Na - d e p e n d e n t PAH u p t a k e into BLMV was s ignif icantly acce lera ted com­
p a r e d to t h e contro l w h e r e e x t r a - a n d i n t r a v e s i c u l a r were equal a t pH 
7.4. Valinomycin did not affect pH-st imulated Na - d e p e n d e n t u p t a k e (data 
not s h o w n ) . T h e s e r e s u l t s a r e similar to t h o s e o b s e r v e d by Eveloff [11] 
in t h e r a b b i t , who showed t h a t PAH t r a n s p o r t into BLMV o c c u r s by a Na 
grad ient-s t imula ted OH - e x c h a n g e mechanism. 
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Table 9.4 Effect of a H gradient on the time course of Na 
gradient-dependent PAH uptake into BLMV and BBMV. 
g r a d i e n t 
PAH uptake 1 1 
(pmol/mg p r o t e i n ) 
15 sec 1 min 90 min 
BLMV 
»a' Na ( c o n t r o l ) 
H 
Na+ + H+ d 
45 ± 2 
2 9 + 3 
68 ± 5* 
66 ± 7 
44 ± 2 
97 ± 6" 
76 ± 4 
65 ± 4 
82 ± 5 
BBMV 
Ua' 
„+ с 
Na ( c o n t r o l ) 
+ b 
H 
Na 
Na+ + H+ d 
+ ami lor ide (5 mM) 
107 ± 5 
93 ± 10 
109 ± 6 
192 ± б* 
156 ± 12 
156 ± 7 
149 ± 5 
218 ± 9* 
125 ± 8 
126 ± 14 
159 ± 14 
139 ± 9 
Uptake of 50 yM PAH was measured. The v e s i c l e s were suspended in 100 mM 
KCL, 100 mM m a n n i t o l , 5 mM HEPES-Tris pH 7.4. Values a re expressed as 
means ± SE of t h r e e exper iments . 
The i n i t i a l c o n t e n t of t h e e x t r a v e s i c u l a r medium was: 
b 100 mM NaCl, 20 mM KCl, 100 mM m a n n i t o l , 5mM HEPES-Tris pH 7.4, 
c 100 mM KCl, 100 mM m a n n i t o l , 5 mM MES-Tris pH 6.0, 
d100 mM NaCl, 20 mM KCl, 100 mM manni to l , 5 mM MES-Tris pH 6.0. 
p<0.05 and p<0.01 v s . r e s p e c t i v e c o n t r o l s . 
Because BBMV a r e known to contain an act ive Na -H e x c h a n g e sys tem 
[28] , Na - d e p e n d e n t u p t a k e into BBMV was f u r t h e r e v a l u a t e d by d e t e r ­
mining w h e t h e r an inward d i r e c t e d Na g r a d i e n t i n d i r e c t l y st imulated PAH 
t r a n s p o r t by g e n e r a t i n g an o u t w a r d OH - g r a d i e n t . Uptake in p r e s e n c e of 
t h e Na -H e x c h a n g e i n h i b i t o r amiloride (5 mM) was not di f ferent from t h e 
c o n t r o l (Table 9 . 4 ) , ind icat ing t h a t Na -H e x c h a n g e does not play a ro le 
in Na - d e p e n d e n t PAH u p t a k e . Simultaneous imposition of a H a n d Na 
g r a d i e n t r e s u l t e d in an almost 2-fold e n h a n c e m e n t of t h e initial u p t a k e 
r a t e compared to va lues m e a s u r e d when e i t h e r a Na o r H g r a d i e n t was 
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present alone. In presence of valinomycin the 15 sec uptake was signifi­
cantly decreased to 142 ± 11 pmol/mg protein (p<0.05). Although this val­
ue was still higher than the control uptake the difference failed to reach 
the 5% level of significance. The results suggest that the PAH-OH 
anion-exchanger is stimulated by an inside-positive Na potential. How­
ever, an alternative explanation would be that Na -dependent uptake and 
OH -exchange represent two distinct transport pathways. 
9.4 DISCUSSION 
Basolateral Membrane 
Our findings demonstrate that PAH uptake into BLMV is mediated, func­
tionally coupled to a Na gradient across the membrane and insensitive to 
the membrane potential. These results are consistent with an electroneu-
tral Na /PAH cotransport system in the basolateral membrane. Kinetic 
analysis demonstrated saturable probenecid-sensitive uptake in presence 
of a Na gradient. The apparent К value determined for PAH was 0.79 
mM. This value is in good agreement with previously reported values of 
0.56 mM in the dog [9] and 0.54 mM in the rat [3], but considerably 
higher than the value of 0.054 mM also reported in rat [5]. The value 
for V of 0.80 nmol/mg protein, 15 sec is somewhat high compared to 
previously reported values of (converted to nmol/mg protein, 15 sec) 0.22 
in the dog [9] and 0.11 [3] or 0.06 [5] in the rat . The K. value for 
probenecid (0.08 mM) is again in good agreement with values of 0.14 mM 
[9] and 0.054 mM [3] reported for dog and rat BLMV, respectively. 
In accordance with the wide variety of organic anions that are secreted 
in vivo by the kidney, various compounds showed affinity for Na 
gradient-stimulated PAH uptake in BLMV (Table 9.3). Only the endoge­
nous anions glycine and urate hardly interfered with PAH transport . The 
lack of inhibition of urate supports the findings of Kahn et al. [29] in 
the rat that in contrast to the brush border membrane, the basolateral 
membrane seems to contain separate transport systems for PAH and urate. 
The fact that a large Na gradient is not able to achieve uphill t rans­
port in BLMV does not necessarily mean that a Na gradient cannot drive 
the intracellular accumulation of PAH in vivo. In isolated membrane vesi-
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cíes an overshoot is only achieved when Vmax is relatively high compared 
to the rate of Na gradient dissipation, whereas in vivo the transmem-
brane Na gradient is permanently present An alternative pathway for 
transport across the basolateral membrane might be an anion exchange 
mechanism like that described for PAH m the brush border membrane 
[13,16] However, in presence of an outwardly directed OH gradient 
alone PAH uptake was only slightly stimulated, but when simultaneously 
an inward Na gradient was imposed uptake was greatly stimulated Our 
results provide supporting evidence for the Na gradient-stimulated anion 
exchanger hypothesized by Kasher et al [5], although we cannot fully 
exclude the possibility that uptake is the result of additive effects of two 
separate pathways Very recently, Eveloff [11] reported Na -dependent 
PAH/OH exchange in BLMV from rabbit kidney She concluded that anion 
exchange is directly coupled to Na , as it was found that PAH counter-
transport was also stimulated when Na was equilibrated across the mem-
brane 
What other anions than OH and PAH itself might be accepted by this 
anion exchanger remains to be examined Low et al [30] proposed a 
multispecific anion exchanger in the basolateral mebrane of the rat that 
could mediate exchange of sulfate for several inorganic and organic anions 
including PAH This common exchanger could additionally be driven by a 
Na gradient and a pH difference However, capillary perfusion studies in 
the rat have indicated that the substrate specificities for PAH and sulfate 
transport into the tubular cell are clearly distinct [31] 
Brush Border Membrane 
The results of our transport studies in isolated BBMV indicate that PAH 
uptake can be stimulated by a transmembrane pH gradient (outward OH 
gradient) as well as by an inwardly directed Na gradient It is conclud-
ed that both gradients can drive PAH transport via a mediated pathway, 
since uptake in either case is concentration-dependent, probenecid-
sensitive and susceptible to competition by other organic anions Stimula-
tion by an outwardly directed OH gradient is consistent with PAH/OH 
exchange mediated by the well recognized anion exchange mechanism in 
the brush border membrane that is also shared by urate [13-16] Which 
transport system is involved in Na -stimulated uptake is less well under-
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stood, although it is generally accepted that Na stimulation is not 
achieved via a cotransport mechanism but strictly by electrochemical 
effects [4,12]. Hori et al. [4] proposed a gated channel through which 
PAH is transported in its anionic form driven by the transmembrane 
potential. 
The question that arises from our experiments is whether an outward 
OH gradient and a Na -induced potential difference stimulate ΡΛΗ uptake 
via the same carrier system or via separate carr iers . The extra stimula­
tion of PAH uptake by simultaneous imposition of both a Na and a pH 
gradient provides little additional information. These results are as much 
consistent with additive effects of uptake via two distinct pathways as 
with stimulation of the PAH/OH exchanger by a Na -induced inside posi­
tive membrane potential. However, some evidence in favor of the latter 
mechanism comes from a study by Kahn et al. [16] , who found a decrease 
in PAH/OH exchange when the intravesicular space was rendered more 
electronegative. 
The fact that the kinetic parameters (K and V ) and probenecid 
r
 m m a x ' ^ 
inhibition constant (K.) for sodium- and pH-dependent transport are vir­
tually the same argues for a simple transport pathway. The parameters 
we found are, except for a higher V value, in good agreement with 
those observed by Kinsella et al. [9] for sodium-stimulated PAH uptake in 
dog BBMV. They reported а К (apparent) of 3.87 mM, a V of 1.3 
nmol/mg protein, 15 sec and a K. for probenecid of 0.30 mM. Surprisingly, 
this appears to be the only study reporting kinetic data on РАН transport 
in BBMV and to our knowledge there are no data available allowing for a 
comparison of the kinetic parameters obtained in presence of a pH gradi­
ent. 
On the other hand, the inhibition experiments with various organic 
anions show a considerable but not a complete overlap in the substrate 
specificities of Na - and pH-stimulated PAH transport . For some anions, 
e .g . , phenolsulfonphthalein, urate and hydrochlorothiazide, the difference 
in inhibitory effect may be related with the degree of dissociation of the 
anion in the incubation medium. For these compounds, raising the pH 
from 6.0 to 7.4 greatly reduces the concentration of undissociated anion. 
However, the reduced inhibitory effects of phenolsulfonphthalein and 
urate at pH 7.4 are opposite to the enhanced inhibitory potency of 
hydrochlorothiazide. 
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At p r e s e n t no decisive answer can be given on t h e precise n a t u r e of 
t h e s y s t e m ( s ) involved in Na - and p H - d e p e n d e n t ΡΛΗ t r a n s p o r t in 
BBMV, n e v e r t h e l e s s o u r r e s u l t s a re in favor of a simple t r a n s p o r t p a t h ­
way. An important ques t ion also yet to be a n s w e r e d c o n c e r n s the p h y s ­
iological re levance of t h e s e d a t a . T h e anion e x c h a n g e r p r e s e n t in t h e 
b r u s h b o r d e r membrane probab ly mediates act ive u r a t e r e a b s o r p t i o n in t h e 
proximal t u b u l e , d r iven by anion g r a d i e n t s d i r e c t e d from cell to lumen. 
T h e s e g r a d i e n t s would also favor r e a b s o r p t i o n of PAH, still PAH u n d e r ­
goes ne t s e c r e t i o n . It is p resumed t h a t the high i n t r a c e l l u l a r PAH concen­
t r a t i o n as compared to t h e luminal c o n c e n t r a t i o n can overcome th i s r e a b -
s o r p t i v e t e n d e n c y [32] . On the o t h e r h a n d , t r a n s p o r t mediated by a 
posit ive membrane potent ia l , e i t h e r via t h e anion e x c h a n g e r a gated c h a n ­
nel or a leaky p a t h w a y , may v e r y well ref lect an important dr iv ing force 
t h a t e x i s t s in vivo, as t h e luminal fluid h a s a more posit ive e lectr ical 
potent ia l t h a n the int race l lu lar compartment. 
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CHAPTER 10 
EFFECT OF SUBSTITUTED BENZOATES ON p-AMINOHIPPURATE 
TRANSPORT IN DOG RENAL MEMBRANE VESICLES1 
Frans G M Rüssel, Marc Heijn, and Cees A M van Ginne ken 
Abstract - The effect of substituted benzoates on the transport of 
p-aminohippurate (PAH) was studied in basolateral (BLMV) and brush 
border membrane vesicles (BBMV) isolated from dog kidney cortex The 
probenecid-sensitive part of Na gradient-dependent uptake of 100 μΜ 
[3H]PAH into BLMV and Na or pH gradient dependent uptake into BBMV 
was measured with or without the presence of 5 mM benzoate Practically 
all benzoates showed an inhibitory effect on PAH transport in BLMV and 
BBMV, the strongest inhibitors were 3-C1- and 4-Cl-benzoate, while the 
weakest inhibition was found for the 3-NH„ and 4-NH„ substitutes The 
inhibitory potency, expressed as the apparent inhibition constant ( K ) , 
correlated significantly with the relative hydrophobicity of the ionized 
benzoates, determined by reversed phase HPLC This indicates that 
hydrophobic and electronic properties are the main determinants of affini­
ty for the PAH transport system It is suggested that the PAH transport 
system present in the proximal tubules is responsible for the active 
secretion of benzoates by the mammalian kidney 
Biochem Pharmacol , submitted Partly published as an abstract m Br 
J Pharmacol 89, 681P (1986) 
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10.1 INTRODUCTION 
The renal organic anion transport system is characterized by a remark-
able diversity of compounds that are accepted. A wide variety of xenobi-
otics and their metabolites as well as numerous endogenous substrates are 
excreted by the kidney by tubular secretion. p-Aminohippurate (PAH) is 
generally considered as the model compound representing the renal t rans-
port of these organic anions. The active step in renal secretion of PAH 
occurs at the basolateral membrane of the proximal tubular cell across 
which the anion is accumulated in the cell by uphill transport. The high 
intracellular concentration provides a driving force for the movament of 
PAH from cell, across the brush border membrane, to lumen [1]. 
Studies with isolated basolateral (BLMV) and brush border membranes 
(BBMV) have demonstrated that PAH transport across both membranes is 
carrier-mediated and probenecid-sensitive. PAH uptake into BLMV occurs 
via a Na gradient-dependent cotransport mechanism, which can be stimu-
lated additionally by an opposing anion gradient [2-4] . PAH transport 
into BBMV occurs primarily via an anion exchange mechanism driven by 
opposing gradients of OH , CI and HCO„ [5], while uptake can also be 
stimulated by a sodium gradient-induced positive membrane potential 
[6-8] . At present it is not clear whether this potential-driven transport 
occurs via the anion exchanger or via another transport system. 
For several endogenous anions, e . g . , lactate [9,10], di- and tricar-
boxylic acids [11,12], sulfate [13,14], urate [15,16] and nicotinic acid 
[17,18], transport systems have been characterized, that are wholly or 
partially distinct from the PAH transport system. Much work is still 
needed to define the respective specificities of these transport systems 
and to understand their functional relationship. 
The purpose of the present study was to determine whether benzoic 
acids have affinity for the PAH transport system in BLMV and BBMV and 
whether affinity is quantitatively related to the structural properties of 
this class of compounds. The characteristics of renal transport of ben-
zoate analogs are very difficult to study in vivo because their renal 
excretion is often modified by concomitant reabsorption [1,19] and exten-
sive metabolism within the tubular cells [20,21]. The technique of isolat-
ed membrane vesicles provides the opportunity to study transport pro-
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cesses in specific membranes independently and without the disturbing 
influence of metabolic events. 
10.2 MATERIALS AND METHODS 
Isolation of Membrane Vesicles 
Kidneys from Beagle dogs that became available from other, mainly sur­
gical, experiments were used as starting material. Brush border (BBMV) 
and basolateral membrane vesicles (BLMV) were prepared from cortical 
homogenate by CaCl„ precipitation and differential Percoli density gradient 
centrifugation. The method is based on procedures described by Sheikh 
et al. [22] and Windus et al. [23] with some modifications. 
Briefly, cortex was minced and homogenized at 10oo w/v in 100 mM man­
nitol, 5 mM 4-(2-hydroxyethyl)-l-piperazine ethane sulfonic acid (HEPES) 
buffered to pH 7.4 with Tris and 0.2 mM phenylmethylsulfonylfluoride. 
The homogenate was centrifuged at 2,500g for 15 min and the supernatant 
was treated with 10 mM CaCl„ during 20 min. After a second centrifuga­
tion step of 2,500g for 15 min the resulting supernatant contained the 
crude BBMV fraction and the pellet contained BLMV and membranes from 
other cell organelles. The crude BBMV fraction was spun at 24,000g for 
20 min in an IEC B-60 ultracentrifuge (A-169 rotor), rosuspended in 100 
mM mannitol and 5 mM HEPES-Tris pH 7.4, and treated again with 10 mM 
CaCl. for 20 min. After centrifugation at 2,500g for 15 min the purified 
BBMV were collected from the resulting supernatant at 30,000g for 20 
min. The BBMV pellet was washed with uptake buffer, consisting of 100 
mM KCl, 100 mM mannitol and 5 mM HEPES-Tris pH 7.4, to which 0.5 mM 
τ 
ethyleneglycol-bis-(ß-aminoethyl ether)N,N -tetraacetic acid (EGTA) was 
added, centrifuged at 30,000g for 20 min and finally resuspended in 
uptake buffer at a protein concentration of 8-12 mg/ml. 
The fraction containing crude BLMV, obtained after the first 
CaCl„-precipitation step, was homogenized in 250 mM sucrose and 5 mM 
HEPES-Tris pH 7.4 and spun at 24,000g for 20 min. The fluffy upper 
layer of the pellet was resuspended in the sucrose buffer, brought to a 
concentration of 8% v/v Percoli and centrifuged at 50,000g for 30 min in 
an SB-283 rotor. BLMV were recovered from the second opaque band 
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from the top of the Percoli gradient corresponding to a density of 
approximately 1.034 g/ml, diluted 1 to 4 with uptake buffer and cen-
trifuged at 96,000g for 30 min. The fluffy layer on top of the glassy 
Percoli pellet was resuspended in uptake buffer at a protein concentration 
of 8-12 mg/ml. 
The purity of the membrane preparations was evaluated by marker 
enzyme analysis. (Na -K )-ATPase was determined after detergent treat-
ment with 0.4 mg/ml deoxycholale, followed by freezing-thawing, to dis-
rupt membrane vesicles [23,24]. Protein was assayed with a commercial 
coomassie blue kit (BiaRad, München, FRG), with bovine plasma globulin 
as the standard. Compared to the initial homogenate, BLMV showed a β­
ίο 10-fold enrichment in (Na+-K+) -ATPase, 0.8-fold in maltase [25], 
2.5-fold in alkaline phosphatase [24], 1.2-fold in acid phosphatase [26] 
and <0.8-fold in succinate dehydrogenase [27] and NADPH-cytochrome-c 
reductase [28] . BBMV were enriched for maltase and alkaline phos­
phatase 12- to 14-fold, while the enrichment factors for the other marker 
enzymes were all <0.9. 
The membranes were rapidly frozen in liquid nitrogen and stored at 
-800C in small aliquote until use. In preliminary experiments, we found 
no difference in transport activity between frozen and freshly prepared 
membrane vesicles. 
Transport Studies 
The uptake of 100 μΜ [3H]PAH in BBMV and BLMV was measured at 
37°C by a rapid filtration technique [29] . Transport was initiated by the 
addition of 40 μΐ solution to 10 μΐ of membrane suspension. PAH uptake in 
BLMV was measured in presence of an inwardly directed 100 mM Na gra­
dient, while uptake in BBMV was measured in presence of an inward Na 
gradient as well as a pH gradient (outward OH gradient). The initial 
content of the extravesicular medium was 100 mM NaCl, 20 mM KCl, 100 
mM mannitol, 5 mM HEPES-Tris pH 7.4 or 100 mM KCl, 100 mM mannitol, 5 
mM 2-(N-morpholino)-ethanesulfonic acid (MES)-Tris pH 6.0, and 100 μΜ 
PAH. In interaction experiments probenecid and benzoates were present 
in a final concentration of 5 mM. The experimental conditions are given 
in the legends of the tables. Uptake of PAH was terminated after 15 sec 
by diluting the incubation mixture with 3 ml ice-cold transport buffer. 
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This sample was immediately filtered under vacuum through a prewetted 
0.45 ym cellulose nitrate filter (Schleicher and Schüll, Dassel, FRG) and 
washed twice with 3 ml of ice-cold buffer. The radioactivity remaining on 
the filters was counted using standard liquid scintillation techniques after 
dissolution in 10 ml Aqualuma plus (Lumac, Schaesberg, The Nether-
lands) . Corrections were made for the radioactivity bound to the filters 
in the absence of vesicles. 
Determination of logk 
Relative retention times were measured by reversed phase HPLC to 
characterize the hydrophobic properties of the bonzoates, according to 
the method described by Yamana et al. [30] . In order to obtain a uni-
form hydrophobic parameter, logk , the capacity factor obtained by 
extrapolation of retention data from binary eluents to 100% water, was 
determined [31] . 
A Hewlett-Packard 1084В Chromatograph equipped with a 254 nm UV 
detector, autosampler and terminal (HP7850LC) was used. The stainless-
steel column (250 χ 4.6 mm I.D.) was packed with CP™Spher C18, particle 
size 10 ym (Chrompack, Middelburg, The Netherlands). The mobile phase 
consisted of a mixture of methanol and twice-distilled water containing 
0.01 M phosphate buffer of either pH 2.9, 5.9 or 7.4. The column tem­
perature was 35°С and the eluent was delivered at a flow rate of 2.0 ml/ 
min. The benzoates were dissolved in methanol at a concentration of 5 
mM and 5 yl of the sample was injected into the column. Retention times 
were measured at varying methanol concentrations of the mobile phase, 
ranging from 5-50% v/v. Retention is quantitatively described by the 
capacity factor, k', 
k' = ( t R - t 0 ) / t 0 (10.1) 
where t-p is the retention time of the compound and t- is the retention 
time of an unretained reference compound, for which potassium bichromate 
was used. For each benzoate k' was determined at at least four methanol 
concentrations, differing 5% or more and lying in a range such that peaks 
with a reasonable retention time (1.5-25 min) were obtained. A linear 
relationship was observed between the logk' and the methanol concentra-
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tion of the mobile phase and extrapolation to 100% water (0% methanol) 
gave the logk value. This procedure was carried out at three different 
pH values of the mobile phase, viz., 2.9, 5.9 and 7.4. The thus 
obtained logk values were used as a relative index for the hydrophobici-
ty of the benzoates at each pH. 
Data Analysis and Presentation 
All experiments were performed on at least three different membrane 
preparations. Under all given conditions, the initial uptake rate of 100 yM 
PAH measured at 15 sec was linear with respect to time and concentra­
tion. The carrier-mediated or specific component of PAH uptake was 
defined as the difference between uptake in the absence and presence of 
5 mM probenecid. Inhibition was expressed relative to the respective 
control uptakes as 
%inh. = lOOCv-v'J/v % (10.2) 
where ν = probenecid-sensitive part of 100 μΜ PAH uptake (control) and 
v' = probenecid-sensitive part of 100 μΜ PAH uptake in presence of 5 mM 
benzoate. Assuming that mediated PAH uptake follows Michaelis-Menten 
kinetics and that inhibition is competitive for a single binding site, the 
apparent inhibition constant K. was calculated as 
K. = I tvViv-v 1 )]/^ ! + S/K ) (10.3) 
where I = concentration inhibitor (5 mM benzoate), S = PAH concentration 
(100 μΜ) and Km the apparent affinity constant. For Km previously deter­
mined values were taken, viz., 0.8 mM for Na gradient-dependent uptake 
in BLMV and for Na and pH gradient-dependent uptake in BBMV 4.9 mM 
and 5.7 mM, respectively [8]. Data are expressed as means ± SE. Curve 
fitting was done by least-squares regression analysis of the unweighted 
data using the computer program NONLIN [32] . Student's t-test was 
used to evaluate the statistical significance of the coefficient of determina­
tion obtained in the regression analysis. The figures presented in this 
study were drawn with the DISSPLA computer package [33]. 
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Chemicals 
p-Amino[3H]hippuric acid (254 mCi/mmol) was from Amersham (Bucking­
hamshire, UK) and Percoli from Pharmacia Fine Chemicals (Uppsala, Swe­
den) . The benzoates were purchased from either Merck (Darmstadt, 
FRG), Fluka AG (Buchs, Switzerland) or Janssen Chimica (Beerse, Bel­
gium). All other chemicals were from Sigma (St. Louis, MO, USA) or 
Merck (Darmstadt, FRG). 
Table 10.1 Literature pK Values [34] and Capacity Factors (logk ) 
Measured at Different pH of the Substituted Benzoates. 
logk
w 
substituent pK pH 2.9 pH 5.9 pH 7.4 
H 
2-CH3 
з-сн3 
4-CH 3 
2-0CH 3 
з-осн3 
4-0CH 3 
2-OH 
3-OH 
4-OH 
2-C1 
3-C1 
4-C1 
2 - N 0 2 
3-N0 2 
4 - N 0 2 
2-NH 2 
3-NH2 
4-NH 2 
•"'a 
4 . 2 0 
3 . 9 0 
4 . 2 5 
4 . 3 7 
3 . 9 0 
4 . 1 0 
4 . 5 0 
2 . 9 3 
4 . 0 8 
4 . 6 7 
2 . 9 0 
3 . 8 4 
3 .99 
2 . 2 1 
3 .46 
3 . 4 3 
2 . 1 1 
3 . 1 2 
2 . 4 1 
Г " - * ' 
1.96 
2 . 3 4 
2 . 5 3 
2 . 4 9 
1.83 
2 . 1 9 
2 . 2 6 
1.98 
1.41 
0 . 7 2 
1.75 
2 . 5 8 
2 . 7 0 
1.04 
1.89 
1.97 
1.34 
1.09 
0 . 7 8 
i " · - • -
0 . 6 4 
0 . 7 6 
1 .21 
1.10 
0 . 7 3 
0 . 9 5 
1.09 
0 . 7 0 
0 . 0 9 
0 . 0 9 
0 . 3 1 
1.14 
1.20 
0 . 1 0 
0 . 7 4 
0 . 6 4 
0 . 1 8 
0 . 1 2 
0 . 0 2 
Г " ' · 
0 . 3 9 
0 . 5 3 
0 . 9 8 
0 . 9 4 
0 . 4 4 
0 . 8 5 
0 . 7 2 
0 . 7 9 
- 0 . 0 5 
- 0 . 3 4 
0 . 3 9 
1.11 
1.12 
0 . 2 8 
0 . 8 7 
0 . 7 4 
0 . 1 9 
- 0 . 0 2 
- 0 . 1 8 
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10.3 RESULTS 
Physicochemical Properties 
T h e physicochemical p a r a m e t e r s pK and logk of t h e s u b s t i t u t e d b e n ­
zoatos a re l i s ted in Table 1 0 . 1 . T h e pK va lues were t a k e n from l i tera-
1
 a 
t u r e [34], while t h e logk values were d e t e r m i n e d by r e v e r s e d p h a s e 
HPLC at pH 2.9, 5.9 a n d 7.4 of t h e mobile p h a s e . Logk , t h e s x t r a p o -
lated capaci ty factor for an a q u e o u s mobile p h a s e , was used as a parame­
t e r to c h a r a c t e r i z e t h e h y d r o p h o b i c p r o p e r t i e s of t h e benzoates at a given 
p H . Capaci ty factors were determined at pH 5.9 and 7.4 because t h e s e 
va lues c o r r e s p o n d with the pH condit ions u s e d in t h e membrane vesicle 
e x p e r i m e n t s . 
Since all b e n z o a t e s a r e weak acids with a pK r a n g i n g from 2.1-4.7, t h e 
logk values d e t e r m i n e d at pH 5.9 and pH 7.4 d e p e n d almost completely 
on t h e h y d r o p h o b i c i t y of t h e ionized spec ies . At pH 2.9 most benzoates 
a r e largely in t h e i r non-ionized form. U n d e r t h i s condit ion the logk is 
mainly d e t e r m i n e d b y t h e h y d r o p h o b i c i t y of t h e undi s soc ia ted molecule. 
Table 10.2 Effect of Probenecid on Na G r a d i e n t - S t i m u l a t e d PAH Uptake i n t o 
BLMV and Na or pH G r a d i e n t - S t i m u l a t e d Uptake i n t o BBMV. 
BLMV BBMV 
N a + N a + pH 
PAH 109 ± 10 2 0 4 ± 24 192 ± 13 
PAH + probenecid 3 8 + 3 25 ± 2 25 ± 6 
Uptake of 100 μΜ PAH a t 15 sec was measured in presence of an inwardly 
d i r e c t e d Na g r a d i e n t (100 mM) or a pH g r a d i e n t (pH = 6 . 0 , pH. = 7.4) 
with or wi thout 5 mM probenecid . Uptake va lues a re expressed in 
pmol PAH/mg p r o t e i n , 1 5 sec as means ± SE of s i x exper iments . 
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Probenecid-Sensitive PAH Uptake 
In Table 10.2 the effect of 5 mM probenecid on Na gradient-dependent 
PAH uptake in BLMV and on Na - or pH-dependent uptake in BBMV is 
shown. Since we found no increase in inhibition with higher probenecid 
concentrations, the difference between uptake in absence and presence of 
5 mM probenecid was considered to represent the mediated or specific 
part of PAH uptake. The probenecid-sensitive part of uptake accounted 
for 650o of total uptake into BLMV and for 880o of Na+-dependent and 87% 
of pH-dependent uptake into BBMV. 
Competition Experiments 
The results of the competition experiments of the benzoates with specif­
ic PAH uptake into BLMV and BBMV are given in Table 10.3. Control 
uptakes were measured in presence of 5 mM gluconate and were not dif­
ferent from the uptake values given in Table 10.2. To test whether the 
benzoates might cause an indirect inhibition of pH-dependent uptake in 
BBMV by influencing the transmembrane pH gradient, PAH uptake was 
measured in presence of acetate, an anion that accumulates rapidly into 
the vesicles by unmediated diffusion [15]. Using concentrations up to 10 
mM we were unable to detect inhibition by acetate, indicating that the 
intra vesicular buffering was sufficient. 
Practically all benzoates showed an inhibitory effect on PAH uptake in 
BLMV and BBMV. In both preparations З-СІ- and 4-Cl-benzoate were the 
strongest inhibitors, in some cases even approaching the maximum possi­
ble probenecid effect. The weakest inhibition was found for the 3-NH_ 
and 4-NH„ analogs. Under the assumption of Michaelis-Menten kinetics and 
competitive inhibition for a single binding site K. values were calculated 
according to Equation 10.3. These values were used to correlate the 
inhibitory potency of the benzoates with the physicochemical parameters 
listed in Table 10.1. 
Correlation Studies 
The most important results of these correlation studies are presented in 
Table 10.4 and in Figs. 10.1 and 10.2. Logarithmic values of к and K. 
were used as it may be assumed that these values are linearly related to 
changes in free energy of the molecule during its interaction with biologi-
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Table 10.3 Effect of Substituted Benzoates on Specific PAH Uptake into 
BLMV and BBMV.a 
., + BBMV Na 
substituent %inh. K.c %inh. K. %inh. K. 
H 
2-CH3 
з-сн3 
4-CH3 
2-0CH3 
з-осн3 
A-0CH3 
2-OH 
3-OH 
4-OH 
2-C1 
3-C1 
4-C1 
2-N02 
3-N02 
4-N02 
2-NH2 
3-NH2 
4-NH2 
50 
43 
71 
76 
54 
67 
63 
73 
51 
50 
58 
88 
90 
69 
87 
76 
57 
42 
38 
+ 
± 
± 
± 
+ 
± 
+ 
± 
± 
± 
± 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
2 
6 
2 
5 
4 
3 
5 
4 
6 
4 
3 
2 
4 
4 
6 
1 
7 
6 
4 
1 
4.4 
5.9 
1.8 
1.4 
3.8 
2.2 
2.6 
1.6 
4.3 
4.4 
3.2 
0.6 
0.5 
2.0 
0.7 
1.4 
3.4 
6.1 
7.2 
69 
41 
79 
60 
42 
75 
62 
50 
49 
10 
42 
96 
81 
13 
79 
46 
3 
8 
-6 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
± 
± 
± 
+ 
+ 
+ 
+ 
± 
+ 
± 
± 
3 
2 
2 
4 
3 
8 
2 
2 
2 
2 
2 
5 
9 
3 
1 
2.2 
7.0 
1.3 
3.3 
6.8 
1.6 
3.0 
4.9 
5.1 
44.1 
6.8 
<0.5 
1.2 
32.8 
1.3 
5.8 
>50 
>50 
>50 
48 
40 
54 
48 
33 
56 
53 
61 
38 
40 
53 
75 
71 
49 
70 
69 
44 
31 
19 
± 
± 
+ 
+ 
+ 
+ 
± 
± 
± 
+ 
+ 
+ 
+ 
± 
± 
± 
± 
± 
± 
2 
7 
6 
6 
3 
3 
4 
5 
7 
6 
2 
6 
2 
3 
3 
3 
3 
3 
2 
1 
5.3 
7.4 
4.2 
5.3 
10.0 
3.9 
4.4 
3.1 
8.0 
7.4 
4.4 
1.6 
2.0 
5.1 
2.1 
2.2 
6.2 
10.9 
21.0 
The probenecid-sensitive part of 100 μΜ PAH uptake at 15 sec was 
measured. The experimental conditions were similar to those given in 
Table 10.2, except for the presence of 5.0 mM benzoate. Control uptakes 
were measured in presence of 5 mM gluconate. 
Inhibition is expressed relative to the respective control uptakes as 
means ± SE of three to five experiments. 
Inhibition constant calculated according to Eq. 10.3, values are 
expressed in mM. For %inh. values <10% or >90% estimates of K. were 
considered too inaccurate and only the upper or lower limits are given. 
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cal receptors. Regression analysis revealed a linear relationship between 
logk and logK.. All correlations were significant (p<0.01), but highest 
coefficients of correlation were observed between logk (pH 7.4) and 
logK.. The correlation coefficients for these regressions were about 0.8, 
which means that G40o of the total variation in logK. was accounted for by 
the linear relationship with logk 
No significant correlation was observed between pK and logK. (r<0.3, 
a ι 
p>0.2), indicating that electronic properties alone are not responsible for 
the variance in inhibitory potency. These results showed that the 
hydrophobic properties of the ionized benzoates were the primary determi­
nants of their inhibitory effect on PAH transport . 
Table 10.4 Correlation Between logK. and logk of Substituted Benzoates. 
logk
w 
BLMV (Na"1") 
pH 7.4 
pH 5.9 
pH 2.9 
BBMV (Na+) 
pH 7.4 
pH 5.9 
pH 2.9 
BBMV (pH) 
pH 7.4 
pH 5.9 
pH 2.9 
logK. = < 
a 
0.70 
0.70 
1.01 
1.17 
1.31 
2.06 
0.95 
0.95 
1.24 
î - blogkw 
b 
0.63 
0.52 
0.35 
0.92 
0.96 
0.73 
0.51 
0.41 
0.30 
η 
19 
19 
19 
15 
15 
15 
19 
19 
19 
г 
0.813 
0.647 
0.620 
0.816 
0.780 
0.828 
0.798 
0.626 
0.657 
s 
0.21 
0.27 
0.29 
0.31 
0.31 
0.28 
0.18 
0.23 
0.22 
logK. = log inhibit ion constant, logk = capacity factor, η = number of 
benzoates studied, r = correlat ion coefficient and s = standard deviation. 
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Fig. 10.1 Correlation between the logarithm of the apparent inhibition 
constant K. and the capacity factor logk determined at pH 7.4, character­
izing the effect of substituted benzoates on sodium gradient-dependent PAH 
uptake into BLMV. 
10.4 DISCUSSION 
The results of this study show that substituted benzoates have affinity 
for the PAH transporter in BLMV and BBMV. The inhibitory potency, 
expressed as K., was predicted best by the relative hydrophobicity of the 
dissociated benzoates, indicating that hydrophobic as well as electronic 
properties are the determinants of substrate affinity. 
The parameter logk , determined by reversed phase HPLC, was used to 
characterize the hydrophobic properties of the benzoates. The hydropho­
bicity of a compound is usually expressed by the partition coefficient, 
logP, derived from distribution studies between η-octanol and water. 
However, the experimental disadvantages of logP determinations have led 
to alternative procedures, of which reversed phase HPLC has become the 
most accepted method. Logk is even considered to be a better hydropho-
224 
log К 
2 0 
15 
i o 
Οδ-
Ο. О · 
- 0 5 
BBMV Na+-grad¡ent 
•COO" 
τ -
οο 
2-CI · · · 2 - 0 Η 3 
^ 2 - O C H , · и 2 
3-Ν02 З-СНд 
! I— 
05 10 
l o g k w 
-0 5 
log К, 
20-, 
15 
10 
0 5 
0 0 
- 0 5 
-0 5 
BBMV pH-grodient 
-COO" 
2-N02 · 2-CI 
4-OCHj »A-CHj 
• 3-CHj 
2-OH 
+ - ' N o 2 " - ^ . д - с ; 
- τ -
οο 
I 
0 5 
1одк
ж 
10 
Fig. 10.2 Correlation between the logarithm of the apparent inhibit ion 
constant K. and the capacity factor logk determined at pH 7.4, character­
izing the effect of substituted benzoates on sodium gradient-dependent 
(top) and pH gradient-dependent PAH uptake into BBMV (bottom). 
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bic parameter than logP, as retention in HPLC is a dynamic process that 
includes additional information on the steric properties of a compound, 
which may be also of importance in the interference with biological sys­
tems [31]. 
Although the К for PAH transport into BLMV is 7- to 8-fold lower 
than for uptake into BBMV, most of the K. values of the benzoates are 
for both membranes in about the same range. On closer inspection it 
appears that some benzoates, e .g . , Ί-ΟΗ, 2-NO„ and 2,3,4-NHp analogs, 
had practically no inhibitory effect on sodium-stimulated PAH uptake in 
BBMV, whereas they clearly inhibited pH-stimulated uptake in BBMV and 
Na -dependent uptake in BLMV. This difference in inhibitory effect sug­
gests that Na - and pH-dependent uptake into BBMV represent distinct 
transport routes with overlapping specificities. Clearly, more detailed 
studies with varying concentrations of benzoate and PAH are required to 
obtain conclusive evidence for the existence of separate transport sys­
tems. 
It can be concluded from the data that active renal secretion of ben­
zoates can occur via the same transport route by which PAH is secreted. 
However, it should be noticed that inhibition of PAH transport primarily 
indicates affinity for the PAH transport system and does not necessarily 
mean that the competitor is actually transported. This can only be deter­
mined when transport of the compound itself is directly measured. 
In previous in vivo studies, it was found that 3-hydroxybenzoate [35], 
pyrazinoate [36] and nicotinate [17] are not only actively transported by 
the organic anion secretory mechanism but also actively reabsorbed in the 
proximal tubule. Ullrich et al. [37] showed that benzoate derivatives 
inhibit Na -dependent lactate reabsorption in the brush border membrane 
and they suggested that active reabsorption of benzoates is mediated via 
the lactate transporter. The relative inhibitory effects on lactate t rans­
port are comparable to the effects we observed on PAH transport . A 
good relationship between interaction with the carrier and the electron 
density at the carboxylic acid group was observed, but the importance of 
molecular size and hydrophobicity was also recognized. PAH did not 
inhibit lactate transport, indicating that the organic anion secretory path­
way does not interfere with the reabsorptive lactate system. 
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T a k e n t h e s e r e s u l t s t o g e t h e r , it is p r o p o s e d t h a t benzoates a r e act ively 
secre ted b y t h e mammalian k idney via the PAH t r a n s p o r t sys tem in t h e 
baso la tcra i a n d b r u s h b o r d e r membrane of t h e proximal t u b u l e s , a n d 
actively r e a b s o r b e d via t h e lactate t r a n s p o r t e r in t h e b r u s h b o r d e r mem­
b r a n e . 
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CHAPTER 11 
EFFECT OF SUBSTITUTED BENZOYLGLYCINES (HIPPURATES) AND 
PHENYLACETYLGLYCINES ON p-AMINOHIPPURATE TRANSPORT IN DOG 
RENAL MEMBRANE VESICLES1 
Frans G.M. Rüssel, Wim G. Vermeulen, and Cees A.M. van Ginneken 
Abstract - The effect of substituted benzoylglycines (hippurates) and 
phenylacetylglycines on the transport of p-aminohippurate (PAH) was 
studied in basolateral (BLMV) and brush border membrane vesicles 
(BBMV) isolated from dog kidney cortex. The probenecid-sensitive part 
of Na+ gradient-dependent uptake of 100 uM [3H]PAH into BLMV and Na + 
or pH gradient-dependent uptake into BBMV was measured with or with-
out the presence of 5 mM glycine conjugate. The benzoyl- and pheny-
lacetylglycines studied were unsubstituted or substituted in the 2-, 3- , 
or 4-position with a CH«, OCH_ or OH group. Benzoylglycines were 
stronger inhibitors of PAH transport than phenylacetylglycines and the 
inhibitory potency of the conjugates was in general lower against t rans-
port into BBMV than BLMV. The strongest inhibitory effect was found 
with 2-OCH„- and 3-CH„-benzoylglycine on BLMV and pH-dependent 
BBMV transport, while only the 3-CH_ analog was a strong inhibitor of 
sodium-dependent BBMV transport . Strikingly, 2-OH-benzoylglycine (sal-
icyluric acid) had no inhibitory potency against PAH transport in BLMV, 
while it clearly inhibited BBMV transport . It is suggested that intramolec-
ular hydrogen bonding between the hydroxy and carbonyl group hinders 
the carbonyl from interaction with the carrier, thus preventing transport . 
The carbonyl group is apparently not essential for transport across the 
brush border membrane. The inhibitory potency of the glycine conju-
Biochem. Pharmacol., submitted 
231 
gates, expressed as the apparent inhibition constant (K.), correlated 
parabolically with the relative hydrophobicity of the ionized compounds, 
determined by reversed phase HPLC. This indicates that both hydropho-
bic and electronic properties are important determinants of affinity for the 
PAH transport system. 
11.1 INTRODUCTION 
Glycine conjugation is next to glucuronidation an important metabolic 
pathway in the elimination of aromatic carboxylic acids [1] . It leads to 
less toxic compounds that are excellent substrates for the renal organic 
anion transport system and therefore more readily excreted than the 
unconjugated molecules [2]. Although aromatic carboxylic acids may be 
actively secreted by the kidney themselves, the efficiency of their renal 
clearance is generally low because of extensive passive backdiffusion and/ 
or active reabsorption [3,4] . A classical example is hippurate (benzoyl-
glycine), the conjugation product of benzoate and glycine. It is excreted 
in large amounts in normal urine, depending on the daily intake of ben-
zoate precursors with the diet [5]. The renal clearance of hippurate and 
related conjugates like p-aminohippurate (PAII) is at low concentrations so 
efficient, that they are completely extracted from renal plasma in a single 
pass through the kidney [2 ,3] . 
In the past, several studies have been undertaken with the hippurate 
class of compounds in an attempt to identify the structural properties that 
are essential for active renal secretion. It was concluded that the car-
bonyl and carboxylate group play a critical role in the secretion of hippu-
rates [6] . Essig and Taggart [7] studied systematically the influence of 
ring substitution on the transport properties of hippurate in rabbit kid-
ney cortex slices. The compounds were substituted in the ortho-, meta-
or para-position by either a methyl, fluoro, chloro, bromo, iodo or nitro 
group. Hippurates substituted in the meta-position were better inhibitors 
of PAH transport than the corresponding para- and ortho-analogs. The 
capacity to inhibit PAH transport was inversely related to their own 
transport rates and within the meta- and para-series the inhibitory poten-
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су was related to the weight or bulk of the substituent and not to the 
electron distribution on the benzene ring. A difficulty in interpreting 
these results is that slice studies do not allow to differentiate between 
luminal and basolateral membrane processes [2] . There is now abundant 
evidence that organic anion transport across both membranes is carrier-
mediated and susceptible to inhibition by other anions [2,3,8]. 
In the present study we used the technique of isolated membrane vesi­
cles to evaluate the specificity of PAH transport across each membrane 
separately. PAH uptake into basolateral membrane vesicles (BLMV) is Na 
gradient-dependent and can be stimulated additionally by an opposing 
anion gradient [9-11]. Uptake into luminal or brush border membrane 
vesicles (BBMV) occurs primarily via an anion exchange mechanism [12] 
but can also be driven by a Na gradient-induced positive membrane 
potential [13-15]. 
The aim of this study was to characterize the relative affinity of mono-
substituted benzoylglycines (hippurates) and phenylacetylglycines for the 
PAH transport system by measuring their inhibitory effect on PAH uptake 
into BLMV and BBMV and to dotermine whether inhibitory potency is 
quantitatively related to the physicochemical properties of these com­
pounds. 
11.2 MATERIALS AND METHODS 
Isolation of Membrane Vesicles 
Brush border (BBMV) and basolateral membrane vesicles (BLMV) were 
isolated from Beagle dog kidney cortex using a CaCl„ precipitation method 
in combination with differential and Percoli density gradient centrifugation 
as described previously [16]. The purified membranes were suspended at 
a protein concentration of 8-12 mg/ml in 100 mM KCl, 100 mM mannitol and 
5 mM 4-(2-hydroxyethyl)-l-piperazine ethane sulfonic acid (HEPES) 
buffered to pH 7.4 with Tris, rapidly frozen in liquid nitrogen and stored 
at -800C intil use. Compared to the initial homogenate BLMV were 
enriched about 9-fold as determined by the increase in specific activity of 
(Na -K )-ATPase and BBMV about 13-fold as determined by the increase 
in alkaline phosphatase and maltase activity, while cross contamination was 
233 
negligible. Protein and marker enzymes were assayed as previously 
described [16]. 
Transport Studies 
The 15 sec uptake of 100 μΜ [Ή]PAH in BBMV and BLMV was measured 
at 37° С by a rapid filtration technique [17]. Transport was initiated by 
the addition of 40 μΐ solution to 10 μΐ of membrane suspension. The ini­
tial content of the extravesicular medium was 100 mM NaCl, 20 mM KCl, 
100 mM mannitol, 5 mM HEPES-Tris pH 7.4 (inward Na+ gradient) or 100 
mM KCl, 100 mM mannitol, 5 mM 2-(N-morpholino) -ethanesulfonic acid 
(MES)-Tris pH 6.0 (outward OH" gradient), with or without 5 mM 
probenecid or glycine conjugate. Uptake of PAH was stopped by the 
addition of 3 ml of the same ice-cold incubation medium. The sample was 
immediately filtered through a 0.45 μπι cellulose nitrate filter (Schleicher 
and Schiill, Dassel, FRG) and washed twice with 3 ml of ice-cold buffer. 
The radioactivity remaining on the filters was counted in a liquid scintil­
lation counter and corrections were made for the radioactivity bound to 
the filters in the absence of vesicles. 
Determination of logk 
In order to study the relative hydrophobicity of the substituted glycine 
conjugates, the capacity factor logk was determined by reversed phase 
HPLC as described by Yamana et al. [18]. A Hewlett-Packard 1084B 
Chromatograph equipped with a 254 nm UV detector, autosampler and ter­
minal (HP 7850 LC) was used. The stainless-steel column (250 χ 4.6 mm 
I.D.) was packed with CP™Spher C18, particle size 10 μπι (Chrompack, 
Middelburg, The Netherlands). The mobile phase consisted of a mixture 
of methanol and twice-distilled water containing 0.01 M phosphate buffer 
of either pH 2.9, 5.9 or 7.4. The column temperature was 35°С and the 
eluent was delivered at a flow rate af 2.0 ml/min. The compounds were 
dissolved in methanol (5 mM) and 5 μΐ was injected into the column. 
Retention is quantitatively described by the capacity factor 
k' = ( t ^ - t - J / t - , where t ^ is the retention time of the compound and t- is 
the retention time of an unretained reference compound, for which potas­
sium bichromate was used. For each compound k' was determined at at 
least four methanol concentrations ranging from 5-50% v/v and differing 
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5% or more, such that peaks with a reasonable retention time (1.5-25 min) 
were obtained. A linear relationship was observed between the logk' and 
the methanol concentration of the mobile phase and extrapolation to 100% 
water (0o6 methanol) gave the logk value. This procedure was carried 
out at three different pH values of the mobile phase, e .g . , 2.9, 5.9 and 
7.4. 
Data Analysis and Presentation 
All experiments were performed on at least three different membrane 
preparations. Under all given conditions, the initial uptake rate of 100 yM 
PAH measured at 15 sec was linear with respect to time and concentra­
tion. The carrier-mediated or specific component of PAH uptake was 
defined as the difference between uptake in the absence and presence of 
5 mM probenecid. Inhibition was expressed relative to the respective 
control uptakes as 
"oinh. = 100(v-v')/v % (11.1) 
where ν = probenecid-sensitive part of 100 yM PAH uptake (control) and 
v' = probenecid-sensitive part of 100 yM PAH uptake in presence of 5 mM 
benzoate. Assuming that mediated PAH uptake follows Michaelis-Menten 
kinetics and that inhibition is competitive for a single binding site, the 
apparent inhibition constant K. was calculated as 
K. = I [ v 7 ( v - v ' ) ] / ( l + S/K
m
) (11.2) 
where I = concentration inhibitor (5 mM), S = PAH concentration (100 yM) 
and Km the apparent affinity constant. For Km previously determined val­
ues were taken, e . g . , 0.8 mM for Na gradient-dependent uptake in 
BLMV and for Na and pH gradient-dependent uptake in BBMV 4.9 mM 
and 5.7 mM, respectively [15]. Data are expressed as means ± SE. 
Curve fitting was done by least-squares regression analysis of the 
unweighted data using the computer program NONLIN [19]. Student's 
t-test was used to evaluate the statistical significance of the coefficient of 
determination obtained in the regression analysis. The figures presented 
in this study were drawn with the DISSPLA computer package [20] . 
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Preparation of the Glycine Conjugates 
Benzoylglycine and 2-OH-benzoylglycine were corranerciaUy available, the 
other conjugates were prepared by chemical synthesis Phenylacetyl-
glycme and the benzoyl- and phenylacetylglycines with a CH„ or OCH-
substituent were prepared according to the Schotten-Baumann method 
from the corresponding benzoyl and phenylacetyl chlorides by reaction 
with glycine in the presence of a slight excess of sodium hydroxide [21] 
Acyl chlorides were obtained commercially from Aldnch (Brussel, Belgium) 
or were prepared by reaction of the substituted acid with a slight molar 
excess of thionyl chloride [22] The Schotten-Baumann method is not 
suitable for the preparation of hydroxy-substituted conjugates because 
the phenolic groups can react with the acylchlondes For these com­
pounds an activated ester was prepared by reaction of the acid with 
N-hydroxysuccinmude in presence of N.N'-dicyclohexylcarbodiimide m dry 
dioxane [23] The activated ester was separated by filtration and subse­
quently added to a slightly alkaline glycine solution to yield the hydroxy-
substituted glycine conjugate 
The substituted benzoyl- and phenylacetylglycines were purified by 
recrystallization from boiling water The identity of the compounds was 
checked by comparing melting points with available literature values 
[21,23,24-28] and incidently by IR, mass spectrometry and NMR analysis 
Purity was checked by TLC and HPLC TLC was performed on silicagel 
GF-j.. plates (Merck, Darmstadt, FRG) with a mobile phase of chloro­
form methanol acetic acid (80 20 3) Spots were detected under UV light 
and by immersing the plates in a saturated iodine solution in carbon 
tetrachloride. The HPLC method was the same as used for the determina­
tion of the logk values 
ь
 w 
Chemicals 
p-Amino[3H]hippuric acid (440 mCi/mmol) was obtained from Amersham 
(Buckinghamshire, UK) Unlabelled PAH, benzoylglycine (hippunc acid) 
and 2-OH-benzoylglycine (salicyluric acid), glycine and thionylchloride 
were from Merck (Darmstadt, FRG), and N-hydroxysuccinimide and 
N.N'-dicyclohexylcarbodnmide from Janssen Chimica (Beerse, Belgium) 
All other chemicals were purchased either from Sigma (St Louis, MO, 
USA) or Merck 
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Table 11.1 Capacity Factors (logk ) of the Substituted Benzoylglycines and 
Phenylacetylglycines Measured at Different pH. 
logk 
substituent pH 2 . 9 pH 5 . 9 pH 7 .4 
b e n z o y l g l y c i n e s 
H 
2-CH3 
з-сн3 
4-СН3 
2-ОСН3 
з-осн3 
4-ОСН3 
2-ОН 
3-ОН 
4-ОН 
phenylacetylglycines 
H 
2-СН3 
з-сн3 
4-СН3 
2-ОСН3 
з-осн3 
4-0СН3 
2-ОН 
3-ОН 
4-ОН 
1.01 
1.35 
1.75 
1.74 
1.76 
1.44 
1.47 
1.54 
0.86 
0.72 
1.29 
1.66 
1.89 
1.91 
1.68 
1.55 
1.43 
1.08 
0.83 
0.65 
0 . 7 0 
0 . 8 8 
1.29 
1.30 
1.34 
1.17 
0 . 9 1 
1.02 
0 . 4 6 
0 . 3 1 
0 . 8 8 
1.33 
1.22 
1.23 
1.38 
1.31 
1.29 
0 . 7 6 
0 . 5 4 
0 . 3 9 
0 . 9 0 
1.06 
1.50 
1.45 
1.54 
1.39 
1.35 
1.16 
0 . 6 6 
0 . 4 7 
1.06 
1.51 
1.61 
1.62 
1.53 
1.49 
1.40 
0 . 9 5 
0 . 7 5 
0 . 6 7 
1 1 . 3 R E S U L T S 
P h y s i c o c h e m i c a l P r o p e r t i e s 
T h e c a p a c i t y f a c t o r s ( l o g k ) of t h e s u b s t i t u t e d b e n z o y l g l y c i n e s a n d 
p h e n y l a c e t y l g l y c i n e s , d e t e r m i n e d b y r e v e r s e d p h a s e H P L C a t p H 2 . 9 , 5 . 9 
a n d 7 . 4 , a r e g i v e n i n T a b l e 1 1 . 1 . L o g k w a s o b t a i n e d b y e x t r a p o l a t i o n of 
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r e t e n t i o n d a t a from methanol-water e l u e n t s to 100Qo w a t e r and was u s e d to 
c h a r a c t e r i z e t h e re la t ive h y d r o p h o b i c i t y of t h e glycine conjugates at each 
p H . T h e pK of most compounds is not known, b u t on theoret ica l g r o u n d s 
it is reasonable to assume t h a t t h e values a r e not much di f ferent from t h e 
pK of benzoylg lyc ine ( 3 . 8 0 ) . Thi s means t h a t logk values determined 
a w 
at pH 2.9 a r e pract ica l ly a measure for t h e h y d r o p h o b i c i t y of the union­
ized molecules, while t h e va lues de termined a t pH 5.9 and 7.4 depend 
almost completely on t h e h y d r o p h o b i c i t y of t h e ionized spec ies . Capacity 
factors at pH 5.9 a n d 7.4 were chosen b e c a u s e t h e s e va lues c o r r e s p o n d to 
those u s e d in t h e membrane vesicle e x p e r i m e n t s . 
It was somewhat u n e x p e c t e d to find t h e logk va lues determined a t pH 
7.4 to be h i g h e r t h a n t h e values at pH 5.9 . T h i s is p r o b a b l y re lated to 
t h e physicochemical influence of the glycine moiety as we did not o b s e r v e 
such a behav ior for t h e c o r r e s p o n d i n g benzoic acids u n d e r identical con­
dit ions [ 2 9 ] . However, we do not have an explanat ion for the exact 
mechanism of t h i s phenomenon. 
Table 11.2 P r o b e n e c i d - S e n s i t i v e Par t of Na G r a d i e n t - S t i m u l a t e d PAH Uptake 
i n t o BLMV and Na+ or pH G r a d i e n t - S t i m u l a t e d Uptake i n t o BBMV. 
BLMV BBMV 
N a + N a + pH 
PAH 108 ± 4 164 ± 9 150 ± 10 
PAH + probenecid 30 ± 3 33 ± 1 30 ± 5 
Uptake of 100 μΜ PAH a t 15 sec was measured in presence of an inwardly 
d i r e c t e d Na+ g r a d i e n t (100 mM) or a pH g r a d i e n t ( p H
o u t = 6 . 0 , p H i n = 7 . 4 ) 
with or without 5 mM probenecid . Uptake va lues a re expressed in 
pmol PAH/mg p r o t e i n , 1 5 sec as means ± SE of e i g h t exper iments . 
Probenecid-Sensit ive PAH Uptake 
T h e effect of 5 mM p r o b e n e c i d on t h e 15 sec u p t a k e of 100 μΜ PAH into 
BLMV a n d BBMV is shown in Table 11.2. U p t a k e into BLMV was mea­
s u r e d in p r e s e n c e of a Na g r a d i e n t a n d u p t a k e into BBMV in p r e s e n c e of 
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a Na as well as a pH gradient as it is currently uncertain whether both 
gradients drive PAH transport via the same or via distinct carrier sys­
tems. Uptake in presence of probenecid was measured in order to distin­
guish carrier-mediated ΡΛΗ transport from unmediated processes. The 
probenecid-sensitive part of uptake accounted for 72% of total uptake into 
BLMV and for 80oo of both Na+- and pH-dependent uptake into BBMV. 
Competition Experiments 
The inhibitory effect of the substituted benzoylglycines and pheny­
lacetylglycines on probenecid-sensitive PAH uptake into BLMV and BBMV 
is shown in Table 11.3. Control uptakes were measured in presence of 5 
mM gluconate and were not different from the uptake values given in 
Table 11.2. Under the assumption of Michaelis-Menten kinetics and com­
petitive inhibition for a single binding site K. values were calculated 
according to Equation 11.2. 
All glycine conjugates inhibited PAH uptake into BLMV, with one 
remarkable exception. To our surprise, 2-OH-benzoylglycine had absolute­
ly no inhibitory effect on BLMV transport, whereas it clearly inhibited 
PAH uptake into BBMV. Furthermore, the inhibitory potency against 
BLMV was restored in the corresponding 2-OH substitute of phenylacetyl-
glycine. The inhibitory potency of the glycine conjugates was in general 
lower against transport into BBMV than BLMV. The strongest inhibitory 
effect was found with 2-OCHg- and S-CH.-benzoylglycine in BLMV and 
pH-dependent transport in BBMV. Only the 3-CH„ analog had a strong 
inhibitory effect on sodium-dependent BBMV transport, while the 2-0CH_ 
analog was one of the weakest inhibitors. For most glycine conjugates the 
inhibitory pattern on Na gradient-dependent PAH uptake in BBMV was 
comparable to that on pH gradient-dependent uptake, although absolute 
values were different. Phenylacetylglycines showed both in BLMV (except 
for the 2-OH substitute) and BBMV a lower and much less differentiated 
inhibitory effect, as compared to the corresponding benzoylglycines. 
Correlation Studies 
The logarithm of the apparent inhibition constant (logK.) was used to 
correlate the inhibitory potency of the glycine conjugates with the physic-
ochemical parameters listed in Table 11.1. Linear and parabolic regression 
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Table 11.3 Effect of Substituted Benzoylglycines and Phenylacetylglycines 
on Specific PAH Uptake into BLMV and BBMV.3 
BLMV 
b с 
substituent %inh. К. 
benzoylglycines 
H 
2-CH3 
з-сн3 
А-СН3 
2-ОСН3 
з-осн3 
4-0СН3 
2-ОН 
3-ОН 
А-ОН 
50 
39 
74 
56 
76 
63 
51 
-5 
46 
56 
+ 
+ 
+ 
+ 
± 
± 
± 
± 
+ 
+ 
5 
6 
6 
6 
5 
6 
7 
9 
6 
6 
4.4 
6.9 
1.6 
3.5 
1.4 
2.6 
4.3 
>50 
5.2 
3.5 
45 
25 
83 
62 
29 
67 
29 
47 
36 
43 
± 
+ 
+ 
+ 
+ 
± 
+ 
± 
± 
+ 
7 
5 
5 
5 
9 
3 
7 
6 
5 
5 
6.0 
14.7 
1.0 
3.0 
12.0 
2.4 
7.7 
5.5 
8.7 
6.5 
30 
26 
54 
43 
56 
47 
37 
52 
43 
50 
± 
+ 
+ 
+ 
+ 
± 
± 
± 
± 
+ 
5 
6 
7 
3 
4 
7 
3 
4 
2 
3 
11.5 
14.0 
4.2 
6.5 
3.9 
5.5 
8.4 
4.5 
6.5 
4.9 
phenylacetylglycines 
H 
2-СН3 
з-сн3 
4-СН3 
2-0СН3 
з-осн3 
4-0СН3 
2-ОН 
3-ОН 
4-ОН 
47 
47 
45 
44 
51 
49 
56 
61 
38 
36 
+ 
+ 
± 
± 
+ 
+ 
+ 
+ 
+ 
+ 
4 
4 
4 
4 
5 
5 
3 
4 
5 
4 
5 
5 
5 
5 
4 
4 
3 
2 
7 
7 
22 ± 
16 ± 
35 ± 
27 ± 
2 ± 
И ± 
6 ± 
3 ± 
2 ± 
8 ± 
1 
4 
4 
2 
2 
4 
3 
5 
3 
8 
17.4 
25.7 
9.1 
13.2 
>50 
39.6 
>50 
>50 
>50 
>50 
25 
33 
34 
40 
29 
29 
30 
20 
30 
26 
± 
+ 
+ 
+ 
+ 
± 
+ 
+ 
+ 
+ 
3 
3 
4 
5 
2 
1 
1 
6 
4 
2 
14.7 
10.0 
9.5 
7.4 
12.0 
12.0 
11.5 
19.7 
11.5 
14.0 
The probenecid-sensitive part of 100 μΜ PAH uptake at 15 sec was 
measured. The experimental conditions were similar to those given in 
Table 11.2, except for the presence of 5.0 mM inhibitor. Control uptakes 
were measured in presence of 5 mM gluconate. 
Inhibition is expressed relative to the respective control uptakes as 
means ± SE of three to five experiments. 
Inhibition constant calculated according to Eq. 11.2, values are 
expressed in mM. For %inh. values <10% or >90% estimates of K, were 
considered too inaccurate and only the upper or lower limits are given. 
Na BBMV pH 
íinh. K. 
ι 
%inh. K. 
ι 
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Table 11.4 Correlation Between logK. and logk of Substituted 
Benzoylglycines and Phenylacetylglyclnes. 
log 
*w 
benzoylglycines 
BLMV 
(Na+) 
BBMV 
(Na+) 
BBMV 
(pH) 
pH 7.4 
pH 5.9 
pH 2.9 
pH 7.4 
pH 5.9 
pH 2.9 
pH 7.4 
pH 5.9 
pH 2.9 
phenylacetylglyc 
BLMV 
(Na"1") 
BBMV 
(pH) 
pH 7.4 
pH 5.9 
pH 2.9 
pH 7.4 
pH 5.9 
pH 2.9 
logK. = a 
a 
-0.44 
0.14 
-0.68 
-0.23 
0.21 
-0.97 
-0.54 
0.08 
-0.91 
a 
:ines 
2.42 
1.37 
1.74 
0.34 
1.03 
0.78 
+ blogk
w
 -
b 
2.72 
1.73 
2.53 
2.89 
2.42 
3.61 
3.29 
2.38 
3.17 
-3.12 
-1.48 
-1.69 
1.68 
0.40 
0.76 
c(logk
w
)* 
с 
1.49 
1.24 
1.13 
1.71 
1.86 
1.66 
1.66 
1.48 
1.30 
-1.29 
-0.72 
-0.61 
0.81 
0.31 
0.36 
η 
9 
9 
9 
9 
9 
9 
9 
9 
9 
10 
10 
10 
10 
10 
10 
г 
0.894 
0.852 
0.793 
0.801 
0.855 
0.750 
0.942 
0.886 
0.800 
0.806 
0.636 
0.770 
0.852 
0.569 
0.828 
s 
0.12 
0.14 
0.16 
0.24 
0.21 
0.27 
0.07 
0.10 
0.13 
0.09 
0.12 
0.10 
0.07 
0.11 
0.07 
logK. = log inhibi t ion constant, logk = capacity factor, η = number of 
compounds studied, r = correlat ion coefficient and s = standard deviation. 
a + 
In BBMV (Na ) pract ica l ly no inhibit ion was observed (Table 11.3), as a 
result data were insufficient for correlat ion analysis. 
analysis was performed and in all cases a quadratic equation described 
the relationship between logk and logK. better than a linear equation. 
Relevant results of these correlation studies are presented in Table 11.4 
and Figs. 11.1 and 11.2. Except for the relation between logk (pH 5.9) 
and logK. of the phenylacetylglyclnes, all correlations were significant 
(p<0.05), but on the whole highest coefficients of correlation were 
observed between logk (pH 7.4) and logK.. It should be noticed that in 
case of the benzoylglycines significant correlations were only obtained 
after exclusion of the 2-OH analog from BLMV and BBMV(pH) and the 
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Fig. 11.1 Correlation between the logarithm of the apparent inhibition 
constant K. and the capacity factor logk determined at pH 7.4, character­
izing the effect of substituted benzoylglycines on sodium gradient-
dependent PAH uptake into BLMV. 
2-OCH3 analog from BBMV(Na ). The correlation coefficients in the 
regressions with logk (pH 7.4) ranged between 0.80 and 0.94, which 
means that 64-889o of the total variation in logK. was due to the hydropho-
bicity of the compounds at pH 7.4. 
11.4 DISCUSSION 
A considerable effort has been made to identify the structural proper­
ties that determine whether an anion is secreted by the renal organic 
anion transport system. Sophisticated models have been proposed to 
rationalize the vast structural diversity in compounds transported [2,6]. 
However, recently UUrich et al. [30,31] showed in a series of elaborate 
microperfusion experiments in the rat that a monocarboxylic or aldehyde 
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constant K. and the capacity factor logk determined at pH 7.4, character­
izing the effect of substituted benzoylglycines on sodium gradient-
dependent (top) and pH gradient-dependent PAH uptake into BBMV (bottom). 
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group in combination with a hydrophobic moiety are in fact sufficient to 
meet the requiroments for interaction with the ΡΛΗ transporter in the 
basolateral membrane. 
In the present study the substrate specificity of PAH transport across 
basolateral and brush border membranes was tested with a series of close­
ly related hippurate derivatives, and an attempt was made to correlate the 
affinity of the compounds with their physicochemical properties. The rela­
tive hydrophobicity of the glycine conjugates was determined by reversed 
phase HPLC. It is now well established that retention parameters, in par­
ticular the extrapolated capacity factor for an aqueous eluent (logk ), 
are very useful for the assessment of the hydrophobic nature of dru^s 
[32]. An important advantage of logk over the classic n-octanol-water 
partition coefficient is the possibility of accurately determining the 
hydrophobicity of ionized solutes. 
The results of the present study show that, apart from two outliers 
(2-0H- and 2-OCH^-benzoylglycine), the hydrophobic properties of the 
ionized glycine conjugates are the primary determinants of their inhibitory 
effect on PAH transport in BLMV and BBMV. This indicates that 
hydrophobic as well as electronic properties are decisive for substrate 
affinity. Benzoylglycines wore better inhibitors than phenylacetyl-
glycines, indicating that insertion of a CIL·-group between the ring and 
the carbonyl reduces the influence of the ring and its substituent on the 
inhibitory potency. 
It was very remarkable that we could not observe an inhibitory effect 
of 2-OH-benzoylglycine on PAH transport in BLMV, all the more since it 
is well-known that this compound is actively secreted by the kidney in 
vivo [33] . An explanation for this unexpected behavior may be related 
with the unique capacity of this compound to form an intramolecular 
hydrogen bond between the hydroxy and carbonyl group. Fixation of the 
carbonyl in an intramolecular hydrogen bond may hinder the interaction 
with the carrier, thus preventing the compound from being transported. 
A similar mechanism has been suggested for 2-acetamidohippurate, to 
explain why this compound is not or practically not actively secreted by 
the kidney [6] . However, it remains unclear why in vivo 
2-OH-benzoylglycine is readily excreted by tubular secretion. It is con­
ceivable that under in vivo conditions intramolecular hydrogen bonding is 
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less favourable. Another explanation, however more tentative, may be 
that 2-OH-benzoylglycine is also in vivo not transported by the PAH car-
rier but by a distinct transport system (urate carrier?) in the basolateral 
membrane. The inhibitory potency of 2-OH-benzoylglycine against PAH 
transport in BBMV was apparently not affected by intramolecular hydro-
gen bonding. On the contrary, pH-dependent PAH uptake was even 
stronger inhibited than predicted from the relation with logk . 
The inhibitory pattern of the glycine conjugates on sodium- and pH-
dependent PAH uptake in BBMV was comparable, except for 
2-OCH„-benzoylglycine. This compound clearly inhibited pH-dependent 
transport in accordance with its hydrophobicity, while it had an unex-
pected weak inhibitory effect on Na -dependent transport . Steric hin-
drance of the bulky 2-methoxy group may be involved, indicating a dif-
ference in substrate specificity between Na - and pH-dependent PAH 
+ 
t ransport . This would support the hypothesis that Na - and pH-
dependent PAH transport across the brush border membrane are separate 
transport routes. 
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SUMMARY AND CONCLUSIONS 
The renal organic anion transport system is responsible for the facili-
tated elimination of endogenous metabolites and foreign substances, which 
are not easily degraded by the body. Many of these substances are 
drugs, and the mode of their renal secretion largely determines their dis-
position and consequently, their pharmacological response. Since carrier-
mediated processes are involved, the potential problem of saturation and 
competition may be the basis for a variety of clinical implications. There-
fore, knowledge of the basic processes that determine the active tubular 
secretion of anionic drugs is of great practical importance. 
The investigations described in this thesis were focused on the mecha-
nisms and interactions of organic anion transport in the dog kidney. 
After a general introduction, the thesis is organized around three major 
themes, i . e . , a new physiologically based modeling approach to describe 
the excretion kinetics of anionic drugs and their interactions, the sub-
strate specificity of organic anion secretion for a series of closely related 
substituted hippurates, and the mechanisms of organic anion transport at 
a subcellular level. 
Introduction 
In Chapter 1 an introduction into the present state of knowledge of the 
renal handling of organic anions is given. The proximal tubular cells of 
the kidney are the main anatomical site of the carrier-mediated secretion 
of anionic drugs . Organic anions are actively transported at the basolat-
eral membrane, concentrated intracellularly, and subsequently transported 
from the cell into the tubular lumen by mediated diffusion. One of the 
remarkable features of the organic anion secretory system is that it 
accepts a wide variety of substances which may compete with each other 
for t ransport . The clinical implications of anionic drug secretion are dis-
cussed briefly. 
Chapter 2 describes a technique for the quantitative collection of urine 
in renal clearance studies in the dog. Quantitative urine collection is of 
crucial importance for accurately assessing the urinary excretion of a 
drug. A double-walled urinary catheter has been developed which allows 
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rapid and quantitative urine collection at short time intervals down to 5 
min. The catheter consists of a polyurethane outer cannula in which a 
small Teflon cannula is inserted. The essential of the catheter is that at 
the end of a collection period residual urine in the bladder is collected 
completely via the outer cannula by flushing the bladder with physiologi­
cal saline through the inner cannula. The use of the catheter was demon­
strated in a study on the renal clearance of hippurate. 
Physiologically Based Kidney Model 
In this part a physiologically based pharmacokinetic model of the kidney 
is proposed, as accurate but also as simple as possible, that is able to 
describe and quantify the relevant processes of tubular secretion and 
competition. The model incorporates the functional characteristics of the 
kidney that determine the excretion of many anionic drugs, i .e . , renal 
plasma flow, urine flow, nonlinear protein binding, glomerular filtration, 
tubular secretion, and tubular accumulation. 
In Chapter 3 the plasma kinetics and renal excretion of intravenous 
phenolsulfonphthalein (PSP, 1.0 g), with and without concomitant infusion 
of probenecid or salicyluric acid (SUA) are studied in 6 male beagle dogs. 
Tubular secretion is an important route of PSP excretion, and secretion is 
inhibited by probenecid as well as SUA. The kidney model enabled an 
accurate description of the measured plasma levels and renal excretion 
rates of PSP. The average values of the parameters characterizing the 
tubular t ransport maximum (T,.) and the apparent affinity for the secre­
tory system (К™) were: TM= 6.6 ± 1.6 mg/min and KT= 16 ± 4 ug/ml. 
The interaction with probenecid and SUA could be adequately accounted 
for by inhibition of the carrier-mediated uptake of PSP into the tubular 
cells. But both compounds differed clearly in their inhibitory action. 
Whereas probenecid showed simple competitive inhibition (KT= 7 ± 6 
Ug/ml), for SUA a considerably more complex interaction (two-site compet­
itive system) had to be taken into consideration (KT= 24 ± 6 vig/ml). 
Especially in the interaction experiments, only satisfactory fits to the 
model were obtained when secretion was assumed to be dependent on 
unbound PSP concentrations. Model calculations predicted a pronounced 
accumulation of PSP within the proximal tubular cells, which was clearly 
diminished in presence of probenecid or SUA. 
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Chapter 4 reports on the renal clearance of SUA (0.8 g, i .v .) and the 
interaction with PSP in 4 dogs. Despite its considerable binding to plasma 
proteins, SUA is almost completely extracted from the renal plasma at low 
concentrations, indicating that protein binding does not limit the extent of 
its tubular secretion. Analysis with the kidney model revealed that PSP 
inhibited the active uptake of SUA into the tubular cells in a noncompeti­
tive fashion (TM= 4.3 ± 0.6 vs . 3.3 ± 0.7 mg/min; paired t-test p<0.05, 
KT= 31 + 5 vs. 32 ± 12 yg/ml; p>0.3). Furthermore, a small but signifi­
cant reduction in nonrenal SUA clearance was observed (14 ± 3 vs . 11 ± 3 
ml/min; p<0.05). The model-predicted cellular accumulation ratios were in 
accordance with previously reported in vitro values, and were decreased 
considerably in presence of PSP. 
The last chapter of Part II (Chapter 5) is concerned with the renal 
handling of iodopyracet and the influence of probenecid in 4 dogs. 
lodopyracet is weakly bound to plasma proteins and its renal clearance is 
characterized by supply-limited elimination at low plasma concentrations 
and, just as the foregoing compounds, capacity-limited elimination at high 
plasma levels (TM= 32 ± G mg/min, Кгг= 36 ± 8 yg/ml) . Also for iodopy­
racet, model calculations showed a substantial tubular accumulation, which 
was reduced by probenecid as a result of competitive inhibition of the 
active cellular uptake (KT= 8 ± 3 yg/ml). 
Substituted Hippurates 
The renal clearance of a series of mono-substituted benzoylglycines 
(hippurates) was investigated, in order to determine systematically the 
influence of ring substitution on the excretory characteristics of benzoyl-
glycine. The physiologically based kidney model was applied to analyze 
the plasma and renal excretion kinetics of the benzoylglycines. The com­
pounds were administered in a dose of about 1 gram ( i .v .) to 3 beagle 
dogs. 
Chapter 6 describes the renal handling of benzoylglycine (hippurate) 
and methyl-substituted benzoylglycines. Benzoylglycine and the 3- and 
4-methyl analogs showed nonlinear plasma protein binding varying between 
20 and 80o& over a concentration range of 5 - 450 yg/ml. For 
2-methylbenzoylglycine an extremely high protein binding of almost 100% 
was observed at low plasma concentrations (<50 yg/ml). All conjugates 
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were largely excreted via the kidney (>80o of the dose) and tubular 
secretion appeared to be a function of the total drug concentration in 
renal plasma, except for the 2-methyl analog, presumably due to its tight 
protein binding. The average values of the kinetic parameters character­
izing tubular secretion were: benzoylglycine TM= 5.5 ± 0.8 mg/min, KT= 
40 ± 5 vg/ml; 3-methylbenzoylglycine TM= 7.1 ± 3.3 mg/min, KT= 49 + 1 
Ug/ml; 4-methylbenzoylglycine TM= 8.0 ± 1.6 mg/min, Κ^= 14 ± G yg/ml. 
Tubular secretion of 2-inethylbenzoylglycine was not saturated. Accord­
ingly, only the intrinsic secretion clearance (CL. .) Τ
Μ
/Κ
Τ
= 163 ± 54 ml/ 
min could be calculated. An interesting observation was the partial 
deconjugation of 4-methylbenzoylglycine to its corresponding benzoate. 
4-Methylbenzoate was only found in plasma and not in urine, indicating 
that the benzoate was either cleared extrarenally, or completely metabo­
lized during transfer through the kidney. 
In Chapter 7 the plasma kinetics and renal excretion of 
4-aminobenzoylglycine (p-aminohippurate) and hydroxy-substituted ben-
zoylglycines were studied. Plasma protein binding of 4-amino-, 
3-hydroxy-, and 4-hydroxybenzoylglycme was low and constant (<15<ò), 
while the 2-hydroxy analog showed concentration-dependent protein bind-
ing ranging from 40 - 80%. The excretory patterns of the 4-amino, 3- and 
4-hydroxy analogs were essentially the same; rapid elimination from plas-
ma into urine (>80oo of the dose), mainly by very efficient supply-limited 
tubular secretion. Conversely, the excretion of 2-hydroxybenzoylglycine 
was characterized by a lower plasma clearance and total renal excretion 
(64°o of the dose), and a limited capacity of the tubular secretory system. 
The kinetic parameters characterizing its tubular secretion were, TM= 4.4 
± 0.9 mg/min and KT,= 23 ± 8 yg/rnl. Since secretion of the other com-
pounds was not saturated, only the CL. . was estimated: 4-amino- CL. .= 
145 ± 50 ml/min, 3-hydroxy- C L j n t - 194 * 2 1 ml/min, and 
4-hydroxybenzoylgycine CL. .= 153 ± 23 ml/min. 
Finally, in Chapter 8 the renal clearance of methoxy-substituted ben-
zoylglycines is characterized. Their plasma protein binding varied 
between 10 and 70%. The methoxybenzoylglycines were rapidly cleared 
from plasma, largely by renal excretion (72 -84% of the dose). Tubular 
secretion of 2- and 3-methoxybenzoylglycine was saturated, while the 
clearance capacity of the secretory system for the 4-methoxy analog was 
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so high that complete saturation was not achieved. The kinetic parame­
ters were: 2-methoxy- TM= 11.7 ± 4.9 mg/min, ! ( = 42 + 9 yg/ml; 
3-methoxy- TM= 8.8 ± 1.0 mg/min, KT= 27 ± 20 Ug/ml; 
4-methoxybenzoylglycine CL. .= 201 ± 47 ml/min. The 4-methoxy analog 
was metabolized to some extent by deconjugation of the glycine moiety and 
the resulting benzoate was found in plasma but not in urine. 
Taking the results of Part III together, it can be concluded that intro­
duction of a substituent in the ring of benzoylglycine results in general 
in a substance for which the renal secretory system has a higher clear­
ance capacity. The most extensive tubular secretion was found for the 
4-amino, 3-hydroxy, and 4-hydroxy substitutes, while the extent of 
secretion of 2-hydroxybcnzoylglycine was small, even less than that of 
benzoylglycine. In between, a large diversity in excretory characteristics 
exists. 
Isolated Membrane Vesicles 
The carrier systems which control the transtubular transport of organic 
anions are confined to the plasma membranes of the proximal tubular 
cells, i . e . , the basolateral and brush border membrane. Isolation of these 
membranes provides an important tool for studies directed at the molecular 
mechanisms of transport at specific membrane sites. 
Chapter 9 describes a technique for the isolation of basolateral (BLMV) 
and brush border membrane vesicles (BBMV) from dog kidney cortex. 
The transport of p-aminohippurate (ΡΛΗ) was studied in these vesicles. 
Imposition of an inwardly directed sodium gradient (100 mM) stimulated 
the uptake of 50 μΜ [Ή]PAH into BLMV, whereas a pH gradient (pH .= 
6.0, pH. = 7.4) only slightly enhanced uptake. The sodium gradient-
dependent uptake of PAH was electroneutral, saturable, and sensitive to 
inhibition by probenecid and several anionic drugs, with (apparent) К = 
0.79 ± 0.16 mM, V = 0.80 ± 0.05 nmol/mg protein, 15 sec, and Κ. , = 
' max
 6
 ^ i .prob 
0.08 ± 0.01 mM. Simultaneous imposition of the pH gradient (outward 
hydroxyl gradient) and inward sodium gradient stimulated PAH uptake 
significantly over that with a sodium gradient alone, suggesting a sodium 
gradient-stimulated РАН/ОН exchange mechanism. 
In BBMV, PAH uptake could be stimulated by an outwardly directed 
hydroxyl gradient as well as an inward sodium gradient. Both gradients 
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could drive PAH transport via a mediated probenecid-sensitive pathway. 
Sodium-gradient stimulated uptake was electrogenic with a (apparent) К = 
4.93 ± 0.57 mM, V = 6.71 ± 0.36 nmol/mg protein,15 sec, and K. . -
max **
 r
 i,prob 
0.13 ± 0.01 mM. The kinetic parameters for PAH/hydroxyl exchange were 
virtually the same, (apparent)К = 5.72 ± 0.49 mM, V = 7 . 8 7 + 0.33 
* '
 y
 ^^ ' m max 
nmol/mg protein, 15 sec, and K. , = 0.16 ± 0.02 mM. Imposition of both 
the sodium and pH gradient stimulated uptake almost twofold over that 
with either a sodium or pH gradient alone. These results suggested that 
both gradients stimulate PAH transport in BBMV via the same pathway. 
However, inhibition experiments with various organic anions showed that 
the specificities of sodium and pH gradient-stimulated uptake did not 
entirely overlap. Thus, it may be possible that two separate pathways are 
involved. 
In Chapter 10 the substrate specificity of the organic anion secretory 
system was studied by looking at the effect of substituted benzoates on 
the sodium-dependent PAH uptake into BLMV and the sodium- or pH-
dependent uptake into BBMV. Practically all benzoates showed an 
inhibitory effect on PAH transport in BLMV and BBMV; the strongest 
inhibitors were 3-C1- and 4-Cl-benzoate, while the weakest inhibition was 
found for the 3-NH_ and 4-NH- substitutes. The apparent inhibition con­
stant (K.) correlated significantly with the relative hydrophobicity of the 
ionized benzoates (determined by HPLC), indicating that hydrophobic and 
electronic properties are the main determinants of affinity for the PAH 
transport system. 
The final chapter (Chapter 11) deals with the effect of substituted ben-
zoylglycines (hippurates) and phenylacetylglycines on PAH transport in 
BLMV and BBMV. Benzoylglycines were stronger inhibitors of PAH 
transport than phenylacetylglycines and the inhibitory potency of the 
conjugates was in general lower against transport into BBMV than BLMV. 
The strongest inhibitory effect was found with 2-OCH„- and 
3-CH_-benzoylglycine on BLMV and pH-dependent BBMV transport, while 
only the 3-CH, analog was a strong inhibitor of sodium-dependent BBMV 
transport . Strikingly, 2-OH-benzoylglycine did not inhibit PAH transport 
in BLMV, while it clearly inhibited BBMV transport . It is suggested that 
intramolecular hydrogen bonding hinders the carbonyl from interaction 
with the carrier, thus preventing transport . Apparently, the carbonyl 
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group is not essential for transport into BBMV. The K. values of the 
glycine conjugates correlated parabolically with the relative hydrophobicity 
of the ionized compounds. This indicates that also for the glycine conju-
gates, hydrophobic and electronic properties are important determinants 
of affinity for the PAH transport system. 
Concluding Remarks 
In this thesis a physiologically based pharmacokinetic model of the kid-
ney has been presented, that was used to analyze the renal clearance of 
organic anions. In combination with an accurate and frequent urine sam-
pling technique, the model appeared to be a useful tool for the quantita-
tive assessment of the mechanisms that govern the renal excretion of 
anionic drugs . Furthermore, the model enabled a comprehensive charac-
terization of drug interactions at the level of tubular secretion. Future 
work has to be aimed at incorporating the mechanisms of active and pas-
sive reabsorption to make it applicable to a broader range of compounds. 
Of course, scaling-up the model to the human situation will be the ulti-
mate goal. 
The different types of interactions that were observed in the clearance 
experiments with PSP and SUA are clearly in favor of the concept of a 
functional heterogeneity of the renal organic anion secretion system. The 
studies with the isolated membrane vesicles also provided supporting evi-
dence for this hypothesis. At least for the brush border membrane there 
were strong indications to suggest separate transport systems with over-
lapping specificities. To solve the intriguing puzzle of transport multiplic-
ity, more detailed membrane vesicle studies on the interaction between 
systems which may influence organic anion transport are required, in 
combination with a greater emphasis on cell and tubule preparations to 
examine the various pathways under physiological conditions, and to 
translate these findings to the in vivo situation. 
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SAMENVATTING EN CONCLUSIES 
Een van de belangrijke functies die de nier in het lichaam vervult is de 
selectieve verwijdering van afbraakproducten en lichaamsvreemde stoffen. 
Voor deze veelomvattende taak beschikt het orgaan over een aantal 
transportsystemen die elk een bapaalde stof of een groep van stoffen 
kunnen herkennen. Onderwerp van dit proefschrift is het 
organisch-aniontransportsysteem in de nier. Naast de uitscheiding van 
enkele endogene substanties zorgt dit systeem er voor dat 
lichaamsvreemde anionen, waaronder vele geneesmiddelen en metabolieten, 
op efficiente wijze uit het lichaam worden verwijderd. De mate van actieve 
renale uitscheiding zal sterk bepalend zijn voor de duur en intensiteit van 
werking en bijwerkingen van deze geneesmiddelen. Bovendien zijn er bij 
dit transport carrier-gemedieerde processen betrokken waardoor er kans 
op verzadiging en competitie bestaat, wat niet zelden leidt tot een 
noodzakelijke aanpassing van de farmacotherapie. Een grondige kennis van 
de processen die een rol spelen bij de actieve uitscheiding van 
anionische-geneesmiddelen is derhalve van eminent belang. 
De experimenten beschreven in dit proefschrift zijn gewijd aan de 
mechanismen en interacties van het organisch-aniontransport in de nier 
van de hond. Na een algemene inleiding is het geheel opgebouwd rond een 
drietal thema's namelijk, fysiologisch-farmacokinetisch modelleren van 
transport in de nier, specificiteit van anionsecretie voor een reeks van 
gesubstitueerde hippuraten en mechanismen en interacties van 
organisch-aniontransport op subcellulair niveau. 
Inleiding 
Hoofdstuk 1 geeft een overzicht van de huidige stand van zaken op het 
gebied van de renale klaring van organische anionen. Het 
aniontransportsysteem is gelocaliseerd in de cellen van de proximale 
tubulus. Organische anionen worden actief opgenomen aan de basolaterale 
membraan waarbij hoge intracellulaire concentraties worden bereikt. 
Vervolgens worden ze in het tubulaire lumen getransporteerd via 
gefaciliteerde diffusie door de brush-border membraan. Een opmerkelijke 
eigenschap van het organisch-aniontransportsysteem is dat het een enorme 
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verscheidenheid aan verbindingen accepteert die met elkaar kunnen 
competeren voor transport . De klinische implicaties van de tubulaire 
secretie van geneesmiddelen worden in het kort besproken. 
Hoofdstuk 2 beschrijft een methode voor de kwantitatieve monstering 
van urine bij renale klaringsstudies in de hond. Het kwantitatief 
verzamelen van urine is van doorslaggevend belang voor een nauwkeurige 
analyse van de 7-enale excretie van een geneesmiddel. Voor dit doel is een 
dubbelwandige blaascatheter ontworpen waarmee urine, snel en 
kwantitatief, in tijdsintervallen van 5 min kan worden verzameld. De 
catheter bestaat uit een buitencanule van polyurethaan waarin zich een 
dunne Teflon-canule bevindt. Het principe van de catheter is dat urine, 
die aan het eind van een verzamelperiode in de blaas is achtergebleven, 
volledig verzameld kan worden via de buitencanule door de blaas via de 
binnencanule te spoelen met een fysiologische-zoutoplossing. Aan de hand 
van een studie naar de renale klaring van hippuurzuur is het gebruik 
van de catheter gedemonstreerd. 
Semifysiologisch Niermodel 
In Deel II van het proefschrift wordt een farmacokinetisch model van de 
nier beschreven dat is gebaseerd op fysiologische overwegingen en 
waarmee het mogelijk is de processen die van belang zijn voor tubulaire 
secretie en competitie te kwantificeren. Het model bevat de functionele 
eigenschappen van de nier die van invloed zijn op de excretie van vele 
anionische-geneesmiddelen dwz., de renalo -plasmaf low, de urineflow, 
niet-lineaire eiwitbinding, glomerulaire filtratie, tubulaire secretie en 
tubulaire accumulatie. 
In Hoofdstuk 3 is het verloop van de plasmaconcentratie en renale 
excretie van phenolsulfonphthaleine (PSP, 1.0 g i .v.) in 6 mannelijke 
honden (beagles) bestudeerd. Tevens is gekeken naar het effect van 
gelijktijdige infusie van probenecide of salicyluurzuur (SUA). Tubulaire 
secretie is voor PSP een belangrijke excretieroute en probenecide en SUA 
remmen beide dit transportproces. Met het niermodel bleek het mogelijk 
een nauwkeurige beschrijving te verkrijgen van do experimentele plasma-
en urinegegevens van PSP. De gemiddelde waarden van de parameters die 
het tubulaire-transportmaximum (T M ) en de schijnbare affiniteit voor het 
secretoire systeem (K™) weergeven waren, Τ = 6.6 ± 1.6 mg/min en Κ_= 
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16 ± 4 yg/ml De interactie met probenecide en SUA kon adequaat worden 
beschreven door een remming te veronderstellen van de 
carrier-gemedieerde opname in de tubuluscel Beide verbindingen 
verschilden echter duidelijk in hun remmende werking Probenecide 
vertoonde een eenvoudige competitieve interactie (KT= 7 ± 6 ug/ml), 
terwijl voor SUA een aanmerkelijk gecompliceerder mechanisme (een 
competitief systeem met twee bmdingsplaatsen) noodzakelijk was om de 
interactie te verklaren (KT= 24 ± 6 ug/ml) Met name in de 
interactie-experimenten konden alleen bevredigende fits worden verkregen 
wanneer werd aangenomen dat de tubulaire secretie een functie van de 
vrije PSP-plasmaconcentratie is Modelberekeningen voorspelden een 
uitgesproken accumulatie van PSP in de proximale-tubuluscellen, die 
duidelijk verminderde in aanwezigheid van probenecide of SUA 
Hoofdstuk 4 rapporteert over de renale klaring van SUA (0 8 g, ι ν ) 
en de interactie met PSP in 4 honden Ondanks een aanzienlijke binding 
aan plasmaeiwitten wordt SUA bij lage concentraties vrijwel volledig door 
de nier geklaard Dit betekent dat eiwitbinding geen beperking vormt 
voor de tubulaire secretie van SUA Analyse van de interactie met PSP 
leverde een non-competitieve remming van de actieve opname van SUA in 
de tubuluscel op (T = 4 3 ± 0 6 v s 3 3 ± 0 7 mg/min, gepaarde t-test 
p<0 05, KT= 31 + 5 vs 32 ± 12 ug/ml, p>0 3) Daarnaast werd een 
kleine maar significante daling van de niet-renale klaring van SUA 
gevonden ( 1 4 ± 3 v s 11 ± 3 ml/min, p<0 05) De met het model 
berekende cellulaire accumulatieratio's komen goed overeen met eerder in 
de literatuur beschreven in-vitro waarden De ratio's waren aanzienlijk 
verlaagd in aanwezigheid van PSP 
Het laatste hoofdstuk van Deel II (Hoofdstuk 5) is gewijd aan de renale 
klaring van lodopyracet en de interactie met probenecide in 4 honden 
lodopyracet heeft een zwakke eiwitbinding en een renale klaring die wordt 
gekenmerkt door een flow-beperkte eliminatie bij lage plasmaconcentraties 
en, net als PSP en SUA, een capaciteits-beperkte eliminatie bij hoge 
concentraties ( Ί \ = 32 ± G mg/min, K ^ 3G ± 8 ug/ml) Ook voor 
lodopyracet voorspelden de modelberekeningen een aanzienlijke tubulaire 
accumulatie, die wordt gereduceerd door probenecide als gevolg van een 
competitieve remming van de cellulaire opname van lodopyracet (K,= 8 ± 3 
Vg/ml). 
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Gesubstitueerde Hippuraten 
In een sybtematisch onderzoek naar de invloed van de ringsubstituent 
op de excretiekarakteristieken van benzoylglycine (hippuurzuur) is de 
renale klaring van een reeks mono-gesubstitueerde bonzoylglycines 
bestudeerd Het eerder beschreven semifysiologische mormodel werd 
gebruikt om de experimentele plasma- en urinegogevens te analyseren De 
bonzoylglycines werden in een dosis van 1 gram intraveneus toegediend 
aan 3 honden 
Hoofdstuk 6 beschrijft de renale klaring van benzoylglycine en de 
methyl-gesubstitueerde benzoylglycines Benzoylglycine en de 3- en 
4-methyl-analoga vertoonden met-lineaire plasma-eiwitoinding die varieerde 
van 20 tot 80o over een concentratiegebied van 5 - 450 ug/ml In het 
geval van 2-methyIben7oylglycine werd bij lage plasmaconcentraties (<50 
Ug/ml) een extreem hoge eiwitbinding van bijna 100oo gevonden Alle 
glycineconjugaten werden voor het grootste deel via de nieren 
uitgescheiden (>80oo van do dosis) Tubulaire secretie bleek een functie te 
zijn van de totale plasmaconcentratie met uitzondering van 
2-methylbenzoylglycine, hetgeen mogelijk te wijten is aan de sterke 
eiwitbinding van deze stof De gemiddelde waarden van de kinetische 
parameters voor tubulaire secretie waren benzoylglycine TM= 5 5 ± 0 8 
mg/min, KT= 40 ± 5 yg/ml, 3-methylbenzoylglycine Τ = 7 1 ± 3 3 mg/mm, 
K= 49 ± 1 ug/ml, 4-methylbenzoylglycine TM= 8 0 ± 1 G mg/min, KT= 14 
± 6 ug/ml Omdat de tubulaire secretie van 2-methylbenzoylglycine niet 
verzadigd was, kon voor deze verbinding alleen de intrinsieke 
secretieklaring (CL .) T../K = 163 ± 54 ml/min worden berekend. Een 
interessante waarneming was de gedeeltelijke deconjugatie van 
4-methylbenzoylglycine tot het corresponderende benzoaat 
4-Methylbenzoaat werd alleen in plasma aangetroffen en niet in urine, 
hetgeen erop duidt dat het benzoaat ofwel extra-renaal geklaard wordt of 
volledig gemetaboliseerd wordt tijdens het transport door de nier. 
In Hoofdstuk 7 zijn de plasmakmetiek en renale excretie van 
4-aminobenzoylglycme (p-aminohippuurzuur) en de hydroxy-
gesubstitueerde benzoylglycines bestudeerd De plasma-oiwitbinding van 
4-amino-, 3-hydroxy- en 4-hydroxybenzoylglycine was laag en constant 
(<150o), terwijl voor 2-hydroxybenzoylglycine concentratie-afhankelijke 
eiwitbinding (40 - 80%) werd gevonden Het uitscheidingspatroon van de 
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4-amino-, 3- en 4-hydroxy-analoga was vrijwel hetzelfde een snelle 
klaring vanuit het plasma naar de urine (>80o van de dosis), voornamelijk 
door zeer efficiente flow-beperkte tubulaire secretie Daarentegen 
kenmerkte de excretie van 2-hydroxybenzoylglycine zich door oen lagere 
plasmaklaring, oen lagere totale renale excretie (640o van de dosis) en een 
beperkte capaciteit van het tubulaire-secretoire systeem De kinotische 
parameters van de tubulaire secretie van 2-hydroxybenzoylglycine waren, 
TM= 4 4 ± 0 9 mg/min en KT= 23 + 8 yg/ml Omdat de tubulaire secretie 
van de andere glycines niet verzadigd was kon alleen de CL· . worden 
berekend 4-amino- CL = 145 ± 50 ml/mm, 3-hydroxy- CL = 194 ± 21 
ml/min en 4-hydroxybenzoylglycine CL " 153 ± 23 ml/min 
In Hoofdstuk 8 is tenslotte de renale klaring van de 
methoxy-gesubstitueerde benzoylglycines gemeten Plasma-eiwitbinding was 
met-lineair en varieerde van 10 tot 70oo en de klaring uit het plasma was 
snel, voor het grootste deel via renale excretie (72 - 840o van de dosis) 
De tubulaire secretie van 2- en 3-methoxybenzoylglycine was verzadigd, 
terwijl de klaringscapaciteit van het tubulaire systeem voor 
4-methoxybenzoylglycine te groot was om volledige verzadiging te 
bereiken De kinetische parameters waren 2-methoxy- Τ = 11 7 ± 4 9 
mg/min, KT= 42 ± 9 yg/ml, 3-methoxy- T . = 8 8 + 1 0 mg/min, KT= 27 ± 
20 ug/ml en 4-methoxybenzoylglycine CL .= 201 ± 47 ml/min 
4-Methoxybenzoylglycine werd voor een dool gometabohseerd door 
deconjugatie van de glycinegroep Ook hier werd het gevormde benzoaat 
alleen in plasma gevonden en niet in de urine 
De resultaten van Deel III samenvattend kan worden geconcludeerd dat 
introductie van een substituent in de benzeennng van benzoylglycine in 
het algemeen leidt tot een substantie waarvoor het tubulaire-secretoire 
systeem een grotere klaringscapaciteit heeft De meest efficiente tubulaire 
secretie werd gevonden voor de 4-amino-, 3-hydroxy- en 
4-hydroxy-analoga, terwijl de mate van tubulaire secretie voor 
2-hydroxybenzoylglycine zelfs geringer was dan die voor benzoylglycine 
Tussen deze uitersten bestaat er een grote verscheidenheid aan 
klaringskarakteristieken 
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Geisoleerde Membraanvesicles 
De carriersystemen die het transtubulair transport van organische 
anionen controleren bevinden zich in de plasmamembranen van de 
proximale-tubuluscel te weten, de basolaterale membraan en de 
brush-border membraan. Isolatie van deze membranen maakt het mogelijk 
om de moleculaire mechanismen van het transport in elk van de membranen 
afzonderlijk te bestuderen. 
Hoofdstuk 9 beschrijft een methode voor de isolatie van basolaterale 
(BLMV) en brush-border membraanvesicles (BBMV) uit de cortex van de 
hondenier. Met behulp van deze vesicles werden de 
transporteigenschappen van p-aminohippuurzuur (PAH) bestudeerd. De 
aanwezigheid van een naar binnen gerichte natriumgradient (100 mM) 
stimuleerde de opname van 50 μΜ [3H]PAH in BLMV, terwijl een 
pll-gradient (pH, .. =6.0, pH, . = 7.4) slechts een geringe verhoging 
van de opname gaf. De natriumafhankelijke opname van PAH was 
electroneutraal, verzadigbaar en gevoelig voor competitie met probenecide 
en verschillende andere organische anionen. De kinetische parameters van 
transport waren (schijnbare) К = 0.79 ± 0.16 mM, V = 0.80 ± 0.05 
^
 v J
 ' m max 
nmol/mg eiwit, 15 sec en K. , = 0.08 ± 0.01 mM. De gelijktijdige 
aanwezigheid van de pH-gradient (naar buiten gerichte hydroxylgradient) 
en een inwaartse natriumgradient stimuleerde de PAH-opname tot 
significant hogere waarden dan die in aanwezigheid van alleen een 
natriumgradient. Deze bevindingen suggereerden de aanwezigheid van een 
natriumgekoppeld-PAH/OH -uitwisselingsmechanisme in de basolaterale 
membraan. 
In de BBMV kon de PAH opname met zowel een uitwaarts-gerichte 
hydroxylgradient als een inwaartse natriumgradient worden gestimuleerd. 
Het transport van PAH vertoonde onder invloed van beide gradiënten de 
kenmerken van carrier-gemedieerd en probenecide-gevoelig transport . 
Natriumgradient-gestimuleerd transport was electrogeen en de kinetische 
parameters waren: (schijnbare)K = 4.93 ± 0.57 mM, V = 6.71 ± 0.36 
nmol/mg eiwit, 15 sec en K. ,= 0.13 ± 0.01 mM. De parameters voor het 
pH-gradient-gestimuleerde transport waren vrijwel hetzelfde: 
(schijnbare)K = 5.72 ± 0.49 mM, V = 7.87 ± 0.33 nmol/mg eiwit, 15 sec 
•' ' m ' max
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en К. ,= 0.16 ± 0.02 mM. De gelijktijdige aanwezigheid van een 
natrium- en pH-gradient resulteerde in een tweemaal zo hoge opname van 
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PAH in vergelijking met de situatie waarin alleen een natrium- of 
pH- gradient aanwezig was. Deze resultaten suggereren dat beide 
gradiënten het PAH-transport stimuleren via hetzelfde carriersysteem. 
Competitie-experimenten met verschillende organische anionen toonden 
echter aan dat de substraatspecificiteiten van natrium- en pH-afhankelijk 
transport niet geheel met elkaar in overeenstemming zijn. Dit wijst erop 
dat er zich mogelijk twee afzonderlijke transportsystemen in de 
brush-border membraan bevinden. 
In Hoofdstuk 10 is de substraatspecificiteit van het 
organisch-aniontransportsysteem onderzocht door te kijken naar het effect 
van een reeks gesubstitueerde benzoaten op het natriumafhankelijke 
PAH-transport in BLMV en het natrium- of pil-afhankelijke transport in 
BBMV. Vrijwel alle benzoaten remden de opname van PAH in BLMV en 
BBMV. De sterkste remmers waren 3-C1- en 4-Cl-bonzoaat, terwijl de 
zwakste remming werd gevonden voor 3-NH„- en 4-NH„-benzoaat. De 
schijnbare inhibitieconstante (K.) correleerde significant met de relatieve 
hydrofobiciteit van de geïoniseerde benzoaten (bepaald m.b .v . HPLC). Dit 
geeft aan dat hydrofobe en electronische eigenschappon beide belangrijke 
factoren zijn die de affiniteit voor het PAH-transportsysteem bepalen. 
Het laatste hoofdstuk (Hoofdstuk 11) behandelt het effect van 
gesubstitueerde benzoylglycines (hippuraten) en fenylacetylglycines op 
het transport van PAH in BLMV en BBMV. Benzoylglycines zijn sterkere 
remmers van het PAH-transport dan fenylacetylglycines en het remmend 
effect van de glycineconjugaten was in het algemeen minder in BBMV dan 
BLMV. De sterkste remming werd gevonden voor 2-OCH«- en 
3-CH„-benzoylglycine op BLMV-transport en pH-afhankelijk 
BBMV-transport, terwijl alleen 3-CH„-benzoylglycine een sterk remmend 
effect op het natriumafhankelijke BBMV-transport had. Het was 
opmerkelijk dat 2-OH-benzoylglycine helemaal geen remming van het 
PAH-transport in de BLMV gaf, terwijl de stof wel een duidelijk effect 
had op het BBMV-transport. Het is mogelijk dat intramolcculaire 
waterstof-brugvorming de carbonylgroep afschermt waardoor er geen 
interactie met de carrier in de basolaterale membraan mogelijk is. 
Kennelijk is de carbonylgroep niet essentieel voor transport door de 
brush-border membraan. De gevonden K.-waarden correleerden 
parabolisch met de relatieve hydrofobiciteit van de geïoniseerde 
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glycineconjugaten. Dit wijst erop dat ook voor deze groep van 
verbindingen hydrofobe en electronische eigenschappen van belang zijn 
voor interactie met het PAH-transportsysteem. 
Slotopmerkingen 
In dit proefscrift is een semifysiologisch niermodel ontwikkeld voor de 
analyse van de renale klaring van organische anionen. Gecombineerd met 
een techniek voor de nauwkeurige en frequente verzameling van 
urinemonsters is gebleken dat het model zeer bruikbaar is voor het 
kwantificeren van de transportprocessen die van belang zijn bij de renale 
klaring van organische anionen. Bovendien is gebleken dat interacties op 
het niveau van de tubulaire secretie op consistente wijze kunnen worden 
beschreven. In de toekomst zal aandacht moeten worden besteed aan het 
incorporeren van de processen van actieve en passieve terugresorptie, 
zodat het model voor een nog bredere groep van verbindingen bruikbaar 
is. Het mag duidelijk zijn dat het uiteindelijke doel is het model 
toepasbaar te maken op de humane situatie. 
De verschillende interacties die werden waargenomen in de 
klaringsexperimenten met PSP en SUA pleiten voor het concept van een 
functionele heterogeniteit van het organisch-anion transportsysteem. Ook 
de experimenten met de geïsoleerde membraanvesicles hebben aanwijzingen 
in die richting opgeleverd. Er zullen echter nog veel gedetailleerde 
membraanexperimenten noodzakelijk zijn alvorens de intrigerende maar 
complexe specificiteit van het organisch-aniontransportsysteem, met name 
in relatie tot verwante systemen, volledig in kaart kan worden gebracht. 
Daarbij is het van belang dat eveneens aandacht wordt besteed aan 
intacte cel- en tubuluspreparaten, zodat de verschillende systemen ook 
onder meer fysiologische omstandigheden worden bestudeerd en de 
resultaten gemakkelijker naar de in-vivo situatie kunnen worden vertaald. 
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daarvan zijn beschreven in dit proefschrift. Tijdens deze periode behaalde 
hij in mei 1984 het diploma Stralingsdeskundige Niveau III. In augustus 
1986 trad hij in dienst van de K.U. Nijmegen en verrichtte hij verder 
onderzoek naar de lotgevallen en effecten van geneesmiddelen in relatie 
tot de nier. Daarnaast is hij sedert april 1986 als docent farmacologie 
verbonden aan de Opleiding tot Mondhygienist te Nijmegen. Per 1 
januari 1988 is hij aangesteld als universitair docent farmacologie. 
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STELLINGEN 
1 Een ondernemende universiteit verwordt tot een universitaire onderneming wan-
neer een te groot deel van haar onderzoek gebonden is 
2 De lagere renale-excretiesnelheid van salicyluurzuur ten opzichte van die van 
p-aminohippuurzuur bij hoge plasmaconcentraties is primair het gevolg van een 
lager tubulair-transportmaximum en met van passieve terugdiffiisie van sali-
cyluurzuur 
Knoefel PK et al, Am J Physiol 1962 203 6-10 
Dit proefschrift 
3 Het is niet aannemelijk dat het effect van kalium op de potentiaalgevoehgheid van 
het natnum-gekoppelde glutamaattransport in basolaterale membraanvesicles van 
proximale tubuluscellen ook van toepassing is op het natnum-gekoppelde 
p-aminohippuurzuurtransport in deze vesicles 
PntthardJB, Biochim Biophys Acta 1987, 906 295-308 
Dit proefschrift 
4 Watari et al gaan er m hun berekeningen ten onrechte van uit dat de tubulaire 
secretie van mtrofurantome afhankelijk is van de vrije plasmaconcentratie, aange-
zien hun resultaten duidelijk laten zien dat de renale klaring van mtrofurantome 
bij lage plasmaconcentraties, ondanks de hoge erwitbindmg, vrijwel gelijk is aan 
de renale plasmaflow 
Watan Net al, J Pharm Sci 1985 74 165-170 
5 De renale klaring van een metaboliet kan met eenduidig worden vastgesteld wan-
neer ook de moederverbindmg m het plasma aanwezig is 
6 Bij de interpretatie van het effect van probenecide op het transport van organische 
amonen dient rekening gehouden te worden met een mogelijk effect op het meta-
bolisme van deze amonen 

7. De gemiddelde verblijftijd (mean residence time) is niet altijd een modelonafhan-
kelijke parameter. 
8. De verdeling van het vak farmacologie over verschillende grote onderwijsblokken 
van het curriculum geneeskunde, zoals het geval is aan de Katholieke Universiteit 
Nijmegen, leidt tot een fragmentarische kermis van de farmacologie en is derhalve 
geen goede voorbereiding op een van de meest voorkomende en ingrijpende 
medische handelingen van de arts: het voorschrijven van geneesmiddelen. 
9. In het nieuwe functionele budgetteringsstelsel voor ziekenhuizen wordt een fusie 
tussen een basisziekenhuis en een centrumziekenhuis budgettair aantrekkelijk. 
10. Het verdient aanbeveling dat apothekers de bevoegdheid krijgen om een goedko-
per identiek en gelijkwaardig geneesmiddel af te leveren indien de arts een node-
loos duur geneesmiddel heeft voorgeschreven, tenzij de arts uitdrukkelijk op het 
recept heeft aangegeven dat alleen het voorgeschreven middel mag worden afge-
leverd. 
11. De in de nieuwe promotieregeling van de Katholieke Universiteit Nijmegen voor-
geschreven tekst op het titelblad van het proefschrift: "een wetenschappelijke 
proeve op het gebied van", gevolgd door de facultaire indeling, suggereert ten 
onrechte dat het onderhavige proefschrift geen volwaardig wetenschappelijk 
werkstuk is en is onduidelijk ten aanzien van het vakgebied waarop het werk 
betrekking heeft. Deze tekst kan dan ook beter vervallen. 
12. De opmerkelijke belangstelling van veel apothekers voor de gastronomie is waar-
schijnlijk bepaald door het grote aantal "kookboek"-practica die zij tijdens de stu-
die genoten hebben. 
13. De aantrekkelijkheid van het toptennis als kijkspel kan beter worden verhoogd 
door de lengte van het servicevak te verkleinen dan door de nethoogte te vergro-
ten. 
Hoogendoorn D, Ned Tijdschr Geneeskd 1986; 130:2343-4. 
Rüssel FGM, Ned Tijdschr Geneeskd 1987; 131:332. 
14. Indien presentator Hans Zoet in het radioprogramma "Für Elise" het jonge muzi-
kale talent wat minder plagerig tegemoet zou treden, zou hij er versteld van staan 
hoeveel jong talent er in werkelijkheid in Nederland is. 
15. De stelligheid waannee sommige stellingen bij promoties worden geponeerd, doet 
afbreuk aan het academische karakter van deze plechtigheid. 
Frans GM. Rüssel Nijmegen, 15 januari 1988. 
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